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Abstract 
Excess fluid and waste products of metabolism, as well as protein, are removed from the 
peritoneal cavity in Peritoneal Dialysis (PD). Increased peritoneal protein clearance (Pcl) is 
associated with a greater risk of mortality. It is not clear whether this association reflects 
systemic endothelial injury or local peritoneal capillary damage and inflammation, or both.  
To investigate this problem a series of analyses were undertaken in different incident, 
prevalent and longitudinal patient cohorts. Transcapillary escape rate of albumin (TERalb) 
was measured to determine systemic capillary permeability. Luminex assays combined 
with principle component analysis were applied to measure endothelial biomarker 
patterns. 
It was demonstrated that: (1) Pcl is a function of both local peritoneal inflammation, 
membrane area (PSTR) and comorbidity (especially cardiovascular) but only its 
association with the latter predicted survival. (2) There is a progressive uncoupling of the 
Pcl, (indicative of large pore pathway) and PSTR (effectively the small pore area) with time 
on PD. (3) Isolated small pore ultrafiltration (due to icodextrin) decreases with prolonged 
time on PD and is also uncoupled from the increase in peritoneal membrane area. (4) The 
systemic endothelial barrier function is decreased in PD patients, especially diabetics, but 
not associated with hypoalbuminaemia which is linked to systemic inflammation. (5) 
Hydration status is related to plasma albumin concentration but not endothelial 
dysfunction as measured by soluble biomarkers. 
 25 
 
Pcl is a function of both local peritoneal factors, e.g. inflammation and progressive fibrosis, 
and systemic patient characteristics, e.g. age and comorbidity. The influence of 
comorbidity is complex depending on type, associated patterns of endothelial injury and 
causes of associated hypoalbuminaemia. The importance of plasma colloidal pressure in 
determining fluid status was emphasized. Strategies to improve fluid distribution should 
focus on reducing peritoneal protein loss and increasing albumin synthesis rather than 
blocking systemic vascular leak.   
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patients” poster presentation in 2010 American Society of Nephrology (ASN) 
meeting and 2011 BRS/RA conference  
3. “Understand the variability in Ultrafiltration obtained by Icodextrin” poster 
presentation in 2011 American Society of Nephrology (ASN) 
4. “Progressive uncoupling of peritoneal small solute transport and protein clearance 
with time on peritoneal dialysis” in 2012 RA conference and ISPD 2012 
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Introduction and Hypotheses chapter 1.
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1.1 Background  
1.1.1 What is the main cause of death for peritoneal dialysis 
(PD) patients? 
Renal replacement therapy is the most successful organ replacement therapy at present. 
Thousands of end stage renal disease (ESRD) patients are saved from death by the 
therapy. Unfortunately, the expected life span of the ESRD patients is still much shorter 
than the general population. Cardiovascular disease (CVD) is the leading cause of death in 
patients with ESRD. Cardiovascular mortality is markedly greater in patients treated by 
renal replacement therapy than in general population. 1, 2 Although the high risk of CVD 
had been recognized early after introduction of maintenance dialysis, 3 the mechanisms 
behind the high prevalence of CVD observed in these patients are still far from 
understood. The prevalence of Framingham’s traditional risk factors for CVD (age, 
hypertension, diabetes, dyslipidemia, and physical inactivity) is high in chronic kidney 
disease (CKD) patients. Some CKD-specific risk factors, such as fluid overload, anemia, 
hyperparathyroidism, oxidative stress, hypoalbuminemia, accumulation of pro-
inflammatory cytokines, elevated asymmetric dimethylarginine (ADMA), 
hyperhomocysteine, and modification of protein by non-enzymatic advanced glycation 
are also thought to play roles in the high prevalence of CVD in dialysis patients 4, 5. 
Moreover, several factors associated with PD therapy, such as advanced altered lipid 
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profile, hyperinsulinemia, and formation of advanced glycation end-products may 
increase the risk in PD patients.5 
1.1.2 What plays the key role in the development of 
cardiovascular disease (CVD) in PD patients? 
The vascular endothelium is a single cell barrier, located between the plasma and the 
underlying tissue. It actively regulates vascular tone and permeability, the balance 
between coagulation and fibrinolysis, the extravasation of leukocytes, and the 
proliferation of vascular smooth muscle. Different risk factors, such as hyperlipaemia, 
smoking, hemodynamic stimuli, may destroy the normal balance followed by endothelial 
dysfunction. Endothelial dysfunction is the main pathway in most forms of CVD not only 
in the general population but also in chronic renal failure. Impaired vasodilation has been 
found in hypertension, type 1 and type 2 diabetes, coronary artery disease, congestive 
heart failure and also chronic renal failure. 6 Moreover, according to a study in the 
offspring of hypertensive patients, endothelial dysfunction may not be only associated 
with its existence but also precede its development. 7 Endothelial dysfunction is an 
important early event in the pathogenesis of atherosclerosis and it also contributes to 
vascular remodeling. 4, 6, 8 Although non-atherosclerotic CVD may also contribute to the 
high cardiovascular mortality rate in ESRD, much evidence suggests that ESRD patients 
are subjected to the process of accelerated atherogenesis. 9 Different measurements of 
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endothelial function, including biomarkers and functional measurements of endothelium, 
show endothelial dysfunction in ESRD patients and predicts patients’ outcome. 10-13 
With the understanding of the importance of endothelial dysfunction in patients’ 
outcome in PD, we have reviewed the measurement methods of endothelial dysfunction 
in patients and investigate the possibility that peritoneal protein leak is a marker of 
endothelial function in PD patients. For this reason, we have also discussed the present 
understanding of the pathophysiology and longitudinal changes of the peritoneal 
membrane and map the gap in our current knowledge. 
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1.2 How is endothelial function measured? 
The importance of the endothelium in CVD has been recognized for many years. Despite 
this the optimal methodology for investigating the multi-aspects of endothelial 
dysfunction is still under debate. Generally speaking, endothelial function can be 
measured by two ways. One is to measure the concentration of the biomarkers that 
mediate endothelial cell function. The other is to measure the functional consequences of 
endothelial cell activity. From a clinical perspective, it can also be divided into invasive 
and non-invasive methods. We will mainly focus on non-invasive methods here.  
1.2.1 Normal function and dysfunction of endothelium 
Normal endothelial function includes the regulation of hemostasis and fibrinolysis, 
vasomotor activity, angiogenesis, permeability to macromolecules, leukocyte adhesion 
and vascular smooth muscle cell proliferation. Endothelial dysfunction can be defined as 
any change in endothelial functions that are inappropriate to the organ function. There 
are many types of endothelial dysfunction depending on which function is affected.  
It should also be noted that endothelial function in different organs is very variable. For 
example, in the glomeruli, capillaries normally allow small amount of protein to cross. In 
contrast, albumin permeability in hepatic sinusoids is much higher than that in 
glomerulus. A normal endothelial function is defined as a suitable condition for a definite 
organ circumstance. 
 40 
 
1.2.2 Biomarkers and their limitations  
Biomarkers are most widely used for estimating endothelial dysfunction in clinical 
research for practical reasons. A wide range of biomarkers have been established so far. It 
is predictable that more biomarkers will be recognized with our increasing knowledge of 
endothelial dysfunction. However, generally speaking, they are either endothelium-
derived regulatory proteins, or may not derive from endothelium but are documented to 
take part in the pathogenesis of endothelial dysfunction or reflect the endothelial 
dysfunction. Detailed reviews of this have been done by others. 14-17  
Some limitations should be realized when using biomarkers. Firstly, each of these 
biomarkers reflects an aspect of endothelial function, but none of them can be regarded 
as the gold standard and can replace each other. Secondly, it is also not clear whether the 
predictive value of endothelium derived regulatory proteins is due to their specific 
function (for example vascular cell adhesion protein 1 (VCAM 1) for leukocyte adhesion) 
or reflects general endothelial dysfunctions. For these two reasons, measuring the 
pattern of the biomarkers might be a better strategy than separate biomarkers. Thirdly, 
high plasma levels of biomarkers may reflect increased synthesis and/or decreased 
clearance. Data on the latter process is limited but it may be an important issue in renal 
disease. Fourthly, they cannot give information about where endothelial dysfunction 
occurs. The endothelium derived products may mainly reflect dysfunction at the level of 
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small resistance arteries, capillaries or venules, because of the large area of them, while 
clinical events such as myocardial infarction mainly occur in larger conduit arteries.  
1.2.3 Measurement of functional consequences of 
endothelial cell activity 
1.2.3.1 Vasoactivity 
1.2.3.1.1 Flow-mediated vasodilation (FMD) – the most widely used 
method 
The technique of assessing flow-mediated vasodilation (FMD) has been developed for 
years. It measures the change in diameter of a conduit artery in response to increased 
flow, typically induced by a period of ischemia in the distal circulatory bed, which is 
predominately nitric oxide (NO)-mediated. There is evidence that it is depressed in 
subjects with atherosclerosis and cardiovascular risk factors and is thought to be 
correlated with coronary vascular endothelial vasodilator function. 18-20 The equipment 
and protocol of FMD are well established by the working group on endothelin and 
endothelial factors of the European Society of Hypertension. 15 Briefly, for endothelium-
dependent FMD, the baseline image is recorded after a blood pressure cuff is inflated to 
supra-systolic pressure for 5 min followed by deflation of the cuff, and recording of the 
post cuff deflation image. The effect of an endothelium-independent stimulation is 
accessed by sublingual administration of nitroglycerin. After the baseline image is 
recorded, nitroglycerin is administered sublingually. The image is recorded for a further 3 
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to 5 min after that. The endothelium-independent dilation, which is also known as 
nitroglycerin-mediated dilation, is expressed as the percentage of maximum change from 
baseline in diameter. FMD of the brachial artery is the most widely used and best 
validated, however similar principles can also be applied to other conduit artery, such as 
radial, femoral and posterior tibial arteries.  
1.2.3.1.2 Other methods 
Non-invasive tests for assessment of coronary endothelial function have been described 
including new ultrasound technology and contrast echocardiography, positron emission 
tomography and magnetic resonance imaging. 21 The ‘gold-standard’ test for the 
evaluation of coronary endothelial function requires invasive coronary angiography. No 
non-invasive assessment method of endothelial dysfunction in the microvasculature has 
been widely accepted in humans until now. The Landis-Michel micro-occlusion technique, 
which involves capillary cannulation and occlusion22, does allow in vivo measurements in 
animals. But it is not feasible in human. The laser Doppler imaging technique provides a 
possible non-invasive approach to the evaluation of microcirculation. 23 The effect of 
beraprost sodium, a prostacyclin analogue, on skin blood flow measured by laser doppler 
flowmetry decreases with an increase in the severity of retinopathy and nephropathy in a 
group of non insulin dependent diabetes patients. 24 The results of laser Doppler 
flowmetry are also consistent with the other risk assessments (Framingham, CRP, etc.) in 
ESRD patients. 13 The method of nail fold capillaroscopy is used in autoimmune rheumatic 
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diseases, especially in scleroderma. 25 But it has not been widely validated in CVD. A study 
using computerized videocapillaroscopic technique has shown the morphological 
difference of gingival microcirculation between smokers and non-smokers. 26 Further data 
about the predictive power of cardiovascular risk for these methods is needed, and 
standardization of protocols would be helpful to improve the reproductive power.  
Whether endothelial dysfunction occurs in all vascular beds is difficult to test in human 
but obviously it is an important question. One study found that a disturbed endothelial 
vasomotor response was associated with microalbuminuria in not only the brachial artery 
but also the renal interlobar arteries. 27 However we are not aware of any studies that 
have been done, for example, on whether protein leak in peritoneum is related to 
endothelial dysfunction in coronary artery. 
1.2.3.2 Barrier function 
1.2.3.2.1 Transcapillary escape rate of albumin 
The transcapillary escape rate of albumin (TERalb) is the most widely used method to 
identify the barrier function of macromolecules in endothelium. The method was 
described as early as 1973. 28 In brief, the TERalb, which is defined as the fraction of 
intravascular mass of albumin that passes to the extravascular space per unit time, is 
determined from the disappearance of intravenously injected radiolabelled albumin and 
usually expressed as the one hour fall of intravenous radiolabelled albumin expressed as 
percentage. Transcapillary permeability to albumin is found to be increased in patients 
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with diabetes, hypertension and atherosclerosis 29-32 and also in acute inflammation 
status, such as sepsis. angiotensin-converting enzyme (ACE) D/D homozygosity, which is 
related to an increase risk of atherosclerotic vascular disease in essential hypertension, is 
also associated with higher TERalb despite identical 24 hour blood pressure readings. 33 
High-dose simvastatin reduces low-density lipoprotein cholesterol by 39%, and 
normalizes TERalb. 34 However, we have to realize that the TERalb is a complex parameter 
which combines the effect of hemodynamic forces, endothelial surface area and 
endothelial permeability.  
1.2.3.2.2 Microalbuminuria 
1.2.3.2.2.1 Microalbuminuria is closely related to CVD 
Microalbuminuria is thought to reflect the systemic endothelial function and considered 
to be a marker of endothelial dysfunction. Microalbuminuria is usually defined as the 
urinary albumin excretion rate of 30-300mg/24h urine, or of 30-300(mg/g creatinine) in 
spot urine sample. Microalbuminuria, even below the conventional cut-off values is 
demonstrated to be a predictor for cardiovascular events in both diabetic and general 
population. 35-38 Microalbuminuria in diabetes has been shown to relate to endothelial 
dysfunction as measured by biomarkers, eg von Willebrand factor, tissue-type 
plasminogen activator, soluble vascular cell adhesion molecule 1 (VCAM-1), and soluble E-
selectin, and functional measurement, FMD. 39 This association between 
microalbuminuria and endothelial dysfunction has also been found in non-diabetic 
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individuals. 40-42 The observation that changes in albuminuria during treatment translate 
into changes of cardiovascular events further suggests that albuminruia reflects a 
systemic endothelial dysfunction. 43   
1.2.3.2.2.2  Is there a common pathway of microalbuminuria and CVD? 
The Steno Hypothesis, published in 1989,44 introduced the concept that microalbuminuria 
might reflect a systemic transvascular leakage of albumin. 
Data from Jensen, et al have shown that in patients with microalbuminuria the fractional 
disappearance rate of albumin from the plasma compartment is higher than in the normal 
group. It is positively correlated with urinary albumin excretion rate and is independent of 
age, sex, smoking status, blood pressure, body size, plasma volume, plasma albumin 
concentration and blood glucose, serum insulin and serum lipids. 45 Falqui has shown that 
in a group of never-treated non-diabetic hypertensive patients, microalbuminuria is 
associated with higher capillary permeability to albumin. 46 Furthermore, Viazzi has 
shown that in primary hypertension patients, 1% increment in TERalb or 10mmHg 
increase in systolic BP results in an almost three times higher risk of having 
microalbuminuria. 47  
However, the association between increased TERalb and microalbuminuria is not present 
in all circumstances. Pedrinelli and his colleagues have shown that in essential 
hypertension and in atherosclerotic and hypertensive men transcapillary albumin leakage 
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is altered, but the abnormality is dissociated from the amount of albuminuria. 31, 48 They 
found that microalbuminuria was associated with the hemodynamic response to 
acetylcholine in the forearm, another assessment of endothelial function. 49  
In the case of glomerular protein leak, apart from the endothelium, it also depends on 
glomerular basement membrane composition, slit diaphragm structure, podocyte and 
interstitial-tubular lesion, which may partly explain the paradoxical results. (Figure 1-1) 
On the other hand, as mentioned before, hemodynamic factors could also affect the 
protein leak, and the intra-glomerular-capillary pressure is not only regulated by systemic 
blood pressure but also by the local factors. Actually, in the data from Pedrinelli, both 
TERalb and albuminuria were related to blood pressure 48, but they are not related to 
each other. 31, 48  
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Figure 1-1 The main filtration barrier of glomerulus  
It includes glomerular endothelial, glomerular basement membrane, podocyte and slit 
diaphragms. After filtration, the tubule of kidney selectively reabsorbs substances 
back into the blood. 
 
Adapted from http://www.health.bcu.ac.uk/physiology/renalsystem.htm and 50 
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1.3 Could peritoneal protein clearance (Pcl) be regarded as a 
marker of endothelial function in PD patients? 
1.3.1 Is peritoneal Pcl related to CVD in PD patients? 
1.3.1.1 The small solute clearance is the important but not the only 
important factor for patient survival in PD  
Removal of extra fluid and toxin is the major function of dialysis. Kt/V and the creatinine 
clearance rate (Ccr) represent the small molecular solutes clearance in dialysis patients 
and are the most widely used measurement of dialysis adequacy. Kt/V is the product of 
dialyzer (which in the case of PD is the peritoneal membrane) urea clearance and 
treatment time divided by the volume of distribution of urea, and Ccr is the volume of 
blood plasma that is cleared of creatinine per unit time.  
Kt/V 
K - dialyzer clearance of urea 
t - dialysis time 
V - volume of distribution of urea, approximately equal to patient's total body water 
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The importance of small molecular solutes clearance has been well established in recent 
years. Almost all the guidelines for clinical practices on PD recommend a dialysis 
adequacy target in terms of Kt/V and Ccr. Studies have shown that the greater the small 
molecular solute clearance the better the patients survival is, although the variance in 
clearance that explains this survival effect is entirely due to residual renal function. The 
data from the Stoke Study showed that weekly Kt/V was an independent predictor of 
survival in CAPD patients. 51 Increasing the delivered dialysis dose may have a beneficial 
effect on nutrition in malnourished patients without comorbidity 52 but not in patients 
with comorbidities. Studies have also shown that increasing peritoneal Kt/V and Ccr 
above the minimum recommended threshold cannot improve the survival rate in PD 53, 54, 
and numerous studies have tried and are trying to find the underlying contributors for 
patient survival other than small solute clearance. 
1.3.1.2 The changing role of high peritoneal membrane transport 
status (PSTR) as a strong predictor of worse patient outcome 
In addition to total small solute clearance, the rate at which small solutes diffuse across 
the peritoneal membrane, usually referred to as peritoneal solute transport rate (PSTR), 
usually measured by the dialysate to plasma creatinine ratio (D/Pcrea) at four hours, is 
also regarded to associate with patient  
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failure, independent of comorbidity and small solute clearance, 55 at least historically. 
Data from our own centre showed a relationship between increased PSTR and reduced 
survival in CAPD patient before 1995. 51 The underlying reasons for this relationship may 
include a reduced peritoneal membrane ultrafiltration capacity resulting from a more 
rapid dissipation of the glucose osmotic gradient and fluid reabsorption, 56 which 
consequently causes extracellular water (ECW) expansion and hypertension. 57 More 
recently high PSTR is no longer a risk factor for technique failure or death in 
contemporary PD patients treated with dialysis methods such as automated peritoneal 
dialysis (APD) and polyglucose solutions, such as icodextrin, which counter balance the 
negative effects on ultrafiltration. 58-61.  
With the improved understanding of the peritoneal membrane, it has been hypothesized 
that the high PSTR patients may not be a homogeneous group. They could be subdivided 
into at least three groups. Type I is an early inherent type which is potentially associated 
with increased mortality and is usually associated with inflammation and comorbidity. 
This group of patients would also have a poor outcome even if they were treated by 
haemodialysis, although this has not been shown. Type II is also an early inherent type 
which is mainly related to a large peritoneal surface area. Most of these patients are not 
inflamed. Type III is a late acquired type, which develops over time of PD. Inflammation 
and comorbidities are also not necessary in this group of patients although local (as 
opposed to systemic) inflammation may be the driving mechanism. (Table 1-1) The use of 
icodextin and APD improves the fluid management especially in high PSTR patients 62-64 
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which help to convert the poor outcome tendency in type II and type III high PSTR but is 
not helpful to type I patients. 
Table 1-1 characteristics of the three types of high PSTR 58 
 
 
1.3.1.3 Peritoneal protein clearance (Pcl) is an independent predictor 
of mortality in incident PD patients 
More clearance of mid-molecular weight toxin is regarded as an advantage of PD 
compared with haemodialysis. It should be noted that the clearance of large molecular 
weight substances are also increased in PD patients. PD patients may lose 5-15 gram of 
protein per day through the peritoneum. 65 This extrarenal protein loss contributes to the 
low albumin level in PD patients to some degree on the population base 66 and it also 
likely explains why for a given degree of hypoalbuminaemia survival in PD patients is 
superior to those on haemodialysis. 67 
Recent studies have shown that increased peritoneum Pcl may predict a poor outcome in 
incident PD patients even with the use of icodextin and APD. Johansson used the method 
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of personal dialysis capacity test 68 which was based on the three-pore theory of capillary 
transport to identify large-pore flow in a group of 249 patients. They found that large-
pore flow is greater in patients with severe comorbidity than in patients with fewer 
comorbid conditions. 69 This is in keeping with the observation by Szeto, C.C., that a single 
measure of dialysate albumin >300mg/l is associated with increased cardiovascular 
events.70 Van Biesen has shown that a large-pore flux higher than expected from the 
membrane area parameter is related to an increased mortality and is weakly correlated 
with systemic inflammation. 71 Heaf also has found that mortality is increased significantly 
with increased large pore flow and is related to hypoalbuminaemia after PD initiation. 72 
More recently, Pcl  has been confirmed to relate to peripheral arterial disease in a cohort 
of 133 PD patients. 73 Data from our centre show that peritoneal Pcl is an independent 
predictor of mortality and is related to increased pulse pressure and the presence of 
peripheral vascular disease while PSTR is no longer a predictor. 61 Most of the clinical 
observations support that peritoneal Pcl is correlated with poor outcome and vascular 
disease. However, data from a Netherland group, showed that baseline peritoneal 
albumin and protein clearances from a 4 hour dwell with 3.86% glucose dialysate were 
associated with signs of comorbidity but no measurable effect on patient survival could 
be found. 74 The reasonable number of patients and duration of follow up in that study 
make it unlikely that the negative result is due to a lack of power. The reason for the 
different observations calls for further investigation. 
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1.3.1.4 The predictive power of peritoneal Pcl is independent from 
PSTR 
A larger membrane tends to have a higher PSTR, measured as the diffusive transport rate 
for small solute, for example, D/Pcrea, and also tends to have a higher peritoneal Pcl. The 
membrane transport status would change proportionally with the peritoneal Pcl in an 
anatomic large membrane (probably type II high PSTR) while if the high PSTR is a result of 
inflammation or vascular injury (probably type I high PSTR) they may change in-
proportionally. (Figure 1-2)  
One way to distinguish these two possibilities is to dissociate the PSTR from peritoneal Pcl 
by using the three-pore model. According to the three-pore model, PSTR depends on 
effective membrane area while peritoneal Pcl mainly reflects large pore function. Several 
studies have dissociated the effective membrane area from large pore flow and found 
that large pore flow was an independent predictor of survival while membrane area 
parameters tend to lose its predictive value in multivariate models. 61, 71, 72 It is likely that 
the membrane transport status has lost its power to predict worse survival, because of 
the use of icodextin and APD which relieve the disadvantages of high PSTR in fluid control, 
and reveals an underlying relationship between peritoneal Pcl and survival. 
 54 
 
Figure 1-2 A) model of normal membrane with large and small pores B) model of 
anatomic large membrane with proportionally increased large and small pores C) 
model of inflamed membrane with more small pores and even much more large 
pores. In this situation, small pores and large pores increased in-proportionally.  
(This diagrammatic representation shows a much lower ratio of small to large pores 
than seen in reality.) 
 
1.3.2 What are the main determinations of peritoneal Pcl? 
1.3.2.1 Main barrier in peritoneal membrane 
As shown in Figure 1-3, the anatomic barrier separating the blood from the peritoneal 
fluid in PD contains a number of structures, including the peritoneal capillary walls, the 
cellular-interstitial matrix and the single layer of mesothelial cells. The mesothelium is not 
a major transport barrier to solute and water transfer. Complete removal of the 
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mesothelium in rodents does not affect the solute or water transfer significantly. 75 The 
capillary endothelium is the most important resistance in PD.  
Figure 1-3 The anatomic barrier separating the blood from the peritoneal fluid in PD  
It contains the peritoneal capillary walls, the cellular-interstitial matrix and the 
mesothelium. 
 
Adapted from ref 76 
1.3.2.1 Physiology and pathophysiology of trans-capillary protein leak 
Over the last century several physiologists including Starling, who formulated Starling 
equation in 1896, 77 Pappenheimer, Michel, Curry, Rippe, Bates, Renkin, Crone, Levick, 
and Landis 78-83 have investigated the mechanisms of transport across the vascular barrier. 
Gases, water, and other small molecules cross the endothelial cell barrier freely whereas 
larger molecules such as plasma protein are tightly restricted.  
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Diffusion is the most important mechanism for the exchange of small molecules and is 
driven by the molecular concentration gradient across vascular endothelium. This is not 
the case for large molecular weight substances, such as protein. The diffusion of albumin 
across the vessel is estimated to be 1000-fold less than that of water. 81 Convection is the 
most important determinate for the flux of large molecules such as plasma proteins, 
which is determined by the forces of the Starling equation. 
The Starling equation reads as follows: 
 
Jv is the net fluid movement between compartments.  
Lp is hydraulic conductance. 
A is surface area available for molecular exchange. 
(Pv-Pi) is the hydrostatic pressure gradient between capillary and interstitial. 
(πv-πi) is the oncotic pressure gradient between capillary and interstitial. 
(σ) is reflection coefficient. 
[(Pv-Pi)- σ(πv-πi)] is the net driving force. 
As established by Rippe B, according to the three-pore model, the size-selectivity for 
macromolecules larger than albumin is compatible with the presence of large pores by 
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pressure-driven flow, without being affected by the oncotic or colloid osmotic pressures 
acting across small and transcellular pores. In other words, large pore transport is 
affected only by changes in the transcapillary hydrostatic pressure gradient and/or the 
number of large pores available for transport. 84  
1.3.2.1.1 Three-pore model 
In the three pore theory developed by Rippe and his colleagues, the capillary endothelium 
is modeled as a barrier with pores. There are three types of pores in capillary 
endothelium:  ultra-small pores, small pores and large pores. (Figure 1-4) The presence of 
ultra-small pores is supported by the discovery of aquaporin-1, a molecular structure that 
penetrates the cell wall and provides a water only pathway. 85 The small pores, which are 
40-55 Å in radius, are responsible for small solute transport and are thought to be the 
intercellular clefts between the endothelial cells. Most of the protein is thought to go 
through large pores which are approximately 250 Å in radius. The nature of the large 
pores is not clear.  
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Figure 1-4 three-pore model 
According to the three-pore model, there are three kinds of pores in capillary 
endothelium: small pores, large pores and ultra-small pores. The ultra-small pores are 
probably the transendothelial aquaporin-1 and provide a water only pathway. The 
numerous small pores, which are 40-55 A  in radius, are the principal pathway for 
water-solute substances and water. The small pores are thought to be the intercellular 
clefts between the endothelial cells. Most of the protein is thought to go through large 
pores which are approximately 250 A  in radius and fewer in numbers. The nature of 
the large pores is not well known. 82 
 
1.3.2.1.2 The glycocalyx 
The glycocalyx is a thin layer of proteoglycans, glycoprotein and glycosaminoglycans 
located on the luminal surface of endothelial cells. (Figure 1-5) It conveys a negative 
charge to the endothelium, which may be important for the glomerular filtration barrier. 
86 It is also possible that it affects the peritoneal permeability for macromolecules through 
the endothelial barrier. The glycocalyx appears to be damaged in several clinical 
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situations such as inflammation, ischaemia/reperfusion and hyperglycaemia, all of which 
are likely to be associated with an increased capillary permeability. 87, 88 Hyaluronan, a 
major component in the interstitium, has been found to make up a major part of the 
glycocalyx endothelial barrier. Treatment with hyaluronidase results in a marked increase 
in permeability of 70- and 145-kDa dextrans. 89 Pro-inflammation cytokines, such as TNF-α, 
cause modification of the glycocalyx and result in increased permeability to 
macromolecules, even when TNF-α-enhanced white cell adhesion is inhibited. 90 
Glycocalyx modification also occurs in ischemia-reperfusion injury, which may be reversed 
by pretreatment with adenosine. 91, 92 Short-term hyperglycemia results in a rapid 
decrease of the ability of glycocalyx to prevent 70-kda dextran from transporting across 
the endothelial barrier. 93 Although the effect of short-term hyperglucemia on decreased  
endothelial barrier function is complex. The cytoskeleton of the cells in the glomerular 
barrier may also be involved in the alterations. 94  
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Figure 1-5 glycocalyx - a thin layer of proteoglycans, glycoprotein and 
glycosaminoglycans located on the luminal surface of endothelial cells, which conveys 
a negative charge to the endothelium 
 
 
1.3.2.1.3 The longitudinal change of peritoneal membrane 
1.3.2.1.3.1 Functional changes 
Different from haemodialysis, the dialysis membrane we use in PD, the peritoneum, 
changes with time. Membrane failure is the main cause for technical failure in long term 
PD. It has been shown that ultrafiltration decreases and PSTR increase with time on PD. 95, 
96 The increase in PSTR with time is preceded by increased peritoneal exposure to 
hypertonic glucose. 96, 97 Apart from dialysate, severe and repeated peritonitis may also 
contribute to the change of membrane function. 98 
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Membrane failure, as a result of membrane deterioration, can be subdivided into two 
group, type I and type II. Type I membrane failure is the most common cause of 
ultrafiltration failure and is characterized as an increase in PSTR. The increased PSTR 
causes the rapid loss of the osmotic gradient and insufficient fluid ultrafiltration 
combined with increased reabsorption in the long dwells. Type II membrane failure is 
relatively rare and usually seen in long-term patients and is characterized by a reduction 
in osmotic conductance of the membrane. Clinically, it is evidenced by the observation 
that in long term PD patients, UF capacity decrease disproportionally to the increase of 
PSTR. 95  
Data on longitudinal change of macromolecular transport is limited. Large observational 
cohort study is needed to understand the longitudinal change of the peritoneal protein 
permeability. 
1.3.2.1.3.2 Morphological change 
It is known that peritoneal membrane changes in morphology with prolonged time on PD. 
The morphological changes include mesothelial cell denudation, interstitial fibrosis, 
vascular changes and neovascularization. (Figure 1-6) Vascular changes include 
progressive subendothelial hyalinization, with luminal narrowing or obliteration. The 
vascular changes are similar to diabetic vascular changes but are unique in terms of the 
fact that it affects both venules and arterioles. Williams and colleagues examined biopsy 
samples from four groups of patients, including those who had normal renal function, 
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patients who had been treated only with haemodialysis, uremic patients who had never 
been dialyzed and PD patients. The results have shown that membrane morphology 
changes are present even in uremic patients who are not yet on dialysis and more severe 
in patients undergoing PD. In the PD group, the dialysis regimen is likely to associate to 
the morphology change of peritoneum. The prevalence of vasculopathy increases 
significantly with time on therapy. The degree of fibrosis and thickness of the overlying 
structure under the peritoneum are also directly related to the duration of PD. 99 The 
increase of the submesothelial fibrous tissue was related to cumulative glucose load on 
PD. 100 Patients on automatic PD (APD) tend to have increased submesothelial stroma and 
vascularization, in spite of the fact that they are treated for a shorter period of time than 
the continuous ambulatory PD (CAPD) group. Peritonitis is also a contributor for 
morphological change. A marked loss of mesothelial cells has been observed in cases with 
two or more episodes of peritonitis. 100  
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Figure 1-6 typical morphology change of long term PD 
 
a) at the beginning of PD b) after 6 years of PD 
Sub-mesothelial fibrosis, increased numbers of vessels and vasculopathy are obvious 
in long term PD. 101 
 
1.3.2.1.3.3 Link between functional change and morphological change 
Plum and colleagues further reported the relation between functional changes and 
histological changes in the peritoneum. Patients with a high PSTR have significantly 
thicker submesothelial fibrous layers. 100 Numata and his colleagues gave more data on 
the link between morphology change and transport rate of β2-microglobulin and albumin. 
They have found that both PSTR of creatinine and β2-microglobulin is associated with 
relative microvessel area (RVA) which is calculated as total area of microvessels/total area 
of peritoneal field but not with relative microvessel number (RVN), while no statistic 
relationship is found between the dialysate and plasma ratio for albumin and RVA or RVN. 
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102 The synchronous data for the relationship between peritoneal Pcl and fibrosis and 
vasculopathy is not seen. 
1.3.2.1.3.4 The three-pore membrane/fiber matrix model 
Recently, the three-pore model has been extended into the three-pore membrane/fiber 
matrix model (Figure 1-7), the three-pore model to the capillaries and the fiber-matrix 
model to the intestitium. 103 It fits the observation in severe ultrafiltration (UF) failure 
(type II membrane failure) by uncoupling PSTR (peritoneal mass transfer area coefficient 
for glucose (PS(g))) from peritoneal glucose osmotic conductance (LpSσg). When increases 
in vascular surface area are combined with further increase in fiber density, peritoneal UF 
coefficient (L(p)S) remains largely unchanged. However, it is not known whether this fiber 
matrix restrict the large molecular flow.  
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Figure 1-7 three-pore membrane/fiber matrix serial barrier model 
 
 
1.3.3 What causes protein leak in capillary through an 
“endothelium-dependent” pathway? 
1.3.3.1 Is there a link between systemic factors and peritoneal Pcl? 
In PD, Van Biesen and colleagues have shown that patients with systemic inflammation 
have a higher peritoneal Pcl. Furthermore, there was no difference in membrane area 
parameters between patients with and without systemic inflammation in that study 
raising the possibility that this relationship may not couple with PSTR. 71 It is not clear 
whether the relationship between systemic inflammation and peritoneal Pcl is because 
the patients with systemic inflammation also have inflamed membranes.  
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One study in a group of pediatric PD patients has shown that peritoneal protein losses in 
patients with steroid-resistant nephrotic syndrome (SRNS) are twice as great as in those 
without nephrotic syndrome which is thought to be the result of the systemic effect of a 
“circulating factor” in SRNS. 104 It gives us another example of how a systemic factor might 
affect local protein leak. 
1.3.3.2  Is there a link between local peritoneal membrane injury and 
peritoneal Pcl? 
Peritoneal membrane inflammation does occur in PD and is thought to be the main cause 
of membrane deterioration in PD. The non-physiologic nature of dialysate includes 
different factors, eg. high osmolarity, buffer composition, high dextrose concentrations, 
and glucose degradation products (GDPs) formed during heat sterilization have been 
shown to damage different type of peritoneal cells, 105-109 all of which may trigger an 
inflammatory response. GDPs and subsequent formation of advanced glycation end 
products (AGE) induce inflammatory activation of cells. 110-112 The use of a more 
biocompatible, neutral pH PD solution with a low concentration of GDPs has been shown 
to result in a significant decrease in dialysate effluent IL-6 levels compared to a 
conventional acidic PD solution, suggesting a reduction of intra-peritoneal 
inflammation.113, 114  
Several studies have shown that local chronic inflammation is associated with PSTR in 
incident patients 115, 116 and may be related to PSTR change with time. 117 The 
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synchronous data on large pore flux is limited. As the absolute large pore flux is a function 
of membrane area, it is also important to understand whether the change of large pore 
flux is proportional to the change of membrane area. The peritoneal Pcl is sharply 
increased in acute peritonitis 68 and clearly it is not proportional to the increase of PSTR in 
this condition. Data in stable CAPD patients have shown that the dialysate appearance of 
IL-6 correlates with albumin and IgG clearances, which is also related to small solute 
transport at the same time. 118 It is not clear whether the inflammation associated 
peritoneum Pcl increase is coupled with the change in PSTR through that study.  
1.3.3.3 The association between local peritoneal membrane factors 
and systemic factors 
Another point need to be noted is the intraperitoneal inflammation is related to systemic 
inflammation 117 but cannot be completely explained by systemic inflammation. Actually, 
dialysate IL-6 levels are even higher than plasma levels despite dilution by dialysate. 
Other pro-inflammation factors, such as IL-1, TNF-α, IFN, are usually low but can be 
elevated above plasma. (unpublished data from the GLOBAL study)  A short-term 
randomized controlled study has shown that a new biocompatible bicarbonate/lactate-
based solution having low concentration of GDPs, resulted in decreased peritoneal 
appearance rate of IL-6 compared with conventional lactate-based PD solution, whereas 
systemic levels of inflammatory markers did not differ between the two solutions. 119 The 
clinical benefit of the biocompatible solution is still under debate. 120 Actually, the largest 
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randomized study comparing biocompatible and conventional solutions did not detect 
any clinically significant advantages in terms of technique survival or peritonitis. 121 
1.3.3.4 The potential cause of protein leak in capillary 
1.3.3.4.1 Inflammation and others 
1.3.3.4.1.1 Inflammation 
Inflammation is the predominant cause of capillary hyperpermeability. Capillary 
permeability is increased both in acute and chronic inflammation. TNF-α, as an example 
of classical pro-inflammation cytokine, has been well investigated in this area and it 
regulates vascular permeability through different pathways. Koga et al has shown that 
TNF increases endothelial cell permeability by decreasing adenosine 3’, 5’-cyclic 
monophosphate (cAMP). 122 The TNF-α induced hyperpermeability can be suppressed by 
adiponectin via a cAMP/protein kinase A (PKA) signaling. 123 TNF-α also up-regulates the 
phosphodiesterase2 expression in a p38 mitogen-activated protein kinase (MAPK)-
dependent manner and results in destabilization of endothelial barrier function. 124 
Others have found that TNF-α induces endothelial actin microfilament rearrangement, 
microtubule destabilization and intercellar gap formation that parallels the development 
of transendothelial permeability. 125-127 TNF-α is also thought to disrupt the glycocalyx and 
lead to an increase in macromolecular permeation. 90  
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1.3.3.4.1.2 Platelet activation 
There is a link between inflammation as a trigger for platelet activation in vascular lesions. 
These pathways may however act either independently or sequentially; activated 
platelets can induce secretion of chemokines for monocyte recruitment 128 whereas single 
microvessel perfusion with TNF- alone, without platelet activation, does not alter the 
endothelial permeability 129. In an aseptic animal injury model, systemic depletion of 
neutrophils with antibody failed to prevent the increase in vascular permeability, whereas 
antiplatelet pre-treatment reduced this by 25% 130. These findings suggest that platelet 
activation may have a critical role in endothelial hyper permeability that may not 
necessarily be through inflammation, especially in the low grade inflammatory status 
seen in uremia. 
1.3.3.4.1.3 Others 
In addition to inflammation and platelet activation,  hyperglycemia 131, reactive oxygen 
species 132 and AGEs 133 are also thought to increase endothelial permeability. 
1.3.3.4.2 Angiogenesis 
The importance of angiogenesis to protein leak is not only the increase in the endothelial 
surface area but also the increasing permeability. New vessels tend to be leaky vessels. 
Vascular endothelial growth factor (VEGF), which was initially discovered as a prime 
regulator of angiogenesis, has also been found to effect vascular permeability. 134, 135 
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Brown and colleagues have shown a possible link between angiogenesis and 
hyperpermeability. The study in rat has shown that after electrical stimulation which 
resulted in the growth of new microvasculature. The glycocalyx is continuous in only 10% 
of the capillaries and totally absent on 44%-58% of the angiogenic capillaries. The fact 
that new born vessels have less glycocalyx may lead to hyper permeability. 136  
ESRD patients have a significantly increased density of small vessels and capillaries in the 
peritoneal membrane compared with normal controls and this morphological change 
tends to be more severe in PD patients. 99, 100 Angiogenesis is an important cause of 
increase in membrane surface area and is thought to contribute to type III high PSTR.  
In fact, it is found that the dialysate appearance of VEGF correlated with albumin and IgG 
clearances, as well as with small solute transport, while it is not clear whether it is a result 
of the increased effective surface area. 118 In theory, as mentioned before, new vessels 
also tend to be leaky. However based on the limited longitudinal data about peritoneal 
leak, the peritoneal Pcl tends to be stable through the time on PD 69, 72 while the small 
solutes transport rate, a measure of membrane area, increases with time. Actually, it is in 
keeping with the findings by Numata, M. that no statistical relationship was found 
between the dialysate and plasma ratio for albumin and relative microvessel area or 
relative microvessel number, which represents the degree of angiogenesis. 102  
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1.3.3.4.3 Hemodynamic factors 
According to the Starling Equation and three-pore model, intracapillary hydrostatic 
pressure is one of the determinate factors of capillary Pcl. Local intracapillary hydrostatic 
pressure is determined by both systemic and local factors and it is different between 
organs. We will focus on peritoneal cavity.  
Intracapillary hydrostatic pressure is highest at the arteriolar end of the capillary and 
lowest at the venular end. The average capillary hydrostatic pressure is determined by 
arterial and venous pressures and also by the ratio of post-to-precapillary resistances. The 
signaling molecules released by endothelial cells act on the smooth muscle cells in the 
walls of nearby vessels and take part in the control of vascular resistance. It is also 
affected by the autonomic nervous system and the viscosity of blood. Pre-capillary 
(mainly arteriolar) vasodilation increases intracapillary hydrostatic pressure and post-
capillary vasodilation decreases it. An increase in either arterial or venous pressure will 
increase intracapillary pressure. Change in venous pressure has more effect on 
intracapillary pressure changing because venous resistance is relatively low and pressure 
in veins is easily transmitted to the capillary in general. 77 However, in the case of PD, at 
least for visceral peritoneum, because the venous pressure is coupled with 
intraperitoneal hydrostatic pressure, which is also coupled with interstitial hydrostatic 
pressure, the importance of venous pressure in net Starling force is decreased. As a whole, 
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both systemic artery pressure and local control of vascular resistance may contribute to 
Starling force of protein in PD. 
Few data are available about the relationship between systemic artery pressure and 
peritoneal Pcl. Data from our centre have shown that pulse pressure is positively related 
to peritoneal Pcl. 61 (Figure 1-8) However, it is difficult to distinguish whether the 
relationship between Pcl and pulse pressure is from the hemodynamic effect or as it 
reflects general vascular damage. 
Figure 1-8 The association between peritoneal protein clearance (Pcl) and pulse 
pressure. 61 
 
Peritoneal vasodilatation is thought to occur in the early phrase of the dwell in PD in most 
of commercially available clinical PD solutions. 137-139 Data from rats have shown that 
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infusion with glucose 4.25% Dianeal (Baxter Healthcare), the most widely used standard, 
low biocompatibility dextrose based commercially available dialysate, results in a 
doubling of the arteriolar flow and a 20% increase of the perfused capillary length per 
area. The glucose 1.5% Dianeal (Baxter Healthcare) fluid induces similar but less 
pronounced changes. 140 No significant difference in Pcl between different dialysates was 
found in acute exposure human studies 141 in spite of the fact that their vasodilatation 
effect is different. Peritoneal blood flow seems to have minor effect on Pcl, 137, 142, 143 
while small solute transport is blood flow limited. 143 It is not clear whether long term 
exposure to elevated blood flow and perfusion pressure will cause structural and 
functional changes as seen in hypertension and diabetic nephropathy. 
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1.4 Hypothesis and research questions 
It is hypothesized that peritoneal Pcl reflects a systemic abnormality of the capillary 
circulation, specifically at the level of the endothelium, rather than evidence of the local 
effects of the process of dialysis treatment which is known to cause local peritoneal 
membrane injury especially with time on therapy. This systemic injury has important 
implications for patient management through its effects on plasma albumin. (Figure 1-9) 
Figure 1-9 hypothesis of the thesis 
 
To test this hypothesis, several focused research questions were developed: 
1. Is peritoneal Pcl related to comorbidity, local peritoneal membrane inflammation 
or both at the commencement of PD? Which of these are predictors of patient 
survival? 
2. Does peritoneal Pcl change with time on PD? If so, is this change over time 
coupled with the known increase in peritoneal membrane area? 
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3. Does the UF obtained with icodextrin – which only occurs via the small pore 
pathway, change with time on PD? If so, is this change over time dissociated from 
the increase in peritoneal membrane small pore area? 
4. What is the relationship between soluble biomarkers of inflammation and 
endothelial damage, systemic transcapillary albumin leak and hypoalbuminaemia 
in PD patients?  
5. What is the relationship between soluble endothelial biomarker pattern, 
hydration status and hypoalbuminaemia in PD patients? 
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Methodology chapter 2.
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2.1 Study setting and cohorts 
Three different patient cohorts were used in this project-the Stoke PD cohort, the 
GLOBAL fluid study (Longitudinal evaluation of peritoneal membrane function, 
inflammation and structural integrity in peritoneal dialysis MREC 02/9/14) cohort and the 
BIA study (Developing Bioimpedance (BIA) as a tool for fluid management in Peritoneal 
Dialysis Patients: A validation Study ClinicalTrials.gov NO: NCT00801112) cohort.  The 
study specific eligible and exclusive criteria were described in each study.  
2.1.1 The Stoke PD cohort 
This was a single centre, longitudinal, observational cohort. The data were prospectively 
collected since 1990. Peritoneal membrane function using peritoneal equilibration test 
(PET) and dialysis adequacy were routinely measured within the first one or two months 
of treatment, and then usually at 6 monthly interval unless prevented by acute illness or 
subject availability. The information about PD prescription, ultrafiltration (UF) of each 
exchange and urine volume on the day of dialysis adequacy test was recorded.  Baseline 
data including demography, primary renal disease and comorbidity, were recorded when 
commencing PD.    
There was a major change in clinical policy in June 1998. Before June 1998, vast majority 
of the patients had been treated with CAPD and glucose based solutions. The clinical 
policy has changed since then. In brief, an increasing proportion of patients were treated 
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with APD, particularly when anuric and with difficulties in achieving clearance target of 
60L/week/1.73m2, as described in the European Automated Peritoneal Dialysis Outcome 
Study. Patients’ choice, mainly related to their life style, was also taken into concern in 
the modality choice (APD or CAPD). Icodextrin was more likely to be used in faster 
transporters, especially when combined with clinical difficulties of fluid management. No 
more than one bag of icodextrin was used per day. 95 Apart from this major practice 
change in 1998, it is also important to note the drift of the prevalent PD cohort, which 
generally accompanied with the global change of PD therapy. For example, there were 
more diabetic patients on PD therapy compared with 20 years ago (Figure 2-1). (Data 
censored at Oct 2010) 
Figure 2-1 the prevalent Stoke PD cohort and the change of practice pattern (Jan 
1990-Oct 2010) 
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2.1.2 The GLOBAL fluid study cohort 
The GLOBAL Fluid Study was a multi-centre, multi-national prospective, cohort study. 
Samples of dialysate and plasma and complete clinical phenotype were prospectively 
collected when patients were undergoing routine pre-determined clinical assessments of 
membrane function. Baseline data and samples were collected within three months of 
treatment start. The clinical characteristics, including membrane function, biochemistry 
profiles and comorbidity were estimated locally. Dialysate and plasma samples were sent 
to central lab for inflammation cytokine measurements.  
2.1.3 The BIA study cohort 
The BIA study was a multicentre, prospective, randomized controlled trial. The detailed 
study design is shown in appendix. (chapter 9.3) It was a prevalent cohort. The baseline 
data in the three UK centres was used in this project. The three UK centres were 
University Hospital of North Staffordshire, St. James’s University Hospital and Sheffield 
Kidney Institute Northern General Hospital. All of them were university hospitals with 
well established PD programmes. The patients in the study were clinically stable and with 
optimal fluid status from clinical point of view.  
The clinical characteristics, including membrane function, biochemistry profiles and 
comorbidity were estimated locally. The blood samples were sent to University Hospital 
of North Staffordshire shortly after being collected for biomarker analysis. 
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2.2 Measurement of biomarkers 
2.2.1 Luminex 
Luminex suspension array system (Bio-Rad) was used in this project to measure a panel of 
soluble endothelial biomarkers. The system is fundamentally a bead-based ELISA. The 
microsphere beads contain a 2-dye fluorescent variable intensity, which creates a 100-
distinct bead set, each of which is coated with a specific capture antibody. The capture 
antibodies bind to analyte, which are then tagged by fluorescent reporter labels. The 
beads pass through 2 laser column. One laser column excites the internal dyes marking 
the microsphere set. The other laser column detects the fluorescent dye on the reporter 
molecules. (see Figure 2-2) 
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Figure 2-2 principle of Lumenix 
 
(Adapted from http://www1.imperial.ac.uk/resources/6DB4DBCF-7A48-4655-85ED-
21C3E2C63932/) 
The assay procedure were followed the manufacturer’s recommendation.  It was read on 
a Bio-Plex 200TM system (Bio-Rad). Duplicate measurement was carried out. For those 
with more than 10% difference between the duplicated wells, the measurements were 
repeated. The quality was also controlled by the in-house Quality Control. Two Quality 
Controls with known concentration were available in each kit. Interleukin-6 (IL-6), tumour 
necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), CD40 ligand (CD40-L) and 
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vascular endothelial growth factor (VEGF) were measured by Human cytokine/chemokine 
MAP multiplex kit (Millipore corporation, USA). The brief description of the protocol was 
as following. 
2.2.1.1 Preparation of samples 
The plasma samples were removed from storage at -20°C and were thawed at 4°C. 
Samples were centrifuged at 13,200 rpm for 10 minutes at 4°C to clear the precipitate.  
2.2.1.2 Preparation of antibody-immobilized beads 
1. Sonicate each antibody-bead vial for 30 seconds and vortex for 1 minute.  
2. Add 60 μl from each antibody bead vial to the mixing bottle (60×5=300μl) and 
bring final volume to 3.0ml with bead diluent (2.7ml).  
3. Vortex the mixed beads for 1 minute. 
2.2.1.3 Preparation of Quality Controls 
Reconstitute quality control 1 and quality control 2 with 250 μl deionized water. Invert 
the vial several times and vortex for 30 seconds.  
2.2.1.4 Preparation of Wash Buffer 
Vortex the 10X Wash Buffer for 1 minute to bring all salts into solution. Dilute 30 ml of 
10X Wash Buffer with 270ml deionized water.  
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2.2.1.5 Preparation of Serum Matrix 
Add 1.0 ml deionized water to the bottle containing lyophilized Serum Matrix. Invert the 
vial several times. 
2.2.1.6 Preparation of Standard 
Reconstitute the Human Cytokine Standard with 250 μl deionized water. Invert the vial 
several times and vortex for 10 seconds. After sitting the vial for 10 minutes, transfer the 
standard to the polypropylene microfuge tube labeled as S1, which serve as the highest 
standard (10000pg/ml). 
Add 200 μl of Assay Buffer to each of the five tubes labeled as S2-S6. A 1 in 5 series 
dilution was carried out by transferring 50 μl of solutions from the tube ahead to the next 
one. The Standard Concentration was as following, S1-10000pg/ml, S2-2000pg/ml, S3-
400pg/ml, S4-80pg/ml, S5-16pg/ml, S6-3.2pg/ml. Assay Buffer was used for background 
(S7-0pg/ml). 
2.2.1.7 Assay procedure 
1. Bring all diluted standards, samples and controls, and buffer solutions to room 
temperature 20 minutes prior to use. Sit the plate on a plate holder so that the 
bottom of the plate does not touch any surface during the whole assay process. 
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2. Pre-wet the 96-well filter plate with 200 μl of Assay Buffer. Seal and shake the 
plate on a plate shaker for 10 minutes. Remove Assay Buffer by vacuum. Blot 
excess fluid from the bottom of the plate with paper towels.  
3. Add 25 μl of each Standard or Control into the appropriate wells.  
4. Add 25 μl of Assay Buffer to the sample wells 
5. Add 25 μl of Samples to the sample wells 
6. Add 25 μl of Serum Matrix to background, standards and control wells 
7. Vortex Mixing Bottle for 1 minute. Add 25 μl of the Mixed Beads to each well.  
8. Seal the plate with a plate sealer and wrap it on the plate shaker together with the 
plate holder. Shake on the plate shaker for 1 hour at room temperature.  
9. Remove fluid by vacuum. 
10. Wash the plate with 200 μl of Wash Buffer per well and remove Wash Buffer by 
vacuum. Repeat the wash/vacuum step for 2 times. Blot excess fluid from the 
bottom of the plate with paper towels. 
11. Add 25 μl of Detection Antibodies into each well. 
12. Seal the plate with a plate sealer and wrap it on the plate shaker together with the 
plate holder. Shake on the plate shaker for 30 minutes at room temperature.  
13. Add 25 μl Streptavidin-Phycoerythrin to each well. 
14. Seal the plate with a plate sealer and wrap it on the plate shaker together with the 
plate holder. Shake on the plate shaker for 30 minutes at room temperature.  
15. Remove fluid by vacuum. 
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16. Wash the plate as in step 10 for 2 times.  
17. Add 150 μl of Sheath Fluid to each well.  
18. Resuspend the beads on a plate shaker for 5 minutes.  
19. Run the plate on Bio-Plex 200TM system (Bio-Rad). 
2.2.2 ELISA 
ELISA was applied in this project to measure MMP 8, MMP 9 (in the BIA study) and 
platelet factor (PF) 4. Duoset Human ELISA kits (R&D Systems, Minneapolis, USA) based 
on a sandwich ELISA method were used.  It was read on a TiterTek Multiskan Plus MKII 
microplate reader (Flow Laboratories Ltd., Richmansworth, UK). The assay was run 
following the manufacturer’s standard protocol. Duplicate measurement was carried out. 
For those with more than 10% difference between the duplicated wells, the 
measurements were repeated. Plasma samples were used in all three biomarkers. A pre-
assay was run to decide the best sample dilution rate. The dilution rate for MMP8, MMP9 
and PF4 was 1:2, 1:400 and 1:4900. 
A brief MMP8 ELISA procedure is descripted as following. 
2.2.2.1 Plate Preparation  
1. Capture antibody (Mouse anti-human MMP-8) was reconstituted with 1 ml of PBS. 
The reconstituted capture antibody (360 μl/ml) was stored at 4°C. It was further 
diluted to a working concentration of 2.0μg/mL in PBS. 100 μl of the diluted 
 86 
 
capture antibody was added into each well of a 96-well microplate (Costar 3590, 
Corning Incorporated, NY, USA) to coat the plate. The plate was sealed with foil 
and incubated overnight at room temperature.  
2. Aspirate each well and wash with was wash buffer. Washing was carried out 4 
times. Each wash step was performed by filling each well with 300 μl of Wash 
Buffer (0.05% Tween® 20 in PBS) and removing the liquid by inverting the plate 
and blotting it against clean paper towels.  
3. 300 μl of Reagent Diluent was added into each well and the plate was incubated at 
room temperature for a minimum of 1 hour to block the plate. 
2.2.2.2 Sample preparation 
The plasma samples were removed from storage at -20°C and were thawed at 4°C. For 
MMP8, sample dilution was done on the plate by adding 50 µL of plasma and 50 µL of 
reagent diluent into each sample well. (For MMP9 and PF 4 sample dilutions were done in 
the sample preparation step.) 
2.2.2.3 Standard preparation 
Reconstitute Recombinant Human MMP-8 with 0.5 mL of deionized water to a 
concentration of 120ng/mL. A seven point standard curve was prepared by using 2-fold 
serial dilutions with reagent diluent. The high standard was at 4000 pg/mL. 
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2.2.2.4 Biotinylated Detection Antibody preparation 
Reconstitute Biotinylated goat anti-human MMP-8 with 1.0 mL of reagent diluent to a 
concentration of 36μg/mL. A working concentration of 200 ng/mL was prepare 1-2 hours 
prior to use with reagent diluent with 2% heat inactivated normal goat serum (NGS).  
2.2.2.5 Streptavidin-HRP 
Dilute to the working concentration of 1:200 using reagent diluent. 
2.2.2.6 Assay Procedure  
1.Add 100 µL of standards in Reagent Diluent or diluted samples (50 µL plasma and 50 µL 
reagent diluent) per well. Cover with an adhesive strip and incubate 2 hours at room 
temperature. 
2.Repeat the aspiration/wash as in step 2 of Plate Preparation. 
3.Add 100 µL of the Detection Antibody, diluted in Reagent Diluent with NGS, to each well. 
Cover with a new adhesive strip and incubate 2 hours at room temperature. 
4.Repeat the aspiration/wash as in step 2. 
5.Add 100 µL of the working dilution of Streptavidin-HRP to each well. Cover the plate 
with a lightproof adhesive strip to avoid direct light and incubate for 20 minutes at room 
temperature.  
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6.Repeat the aspiration/wash as in step 2. 
7.Add 100 µL of Substrate Solution to each well. Incubate for 20 minutes at room 
temperature with a lightproof adhesive strip to avoid direct light. 
8.Add 50 µL of Stop Solution to each well. Gently tap the plate to ensure thorough mixing. 
9.Determine the optical density of each well immediately, using the TiterTek Multiskan 
Plus MKII microplate reader set to 550 nm for wavelength correction and 450 nm for 
result-obtaining.  
2.2.3 Mesoscale Discovery Platform (in GLOBAL cohort) 
IL-1β, TNF-α, IFN-γ and IL-6 in GLOBAL cohort were measured by the GLOBAL study group. 
Electrochemiluminescence immune assay was used. It was carried out by the 
commercially available Pro-Inflammatory I 4-plex (Meso-Scale Discovery, Gaithersburg, 
Maryland, USA).  
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2.3 Measurement of systemic albumin leak – Transcapillary 
escape rate of 125-I albumin (TERalb) 
Transcapillary escape rate of 125-I albumin (TERalb) was measured by the Medical Physics 
department in University Hospital of North Staffordshire. The method was also applied 
for clinical purposes as a measurement of plasma volume to normalise the red cell mass 
mainly for diagnosis of primary polycythaemia. 
In brief, after a bolus intravenous injection of 10ml 0.185MBq 125I-human serum albumin 
(HSA), blood samples were taken at 10, 20, and 30 min at a remote venous site. The 
isotopic concentration in each case was plotted against time on a semi-logarithmic scale 
and the best linear fit line was performed from these points. TERalb, expressed as 
percentage loss per hour (%/h) was estimated from the disappearance rate of the 125I HSA 
from the gradient of this line. The plasma volume was calculated by extrapolating the line 
to time zero. (Figure 2-3)  
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Figure 2-3 calculate TERalb from the disappearance rate of the 125I HSA from a on a 
semi-logarithmic plot   
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2.4 Measurement of body composition 
2.4.1 Deuterium Oxide (D2O) dilution technique 
The D2O dilution technique was used for absolute measurement of total body water 
(TBW) in the project (chapter 6).  It has been described in detail previously.144, 145 In brief, 
following a baseline blood sample, an oral dose of 99.8% D2O (15-45 ml according to 
body weight, Cambridge Isotope Laboratories) was administered. Two and a half hours 
later, when D2O was equilibrated to TBW, a second blood sample was taken from the 
same cannula. Whole blood samples were stored for further measurement. Based on the 
facile exchange of deuterium/hydrogen with the hydronium ions, H3O+, their hydrates 
H3O
+.(H2O) and water vapour in the gas phase, the blood headspace D abundance was 
measured by Flowing Afterglow Mass Spectrometer (FA-MS). The more detailed principle 
of FA-MS has been described previously. 146 The difference between baseline and 
equilibrated blood D2O concentration was used to determine TBW. A 4% reduction was 
taken to account for the H-D exchange that occurs between the HDO with carboxyl and 
amino groups in body proteins. 147, 148   
2.4.2 Bioimpedance analysis (BIA) 
Estimated total body water (TBW) and extra-cellular water (ECW) were evaluated by the 
multi-frequency bioimpedance  device (BIA, multi-frequency Xitron Hydra device, Model 
4200, Xitron Technologies, San Diego, CA) in pilot biomarker study (Chapter 6). No dialysis 
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fluid was in the peritoneal cavity during measurement.TBW and ECW were derived based 
on the manufacturer’s impedance algorithm. 
The single frequency (50Hz) BIA device (Akern BIA 101 Anniversary) was used in the 
multicentre BIA study (chapter 7) for estimated TBW and ECW measurement. The patient 
might present with or without PD fluid in the peritoneal cavity when the measurement 
was carried out but this was consistent during the follow up. The resistance and reactance 
of the whole body were recorded. TBW and ECW were calculated by formula which had 
good agreement with the manufacturer’s algorithm. (see appendix for detail - chapter 9.4) 
The measurements were carried out according to the operating manuals, respectively. 
The measurement procedure was similar.  In brief, patients lay in a supine position on the 
couch for at least 2 minutes. The electrodes were placed between the ipsilateral bony 
prominences of the wrist and of the ankle with at least 5 cm apart. (Figure 2-4) An 
alternating current passed through the body. The resistance and reactance of the whole 
body were measured for further calculation of TBW and ECW.  
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Figure 2-4 A schematic diagram showing the placement of adhesive pads in BIA 
measurement 
 
 
Adapted from the manual of Akern BIA 101 Anniversary 
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2.5 Measurement of peritoneal membrane function, 
ultrafiltration and peritoneal Pcl in Stoke 
2.5.1 Peritoneal equilibration test (PET) 
We estimated PSTR through measuring dialysate:plasma ratio of creatinine (D/P 
creatinine)  at the end of a standard 2L, 2.27%, 4 hour dwell in peritoneal equilibration 
test (PET).  Net UF from this standard dwell was used as a measure of UF capacity. 
The clinical laboratory upgraded the methodology of measuring plasma creatinine from 
the Oleary method to an enzymatic method on 29th Oct 2008 and the methodology of 
dialysate creatinine had not changed during the study period. This methodology change 
gave an about 0.06 decrease in D/P creatinine. The data had been carefully adjusted for 
longitudinal analysis. See appendix (chapter 9.2)  for detail about this methodology 
change.   
2.5.2 Peritoneal protein clearance (Pcl) 
The peritoneal dialysate protein loss was measured from the collection of 24-hour 
peritoneal dialysate effluent. A validated correction factor was used for the calculation of 
peritoneal Pcl: 24 hour dialysate protein loss / (serum albumin/0.4783). 68 Pcl was 
expressed as mL/day. 
Plasma albumin levels had been measured using the bromocresol green method before 
22th Aug 2007 and was switched to bromocresol purple method afterward. Both 
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methods were run on the Siemens ADVIA 2400 platform. In 86 patients, who had plasma 
albumin measured once within 12 months before and once within 12 months after the 
switch data (22th Aug 2007), an average difference of 5.45g/L was found by paired t test 
(P<0.0001). It fits with the observation by Catherine M. Clase et al, where the average 
difference between the two methods in the same sample was 5.5g/L149 So the convert 
equation, Albbromocresol green=5.5+Albbromocresol purple was used in the study. 
2.5.3 Measurement of ultrafiltration (UF) 
For APD, the UF volume was measured by the APD device. Net UF volume from CAPD was 
accessed by weighing the drainage bag, converting the weight into volume by multiplying 
the specific gravity of 1g/ml and subtracting the expected input volume accounting for 
the average ‘overfill’, which had consistently been measured at 200mls in Stoke. 
Two common issues in measurement of UF have been noticed and carefully addressed or 
acknowledged. Firstly, the ‘overfill’ has been accounted in all of the Stoke cohort based 
studies. It may explain part of the centre effect in the multicentre cohorts. Secondly, the 
specific gravity issue has been noted. The specific gravities of the input and output 
dialysate are different from pure water and it is related to the glucose concentration and 
type of dialysate. See details in appendix. (chapter 9.1) 
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2.6 Statistical analysis 
The study specific statistical methods were described in each study. Multilevel modelling 
and principal component analysis (PCA) combined with hierarchical clustering analysis 
(HCA) were the two main statistical strategies used in the project. The characteristics and 
general approach of the two strategies are summarized as follows.  
2.6.1 Multi-level analysis 
2.6.1.1  Characteristics 
Multi-level modeling is essentially an extension of ordinary multiple regression modeling 
but with special design for data sets with a clustered (hierarchical) structure. (Figure 2-5) 
The importance of recognizing the clustering nature of the data has been recognized for 
long time and has been viewed as a problem in the statistics world. Multi-level modeling 
is a strategy specially designed for this and more importantly, it allows additional features 
of the data to be exploited. (refer to http://www.bristol.ac.uk/cmm/software/mlwin/) 
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Figure 2-5 an example of mulit-level structure   
 
2.6.1.1.1 The situations that multi-level structure has to be considered 
One critical assumption of the single-level multiple regression model is that each 
observation should be independent. From a statistical point of view, the residuals should 
be uncorrelated with one another. It is obviously not the case in the longitudinal cohort 
study. The series observations from the same individual would be expected to highly 
correlate with each other. One potential option is to have a set of dummy variables for 
groups. This approach works well when there are only a few groups. However, in the 
longitudinal cohort studies (eg. chapter 4 and 5), each patient would be a group and 
numerous additional dummy variables would be needed in the model. Because of the 
small number of the observation from each patient the estimates of the coefficients of 
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the dummy variables for each patient may be unreliable. Hence, a multi-level structure 
has to be considered here.  
2.6.1.1.2 The missing data issue 
The repeated measures ANOVA or paired t-test is the traditional way of analyzing 
longitudinal data. However, they both encounter the problem of missing data. To fit the 
assumption of these methods, each individual in the study should have measurement in 
each measurement occasion. The general recommendation is to delete the cases with 
missing data in one or more observations in a list-wise or case-wise manner or fill the gap 
with some assumptions. It works reasonably well especially in short term randomized 
controlled trial. However, it is clearly not suitable in our long term observational cohort 
study.  
2.6.1.1.3 Not just controlling for the clustering but also exploring it 
If one just wants to control the clustering problem, eg, auto-correlation within individual 
in repeated measurement, some other approach can also be used. However, those 
methods generally treat clustering as a nuisance rather than something of potential 
interest on its own. In our case, the effect of patient level characteristics on the 
observational level dependant variable is clearly very much of our interest. Whether the 
change of the dependant variables vary across individuals is also part of our research 
question. The proportion of variance in each level in the total variance is also of interest, 
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eg, within patient variance vs between patient variance.  The multi-level approach 
enables us to answer these questions.   
2.6.1.2  General approach 
The multi-level modeling was performed using MLwin software (Version 2.22, Centre for 
multilevel modeling University of Bristol). Repeat observations (level 1) were nested 
within individuals (level 2).The target of constructing a model was searching for the best, 
most simple combination of independent variables to predict the dependent variable. 
Wald tests were used to test the statistical significance of the fixed effects. Nested 
models were compared by likelihood ratio test. (A nested model is an extreme case or 
restricted version of a more complex model. In other words, nested models can be 
obtained by restricting a parameter in a more complex model to be zero.) Intercepts were 
set as random in level 1 if without specific notice. The independent variables were tested 
and gradually included in the model if they were significantly related to either the 
dependent variables on the uni-level bivariate correlation or the plausible explanatory 
variables according to theoretic model or other studies.   
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2.6.2 Hierarchical clustering analysis (HCA) and principal 
component analysis (PCA) 
2.6.2.1  HCA 
2.6.2.1.1 Characteristics 
The concept of cluster analysis is to separate a set of objects into groups (clusters) in a 
way that the objects in the same cluster are more similar to each other than to those in 
other clusters. HCA is one of the most widely used methods of clustering analysis 
especially in a relatively small data set. Clustering is a main step of explorative data 
mining. No assumption is made about the underlying distribution of the data and even 
the number of groups. The objects clustered together depend on the similarity or 
distance of their characteristics. 150 
Cluster analysis has been more popular in large scale gene expression analysis and it 
enables the investigation of mechanisms of fundamental processed by identifying 
differential gene expression pattern. 150 This idea was used in biomarkers in the present 
project. The pattern of biomarkers was identified and enabled further investigation of 
underlying process.  
2.6.2.1.2 General approach 
Genesis software (version 1.7.2, Alexander Sturn, Institute for Genomics and 
Bioinformatics, Graz University of Technology) was used to carry out HCA. The biomarker 
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concentrations were first converted to Log2 and expressed relative to the mean value for 
normalization. Heat maps were used to visualize the biomarker levels. A two-way 
hierarchical clustering method was run with an agglomerative procedure and followed 
the average linkage clustering agglomeration rule. 
2.6.2.2  PCA 
2.6.2.2.1 Characteristics 
PCA is a useful statistic technique to reduce a number of observed variables into a smaller 
number of artificial variables and contain most of the variance in the data set. It makes no 
assumptions about the underlying causal structure.  
1. A variable reduction procedure  
In brief, a principal component is a linear combination of optimally weighted 
original variables. The phrase ‘linear combination’ refers to the fact that scores on 
a component are the sum of the scores on original variables. The phrase ‘optimally 
weighted’ refers to the fact that the observed variables are weighted in such a 
way that the output components account for a maximal amount of variance in the 
data set. The weight is in proportion to the strength of the relationship between 
the generated PC and original variables. 
The first component extracted in a PCA accounts for a maximal amount of total 
variance in the data set. The second component extracted accounts for a maximal 
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amount of variance in the residual variance after extracting the first component. 
Eigen value is a measure of the amount of variance that is accounted for by a 
certain PC. 
2. no assumptions about the underlying causal structure 
Factor analysis is similar to PCA in the sense that both are variable reduction 
methods. However, the assumption behind it is quite different. Factor analysis 
assumes that the covariation in the observed variables is due to the presence of 
latent variables (factors) that exert causal influence on the observed variables, 
while PCA makes no assumption about an underlying causal structure. The PCs are 
selected based on an eigen value cut-off of 1.0.  
2.6.2.2.2 General approach 
PCA were carried out with IBM SPSS Statistics version 19. Principal components (PCs) 
were extracted using varimax rotation, with the factor selection based on an Eigen value 
cut-off of 1.0. A score was calculated for each subject on each given PC, so called PC score. 
The calculated PC scores were used in further analysis. 
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Is peritoneal protein clearance related to chapter 3.
comorbidity, local peritoneal membrane inflammation or 
both at the commencement of PD? Which of these are 
predictors of patient survival? 
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3.1 Summary 
3.1.1 Purpose 
This study was to investigate whether peritoneal protein clearance (Pcl) was related to 
comorbidity, local peritoneal membrane inflammation or both at the commencement of 
PD and further clarify the link between Pcl and patient survival. 
3.1.2 Method 
Incident PD patients from three centres of the GLOBAL Fluid Study were included in this 
analysis. The patients were enrolled from 2002-2008 and followed up until death or 
censoring at the end of 2011. Demography, co-morbidities and biochemical data were 
collected prospectively as well as baseline peritoneal equilibration test (PET), 
measurement of dialysis adequacy and 24-h dialysate Pcl. Paired plasma and dialysis 
effluent samples were collected at the time of PET. Interleukin-1β (IL-1β), tumor necrosis 
factor-α (TNF-α), interleukin-6 (IL-6) and interferon-γ (INF-γ) were measured by the 
GLOBAL study group. Multivariate mixed linear analysis identified factors associated with 
Pcl. A Cox model was used to identify factors associated with survival. 
3.1.3 Results 
A total of 257 incident PD patients were studied. Peritoneal Pcl was positively related to 
age and higher in those with severe comorbidity. It was positively related to PSTR, plasma 
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and dialysate IL-6 in the univariate analysis. Dialysate IL-6 appearance rate, comorbidity 
grade and PSTR were independent explanatory variables for Pcl in the multivariate model. 
Both Pcl and daily peritoneal protein loss predicted survival in the Cox’s proportional 
hazards regression. Pcl, plasma IL-6, age and comorbidity were independent predictors 
for survival. Daily peritoneal protein loss lost the significance as a predictor of survival, 
especially when adding plasma albumin into the model. 
3.1.4 Conclusion 
Peritoneal Pcl is a function of peritoneal membrane area, local membrane inflammation 
and comorbidity in patients commencing PD. The effect of comorbidity on Pcl is partly 
explained by the association between hypoalbuminaemia and comorbidity, but they are 
different by type of comorbidity. The high peritoneal Pcl predicts worse outcome. This 
prediction is not due to the local factors but to its relationship to hypoalbuminaemia and 
comorbidity. It is again complex and different by type of comorbidity. 
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3.2 Introduction 
Peritoneal protein clearance (Pcl) has been proved to be related to comorbidity in several 
studies. Johansson used the method of personal dialysis capacity (PDC) test 69 which is 
based on the three-pore theory of capillary transport to identify large-pore flow, termed 
the large pore fluid flux (JVL). They found that large-pore flow was greater in patients with 
severe comorbidity than in patients with fewer comorbid conditions. Heaf, using the 
same method observed that JVL was greater in older patients and those with 
cardiovascular comorbidity and also a predictor of poor survival. 72 Van Biesen showed 
that JVL was related to inflammation and predicted survival. 
71 The observation by Szeto 
showed that a single measure of dialysate albumin >300mg/l was associated with 
increased cardiovascular events. 70 More recently, peritoneal Pcl was confirmed to relate 
to peripheral arterial disease by Sanchez-Villanueva 73 and Perl61. Regarding the 
relationship to survival, most of the above studies also showed that high Pcl is related to 
worse outcome. However, data from a Netherland group, showed that baseline 
peritoneal albumin and protein clearances from a 4 hour dwell with 3.86% glucose 
dialysate were associated with signs of comorbidity but no measurable effect on patient 
survival could be found. 74  
The potential link between peritoneal Pcl and comorbidity or survival was not clear. This 
study was to investigate whether Pcl was related to comorbidity, local peritoneal 
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membrane inflammation or both at the commencement of PD and further clarify the link 
between Pcl and patient survival. 
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3.3 Methods 
3.3.1 Study design and patient population 
This was an analysis based on GLOBAL Fluid study. In short, the GLOBAL Fluid study is a 
multi-centre, multi-national prospective, cohort study. Samples of dialysate and plasma 
and complete clinical phenotype were prospectively collected when patients undergoing 
routine pre-determined clinical assessments of membrane function. Baseline data and 
samples were collected within three months of treatment start. The clinical 
characteristics, including membrane function, peritoneal Pcl, biochemistry profiles and 
comorbidity were estimated locally. Dialysate and plasma samples were sent to central 
lab for inflammation cytokine measurements.  
Three centres were in this analysis, two UK centres and one Korea centre, due to data 
availability. All the patients first commencing PD in these three centres in the GLOBAL 
Fluid study during 2002 to 2008 were included. The patients were followed and outcome 
data were censored at the end of 2011. There were two patients using amino acid based 
solution and were excluded from the analysis because of the interfering of measurement.  
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3.3.2 Measurement of membrane function and peritoneal 
protein clearance (Pcl) 
Both of the two UK centres used the original 2.27% PET for the measurement of PSTR 
(D/P creatitine) and the Korea centre calculated the PSTR based on 4 hours result from a 
3.86% exchange.  
The peritoneal dialysate protein loss was measured from the collection of 24-hour 
peritoneal dialysate effluent. A validated correction factor was used for the calculation 
peritoneal Pcl: 24 hour dialysate protein loss / (serum albumin/0.4783). 68 Pcl was 
expressed as mL/day. 
3.3.3 Comorbidity  
Comorbidity was documented according to Stoke comorbidity score. 151 Briefly, 7 
comorbid domains were considered, including noncutaneous malignancy, ischemic heart 
disease (IHD), peripheral vascular disease (PVD) (including cerebrovascular and 
renovascular disease), left ventricular dysfunction (LVD), diabetes mellitus (DM) , systemic 
collagen vascular disease, and any other condition known to reduce life expectancy. The 
comorbidity score for each patient was defined as the number of these domains affected. 
The comorbidity grade was then derived from the comorbidity score. Grade 0 (low risk) 
was a zero score, grade 1 (medium risk) was a score of 1-2, and grade 2 (high risk) a 
cumulative score of ≥ 3. 
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3.3.4 Measurement of inflammatory cytokines 
IL-1β, TNF-α, IFN-γ and IL-6 in GLOBAL Fluid study cohort were measured by the GLOBAL 
Fluid study group. In brief, paired plasma and dialysis effluent samples were measured in 
the study. Four pro-inflammation cytokines were selected to represent the inflammatory 
status, which were IL-1β, TNF-α, IL-6 and INF-γ. Both plasma and dialysis effluent samples 
were measured by electrochemiluminescence immune assay. It was carried out by the 
commercially available Pro-Inflammatory I 4-plex (Meso-Scale Discovery, Gaithersburg, 
Maryland, USA). For correlation and comparisons, dialysate appearance rate (AR) of 
cytokines was calculated as dialysate concentration times the drained volume and divided 
by dwell time. 
3.3.5 Statistical Analysis 
Continuous data were expressed as mean values ± SD for normal distributed variables and 
medium (inter-quartile range) for non-normal distributed variables. One way ANOVA or 
Student’s t-test were used to examine differences in normal distributed continuous data 
among baseline categorical variables, while Mann-Whitney or Kruskal-Wallis test for non-
normal distributed variables. The relationship between peritoneal Pcl and continuous 
variables was examined by Pearson correlation coefficient. Variables not in normal 
distribution were logarithms transformed for further analysis.  
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Mixed linear model was used to identify the determinants of peritoneal Pcl. Multi-level 
strategy was applied to account for the centre effect. Centre was set as a second level 
with patient nested within centre. Cox regression was applied for survival analysis.  
Significance was considered at P values ≤ 0.05. All statistical analyses were performed 
using SPSS 16 (SPSS Inc., Chicago Ill., USA) apart from the mixed linear model, which was 
performed by MLwin software (Version 2.22, Centre for multilevel modeling University of 
Bristol).  
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3.4 Results 
3.4.1 The patient and membrane characteristics  
A total of 257 patients in the three centres were included in the study. Table 3-1 displays 
the main baseline characteristics. There were significant differences between centres in a 
variety of variables, including BMI, comorbidity, PSTR, residual renal function and 
biochemical characteristics and all the plasma and dialysate cytokines levels. The dialysis 
regime was also different among centres. 
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Table 3-1 Patient demographic and biochemical characteristics, peritoneal membrane 
function and systemic and dialysate inflammatory cytokines 
  G05 (n=77) G01 (n=57) K03 (n=123) P value
a
 
Age (yr) 56.3±15.3 57.1±14.3 53.3±14.6 NS 
Gender (M/F) 47/30 37/20 72/51 NS 
BMI (kg/m
2
) 27.0±5.4 28.2±4.5 23.4±2.9 P<0.01 
Comorbidity Grade n (%)       
P<0.01 
Low 23 (29.9%) 26 (45.6%) 49(40.0%) 
medium 43 (55.8%) 27 (47.4%) 73 (59.2%) 
high 11 (14.3%) 4 (7.0%) 1 (0.8%) 
    
DM (yes/no) 27/50 14/43 59/64 P<0.01 
Day of PET(day) 42±20 25±19 38±14 P<0.01 
Alb (g/L) 35.8±4.2 37.6±4.7 33.4±5.1 P<0.01 
Hgb (g/L) 11.9±1.5 11.4±1.4 8.7±2.4 P<0.01 
Urine volume (ml) 1203±785 1324±813 1027±620 P<0.05 
PSTR 0.77±0.14 0.60±0.12 0.73±0.10 P<0.01 
CAPD/APD 59/18 57/0 123/0 P<0.01 
icodextrin (with/without) 20/57 0/57 16/107 P<0.01 
bicarbonate buffered 
solution (with/without) 
2/75 28/29 21/102 P<0.01 
Peritoneal Pcl (ml/day) 89.9±33.6 89.7±46.2 95.5±48.3 NS 
Dialysate IL-1β AR (pg/min) 0(0-0) 0(0-2.12) 0(0-0.32) P<0.01 
Dialysate TNF-α AR 
(pg/min) 
0(0-1.78) 3.30(1.15-8.64) 1.69(0.28-5.62) P<0.01 
Dialysate IL-6 AR (pg/min) 32.91(8.81-59.58) 41.66(23.05-90.59) 73.89(30.65-134.98) P<0.01 
Dialysate INF-γ AR (pg/min) 10.52(0-46.42) 0(0-15.15) 0(0-3.28) P<0.01 
plasma IL-1β (pg/ml) 0.12(0.06-0.26) 0.01(0-0.07) 0.05(0-0.21) P<0.01 
plasma TNF-α (pg/ml) 7.21(5.69-8.71) 8.30(6.68-9.66) 17.61(15.38-21.98) P<0.01 
plasma IL-6 (pg/ml) 1.53(0.70-2.76) 0.80(0.24-2.25) 1.97(1.20-3.70) P<0.01 
plasma INF-γ (pg/ml) 0.97(0.37-1.56) 0.65(0-2.21) 2.16(1.33-3.95) P<0.01 
a, One way ANOVA in normal distributed continuous data, Mann-Whitney test for non-normal 
distributed variables, chi-square test for the comparison of categorical variables  
BMI, body mass index; PSTR, dialysate/plasma creatinine; Pcl, protein clearance. 
Comorbidity Grade – Davies Comorbidity grade as defined previously 
AR, appearance rate 
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3.4.2 Univariate correlation to peritoneal Pcl  
The univariate correlations between peritoneal Pcl and patient and membrane 
characteristics, as well as dialysate and plasma inflammatory cytokines are presented in 
Table 3-2. Peritoneal Pcl was positively related to age and PSTR (Figure 3-1). A strong 
negative correlation was seen between peritoneal Pcl and serum albumin, in part a 
function of mathematical coupling. There was no statistically significant correlation 
between peritoneal Pcl and 24 hours urine volume. No significant difference of peritoneal 
Pcl was found between patients using icodextrin or not, using biocompatible solute or not 
and on CAPD or APD.  
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Table 3-2 univariate associations between peritoneal Pcl and patient and membrane 
characteristics, plasma and dialysate inflammatory cytokines 
  βa P value 
Age (yr) 0.145 0.02 
BMI (kg/m2) 0.045 0.477 
Serum albumin (g/L) -0.474 <0.01 
PSTR 0.441 <0.01 
24 hours urine volume (ml) -0.023 0.711 
Dialysate IL-1β AR (pg/min) 0.037 0.551 
Dialysate TNF-α AR (pg/min) 0.141 0.024 
Dialysate IL-6 AR (pg/min) 0.204 0.001 
Dialysate INF-γ AR (pg/min) 0.037 0.551 
plasma IL-1β(pg/ml) 0.02 0.747 
plasma TNF-α(pg/ml) 0.059 0.346 
plasma IL-6 (pg/ml) 0.127 0.043 
plasma INF-γ (pg/ml) -0.013 0.834 
    mean±SD  P valueb 
Gender 
Male 96.3±45.5 NS 
Female 87.4±41.1   
Comorbidity grade 
Low 79.4±37.0 <0.01 
Medium 99.6±43.1   
High 109.7±67.0   
PD modality 
CAPD 92.4±44.6 NS 
APD 94.5±33.9   
icodextrin  
with 92.9±45.1 NS 
without 90.2±35.5   
bicarbonate 
buffered solution 
With 93.6±45.1 NS 
without 88.1±38.5   
a, Pearson correlation coefficient for normal distributed variables and Spearman correlation coefficient 
for non-normal distributed variables 
b, independent samples t-test 
BMI, body mass index; PP, pulse pressure; PSTR, dialysate/plasma creatinine; Ccr, creatinine clearance; 
IL, interleukin; TNF, tumor necrosis factor; INF, interferon; AR appearance rate. 
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Figure 3-1 Pearson correlation between peritoneal Pcl and PSTR (D/P creatinine) 
  
Both dialysate and less strongly plasma IL-6 appearance rate (AR) was positively related to 
peritoneal Pcl. Dialysate but not plasma TNF-α were related to peritoneal Pcl. The 
relationship between peritoneal Pcl and other cytokine profile was not significant. (Table 
3-2 and Figure 3-2) 
Peritoneal Pcl was associated with the severity of comorbidity status. (Figure 3-3) Higher 
peritoneal Pcl was seen in the presence of IHD, DM, and LV dysfunction. No significant 
difference was found in the other comorbid domains. (Figure 3-4) Plasma albumin level 
according to different comorbidity status is also shown in Table 3-3. 
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Figure 3-2 Spearman correlation between peritoneal Pcl and dialysate IL-6 
appearance rate 
 
Figure 3-3 peritoneal Pcl and comorbidity grade (one way ANOVA) 
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Figure 3-4 Pcl and individual comorbid domains (independent samples t-test) 
 
**, P<0.01 
IHD, ischemic heart disease; PVD, peripheral vascular disease; LVD, left ventricular dysfunction 
Table 3-3 Plasma albumin according to comorbidity status 
  DM IHD LVD Malignancy PVD 
collagen 
disease 
without 
comorbidity 36.77±4.37 35.36±5.1 35.21±4.98 35.04±5.11 35.28±5.03 35.02±5.06 
n 157 213 234 250 228 254 
with comorbidity 32.37±4.89 33.59±4.57 33.57±5.66 35.71±2.36 33.31±4.99 38±3.46 
n 100 44 23 7 29 3 
P value
a
 <0.01 <0.05  NS  NS <0.05  NS 
a, unpaired t test 
DM, diabetes; IHD, ischemic heart disease; PVD, peripheral vascular disease; LVD, left ventricular 
dysfunction 
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3.4.3 Multivariate model for peritoneal Pcl  
A Multi-level strategy was taken in the multivariate analysis: Because of the observed 
centre effects, patients (level 1) were nested within centres, (level 2), with constant set to 
be random at both levels to balance the centre difference. Gender, age, comorbidity 
grade, Lg10 dialysate IL-6 AR, Lg10 plasma IL-6 and PSTR were included in the multivariate 
model.  
In the model with peritoneal Pcl as the dependent variable, dialysate IL-6 appearance rate 
(AR), comorbidity grade and PSTR were independent explanatory variables. (Table 3-4) 
Further models substituting separate comorbid domains instead of the overall 
comorbidity grade showed that IHD and LV dysfunction were predictors for peritoneal Pcl, 
but not DM or other comorbidities. 
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Table 3-4 multivariate model for peritoneal Pcl without albumin as one of the 
dependent variblea 
  peritoneal Pcl 
comorbidity grade β  standard error P value 
constant 84.778 7.383 <0.01 
PSTR (for each 0.1 increase)  15.05 2.03 <0.01 
lg Dialysate IL6 AR (for each unit increase) 11.042 4.179 <0.01 
lg Plasma IL6 (for each unit increase) -0.502 2.25 NS 
albumin (for each 1g/L increase)       
Age (year) 0.14 0.167 NS 
gender (compare with female) -1.849 4.806 NS 
Comorbidity Grade 1 (compared with Grade 0) 14.823 4.992 <0.01 
Comorbidity Grade 2 (compared with Grade 0) 24.775 10.211 <0.05 
diabetes       
constant 91.125 6.54 <0.01 
PSTR (for each 0.1 increase)  146.954 20.875 <0.01 
lg Dialysate IL6 AR (for each unit increase) 11.488 4.231 <0.01 
lg Plasma IL6 (for each unit increase) -0.766 2.279 NS 
albumin (for each 1g/L increase)       
Age (year) 0.272 0.166 NS 
gender (compare with female) -0.978 4.873 NS 
diabetes (compared with if not) 7.793 4.971 NS 
IHD       
constant 91.361 6.58 <0.01 
PSTR (for each 0.1 increase)  155.361 20.253 <0.01 
lg Dialysate IL6 AR (for each unit increase) 10.182 4.221 <0.05 
lg Plasma IL6 (for each unit increase) -0.582 2.254 NS 
albumin (for each 1g/L increase)       
Age (year) 0.155 0.169 NS 
gender (compare with female) -1.738 4.813 NS 
IHD (compared with if not) 17.897 6.378 <0.01 
LVD       
constant 92.771 6.334 <0.01 
PSTR (for each 0.1 increase)  154.214 20.22 <0.01 
lg Dialysate IL6 AR (for each unit increase) 10.779 4.201 <0.05 
lg Plasma IL6 (for each unit increase) -1.025 2.254 NS 
albumin (for each 1g/L increase)       
Age (year) 0.224 0.165 NS 
gender (compare with female) -2.294 4.826 NS 
LVD (compared with if not) 22.306 8.128 <0.01 
a, mixed linear model 
DM, diabetes; IHD, ischemic heart disease; LVD, left ventricular dysfunction; Pcl, protein 
clearance; PSTR, peritoneal solute transport rate; AR, appearance rate; IL-6, interleukin-6 
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To exclude the possible impact of plasma albumin, negatively mathematically related to 
peritoneal Pcl, another two sets of models were constructed in which albumin was an 
independent variable in one set (Table 3-5) and daily peritoneal protein loss a dependent 
variable for the other set. (Table 3-6) 
Plasma albumin was strongly related to Pcl in the multivariate model. It diluted the effect 
of the other variables that had been in the model. When presented as comorbidity grade, 
comorbidity was not a significant predictor for Pcl. When looked into each comorbidity 
domain, IHD and LV dysfunction was still significant, although with some decrease in beta 
value. (Table 3-5) 
When replace Pcl by daily peritoneal protein loss as the dependent variable, albumin was 
not an independent predictor for daily peritoneal protein loss. Neither was comorbidity 
grade. However, when looked into separate comorbidity domains, IHD and LV dysfunction 
took over dialysate IL-6 and was the independent predictor. (Table 3-6) 
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Table 3-5 multivariate model for peritoneal Pcl with albumin as one of the dependent 
variblea 
  peritoneal Pcl  
comorbidity grade β  standard error P value 
constant 90.111 7.444 <0.01 
PSTR (for each 0.1 increase)  11.6 2.05 <0.01 
lg Dialysate IL6 AR (for each unit increase) 9.442 3.984 <0.05 
lg Plasma IL6 (for each unit increase) -1.754 2.15 NS 
albumin (for each 1g/L increase) -2.807 0.537 <0.01 
Age (year) 0.057 0.16 NS 
gender (compare with female) 0.353 4.585 NS 
Comorbidity Grade 1 (compared with Grade 0) 6.124 5.026 NS 
Comorbidity Grade 2 (compared with Grade 0) 10.46 10.087 NS 
diabetes       
constant 95.22 7.065 <0.01 
PSTR (for each 0.1 increase)  115.511 20.62 <0.01 
lg Dialysate IL6 AR (for each unit increase) 9.603 3.982 <0.05 
lg Plasma IL6 (for each unit increase) -2.12 2.144 NS 
albumin (for each 1g/L increase) -3.184 0.535 <0.01 
Age (year) 0.084 0.159 NS 
gender (compare with female) 0.602 4.571 NS 
diabetes (compared with if not) -2.766 4.978 NS 
IHD       
constant 91.723 6.836 <0.01 
PSTR (for each 0.1 increase)  116.404 20.354 <0.01 
lg Dialysate IL6 AR (for each unit increase) 8.385 3.973 <0.05 
lg Plasma IL6 (for each unit increase) -1.709 2.12 NS 
albumin (for each 1g/L increase) -2.948 0.498 <0.01 
Age (year) 0.017 0.16 NS 
gender (compare with female) 0.387 4.526 NS 
IHD (compared with if not) 13.943 6.013 <0.05 
LVD       
constant 92.746 6.707 <0.01 
PSTR (for each 0.1 increase)  115.362 20.309 <0.01 
lg Dialysate IL6 AR (for each unit increase) 8.737 3.951 <0.05 
lg Plasma IL6 (for each unit increase) -2.069 2.114 NS 
albumin (for each 1g/L increase) -2.98 0.496 <0.01 
Age (year) 0.067 0.156 NS 
gender (compare with female) -0.087 4.53 NS 
LVD (compared with if not) 18.636 7.622 <0.05 
a, mixed linear model 
DM, diabetes; IHD, ischemic heart disease; LVD, left ventricular dysfunction; Pcl, protein clearance; 
PSTR, peritoneal solute transport rate; AR, appearance rate; IL-6, interleukin-6  
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Table 3-6 multivariate model for daily peritoneal protein lossa 
  daily peritoneal protein loss  
comorbidity grade β  standard error P value 
constant 6.334 0.508 <0.01 
PRST (for each 0.1 increase)  0.83 0.14 <0.01 
lg Dialysate IL6 AR (for each unit increase) 0.552 0.277 <0.05 
lg Plasma IL6 (for each unit increase) -0.123 0.15 NS 
albumin (for each 1g/L increase) -0.006 0.037 NS 
Age (year) 0.009 0.011 NS 
gender (compare with female) 0.008 0.319 NS 
Comorbidity Grade 1 (compared with Grade 0) 0.557 0.35 NS 
Comorbidity Grade 2 (compared with Grade 0) 0.672 0.702 NS 
diabetes       
constant 6.728 0.48 <0.01 
PSTR (for each 0.1 increase)  8.207 1.436 <0.01 
lg Dialysate IL6 AR (for each unit increase) 0.554 0.278 <0.05 
lg Plasma IL6 (for each unit increase) -0.156 0.15 NS 
albumin (for each 1g/L increase) -0.033 0.037 NS 
Age (year) 0.012 0.011 NS 
gender (compare with female) 0.043 0.319 NS 
diabetes (compared with if not) -0.145 0.347 NS 
IHD       
constant 6.497 0.463 <0.01 
PSTR (for each 0.1 increase)  8.291 1.416 <0.01 
lg Dialysate IL6 AR (for each unit increase) 0.467 0.277 NS 
lg Plasma IL6 (for each unit increase) -0.128 0.148 NS 
albumin (for each 1g/L increase) -0.018 0.035 NS 
Age (year) 0.007 0.011 NS 
gender (compare with female) 0.026 0.315 NS 
IHD (compared with if not) 1.008 0.419 <0.05 
LVD       
constant 6.583 0.455 <0.01 
PSTR (for each 0.1 increase)  8.206 1.417 <0.01 
lg Dialysate IL6 AR (for each unit increase) 0.5 0.276 NS 
lg Plasma IL6 (for each unit increase) -0.154 0.148 NS 
albumin (for each 1g/L increase) -0.022 0.035 NS 
Age (year) 0.01 0.011 NS 
gender (compare with female) -0.001 0.317 NS 
LVD (compared with if not) 1.178 0.533 <0.05 
 a, mixed linear model 
DM, diabetes; IHD, ischemic heart disease; LVD, left ventricular dysfunction; Pcl, protein clearance; 
PSTR, peritoneal solute transport rate; AR, appearance rate; IL-6, interleukin-6  
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3.4.4 Survival analysis 
In the Kaplan-Meier plot, the survival rate was compared between patients with Pcl lower 
and higher than medium value of the whole group. Higher Pcl was showed to be related 
to worse overall outcome and this was also true for daily peritoneal protein loss. (Figure 
3-5, Figure 3-6) 
Figure 3-5 Kaplan-Meier curve for peritoneal protein clearance (Pcl) (log rank test) 
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Figure 3-6 Kaplan-Meier curve for daily peritoneal protein loss (log rank test) 
 
In Cox regression, in the basic model with age, gender, comorbidity, PSTR, local and 
systemic IL-6, Pcl was an independent predictor of survival in incident PD patients. As 
shown in Table 3-7, the predictive value of PSTR disappear when adding peritoneal Pcl 
into the model. By adding plasma and dialysate IL-6 into the model, both Pcl and plasma 
IL-6, but not dialysate IL-6 AR, were independent predictors for survival. (Table 3-8) 
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Table 3-7 Cox regression model of patient survival - with and without peritoneal Pcl 
as one of the confounder in the model 
  RR 95%CI P value RR 95%CI P value 
age  1.069 1.05-1.09 <0.001 1.070 1.05-1.09 <0.001 
PSTR 4.546 1.16-17.8 .030 2.046 0.43-9.64 .365 
gender (male as 
reference) .932 0.63-1.38 .726 .920 0.62-1.37 .681 
lg(plasma IL6)  2.858 1.45-5.64 .002 2.751 1.38-5.49 .004 
lg(peritoneal IL-6 AR)  1.171 0.86-1.59 .314 1.049 0.77-1.42 .760 
Comorbidity grade  2.295 1.63-3.22 <0.001 2.167 1.53-3.07 <0.001 
peritoneal Pcl       1.006 1-1.01 .016 
Pcl, protein clearance; PSTR, peritoneal solute transport rate; AR, appearance rate; IL-
6, interleukin-6; RR, relative risk, CI, confident interval 
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Table 3-8 Cox regression of patient survival - with and without peritoneal IL-6 and plasma IL-6 as the confounders in the model  
  RR 95%CI P value RR 95%CI P value RR 95%CI P value RR 95%CI P value 
age per year 1.071 1.05-1.09 <0.001 1.070 1.05-1.09 <0.001 1.070 1.05-1.09 <0.001 1.070 1.05-1.09 <0.001 
PSTR 2.442 0.54-11.08 .247 2.370 0.52-10.85 .266 2.083 0.45-9.75 .351 2.046 0.43-9.64 .365 
gender (male as 
reference) .964 0.65-1.42 .853 .956 0.65-1.41 .821 .923 0.62-1.37 .691 .920 0.62-1.37 .681 
lg(plasma IL6)              2.798 1.42-5.53 .003 2.751 1.38-5.49 .004 
lg(peritoneal IL-6 
AR)        1.129 0.82-1.55 .457       1.049 0.77-1.42 .760 
Comorbidity grade  2.304 1.63-3.26 <0.001 2.323 1.64-3.29 <0.001 2.158 1.52-3.05 <0.001 2.167 1.53-3.07 <0.001 
peritoneal Pcl 1.007 1-1.01 .003 1.006 1-1.01 .010 1.006 1-1.01 .009 1.006 1-1.01 .016 
Pcl, protein clearance; PSTR, peritoneal solute transport rate; AR, appearance rate; IL-6, interleukin-6; RR, relative risk; CI, confident 
interval 
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Additional models were conducted to clarify the confounding effect of albumin. When add 
albumin into the model with peritoneal Pcl, plasma albumin replace peritoneal Pcl as an 
independent predictor for survival. (Table 3-9) Due to the mathematical link between plasma 
albumin and Pcl, further models with daily peritoneal protein loss rather than Pcl were also 
conducted. Daily peritoneal protein loss was no longer a significant predictor of survival, 
especially when plasma albumin was added into the model. As expected, plasma albumin 
was an independent predictor for survival. (Table 3-10) However, the prediction of daily 
peritoneal protein loss was different according to the type of comorbidities. When controlled 
for DM status, rather than the overall severity of comorbidity (comorbidity grade) as shown 
in Table 3-10, daily peritoneal protein loss and plasma albumin both independently predicted 
survival. (Table 3-11) 
Table 3-9 Cox regression of patient survival - with and without plasma albumin as the 
confounder in the model 
  RR 95%CI P value RR 95%CI P value 
age  1.070 1.05-1.09 <0.001 1.074 1.05-1.09 <0.001 
PSTR 2.046 0.43-9.64 .365 1.436 0.28-7.24 .661 
gender (male as reference) .920 0.62-1.37 .681 .970 0.65-1.44 .880 
lg(plasma IL6)  2.751 1.38-5.49 .004 2.361 1.18-4.74 .016 
lg(peritoneal IL-6 AR)  1.049 0.77-1.42 .760 1.028 0.75-1.41 .866 
Comorbidity grade  2.167 1.53-3.07 <0.001 1.917 1.34-2.74 <0.001 
peritoneal Pcl  1.006 1-1.01 .016 1.002 1-1.01 .340 
albumin        .924 0.88-0.97 .001 
Pcl, protein clearance; PSTR, peritoneal solute transport rate; AR, appearance rate; IL-6, 
interleukin-6; RR, relative risk; CI, confident interval 
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Table 3-10 Cox regression of patient survival - with and without plasma albumin as the 
confounder in the model when measuring daily peritoneal protein loss rather than 
peritoneal Pcl  
  RR 95%CI P value RR 95%CI P value 
age  1.069 1.05-1.09 <0.001 1.074 1.05-1.09 <0.001 
PSTR 2.703 0.6-12.09 .190 1.134 0.22-5.85 .880 
gender (male as 
reference) 1.101 0.74-1.64 .640 1.040 0.7-1.55 .850 
log(plasma IL6)  2.890 1.46-5.73 <0.001 2.361 1.17-4.75 .020 
log(peritoneal IL-6 AR)  1.104 0.82-1.49 .520 1.011 0.74-1.38 .950 
Comorbidity grade  2.270 1.61-3.2 <0.001 1.917 1.34-2.75 <0.001 
Daily peritoneal protein 
loss  1.070 0.99-1.15 .080 1.068 0.99-1.15 .100 
albumin        0.917 0.88-0.96 <0.001 
Pcl, protein clearance; PSTR, peritoneal solute transport rate; AR, appearance rate; IL-6, 
interleukin-6; RR, relative risk; CI, confident interval 
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Table 3-11 Cox regression of patient survival with different comorbidity status as the 
confounder in the model – with and without plasma albumin as the confounder in the 
model  
 
RR 95%CI P value RR 95%CI P value 
age  1.086 1.06-1.11 <0.001 1.088 1.07-1.11 <0.001 
PSTR 1.097 0.24-4.98 .904 .553 0.11-2.85 .478 
gender (male as reference) .931 0.63-1.38 .721 .968 0.65-1.43 .872 
lg(plasma IL6)  3.824 1.98-7.38 <0.001 2.961 1.49-5.86 .002 
lg(peritoneal IL-6 AR) .953 0.69-1.32 .772 .892 0.64-1.24 .496 
DM 2.910 1.96-4.35 <0.001 2.385 1.59-3.57 <0.001 
Daily peritoneal protein loss  1.110 1.03-1.19 .006 1.105 1.02-1.19 .011 
albumin        .920 0.88-0.96 <0.001 
 
RR 95%CI P value RR 95%CI P value 
age  1.068 1.05-1.09 <0.001 1.074 1.05-1.09 <0.001 
PSTR 1.963 0.45-8.57 .370 .733 0.14-3.83 .713 
gender (male as reference) .903 0.61-1.35 .616 .996 0.67-1.49 .986 
lg(plasma IL6)  3.181 1.68-6.01 <0.001 2.378 1.21-4.66 .012 
lg(peritoneal IL-6 AR) 1.053 0.78-1.42 .736 .967 0.71-1.32 .833 
IHD 1.241 0.79-1.96 .349 1.177 0.75-1.85 .484 
Daily peritoneal protein loss  1.074 0.99-1.16 .076 1.069 0.99-1.16 .110 
albumin        .900 0.86-0.94 <0.001 
 
RR 95%CI P value RR 95%CI P value 
age  1.069 1.05-1.09 <0.001 1.075 1.06-1.09 <0.001 
PSTR 1.946 0.46-8.29 .368 .724 0.14-3.66 .696 
gender (male as reference) .916 0.62-1.36 .663 1.003 0.67-1.49 .987 
lg(plasma IL6)  3.283 1.75-6.15 <0.001 2.474 1.28-4.78 .007 
lg(peritoneal IL-6 AR) 1.022 0.75-1.38 .889 .933 0.68-1.28 .667 
LVD 1.576 0.91-2.78 .108 1.532 0.88-2.63 .129 
Daily peritoneal protein loss  1.075 1-1.16 .061 1.068 0.99-1.15 .103 
albumin        .899 0.86-0.94 <0.001 
DM, diabetes; IHD, ischemic heart disease; LVD, left ventricular dysfunction; PSTR, 
peritoneal solute transport rate; AR, appearance rate; IL-6, interleukin-6; RR, relative 
risk; CI, confident interval 
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3.5 Discussion 
The present study confirmed the relationship between peritoneal Pcl and PSTR indicating 
that membrane area is an important determinant. It also showed that peritoneal Pcl is 
related to local membrane inflammation and this association is independent to membrane 
area. The effect of comorbidity on Pcl is partly explained by the association between 
hypoalbuminaemia and comorbidity, but they are different by type of comorbidity. The 
association between Pcl and outcome has been repeated in the current cohort. This 
prediction is not due to the local factors but to its relationship to hypoalbuminaemia and 
comorbidity. It is again complex and different by type of comorbidity. 
3.5.1 Uncoupled increase in Pcl and PSTR in local membrane 
inflammation  
Several studies showed that membrane inflammation is associated with high PSTR, primarily 
a measure of the effective membrane area, specifically of small intercellular pores, in 
incident patients. 115, 116 However, until now it is not clear how this relates to variability in 
large pore flux - and membrane inflammation. It is well known that the large pore flux-
peritoneal Pcl increases dramatically in peritonitis, i.e. in the presence of severe 
inflammation that includes an influx of neutrophils, but less clear in the context of stable, 
non-infected dialysis patients. A study in 40 prevalent CAPD patients showed that the 
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dialysate appearance of IL-6 correlated with albumin and IgG clearances, which was also 
related to PSTR at the same time. 118 However it was not clear from this study whether the 
inflammation associated increase of peritoneal Pcl was coupled with the increase of 
membrane area. Our result confirmed the association between peritoneal Pcl and local 
membrane inflammation in the incident cohort and further illustrated that this relationship 
was independent from but also associated with membrane area. Local IL-6 production may 
associate with an increase in PSTR through increased effective area. But it is not the only 
mechanism of increase in Pcl. It may further increase the permeability of peritoneal 
membrane to protein - large pore area. In other words, there is uncoupled increase in Pcl and 
PSTR.  
3.5.2 Peritoneal cavity - a window for systemic vascular 
damage?  
There was also an independent association between peritoneal Pcl and the severity of 
comorbidity status in this multi-centre incident cohort. It was in keeping with the findings in 
several single centre studies using different methods to measure the peritoneal protein leak 
and different definitions of comorbidity.69 72 71 70 61, 73  
However, we need to be cautious when using Pcl as a marker of systemic vessel damage. 
Firstly, the permeability of peritoneal membrane to protein also depends on the local factors, 
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such as local inflammation as demonstrated in this study. Secondly, the calculation of Pcl 
uses plasma proteins, especially albumin as its denominator and comorbidity may affect 
plasma concentration independently of the effects on endothelial function. Thirdly, the 
factors determining permeability of peritoneal membrane to protein may also change with 
time on PD, as will be demonstrated in the following chapter.  
3.5.3 Where is the link between Pcl and survival? Local or 
systemic factors 
The current study confirmed a strong relationship between Pcl and survival. This relationship 
was independent from PSTR or local membrane inflammation as measured by IL-6. This study 
confirmed the previous finding that Pcl replace PSTR as an independent predictor of survival 
in a contemporary PD cohort, 61 where APD and polyglucose solutions, such as icodextrin, are 
widely used to restrict the unfavourable effect of PSTR on fluid balance. One of the important 
finding of this study is that local membrane inflammation does not predict survival when 
controlled for other confounders. It is generally in agreement with the clinical observations 
that although with some controversy, most of the ‘biocompatible’ solutions actually increase 
effluent inflammation biomarker level, but there is no evidence that they are related to 
worse outcome so far, if not better. 152-154  
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Due to the mathematical coupling to plasma albumin, there is concern that the Pcl is a 
surrogate of plasma albumin for the prediction of survival. To further investigate this, the 
predictive value of daily protein loss on survival was analyzed. Both peritoneal Pcl and daily 
peritoneal protein loss predicted survival in univariate K-M survival analysis. It is different 
from Krediet’s observation 74 as neither peritoneal albumin clearance nor albumin loss from a 
4 hour 3.86% glucose exchange was associated with death in their study. The fact that higher 
proportion of albumin would go through small pore via convection in 4 hour 3.86% glucose 
dwells may partially explain their negative finding. The prediction of Pcl, of course, partially 
relies on, but not solely secondary to, the mathematic correlation to plasma albumin. It also 
reflects other aspect of the pathophysiological change of the body. From the correlation 
analysis of this study, it is likely to be a function of comorbidity, with variation of the 
importance of mechanism according to the different type of comorbidities.  
3.5.4 Limitations  
The findings of the present study must be interpreted in the context of the study design. The 
strengths of the present study include the multi-centre nature of the study, the large number 
of patients studied and adjustment for multiple confounding covariates. There are also 
limitations of the study. Firstly, albumin is in the equation of calculating Pcl. There is 
mathematical correlation between albumin and Pcl, although extra effort has been made in 
the data analysis to interpret the physical relationship. However, as Pcl is the most widely 
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clinically used measurement of membrane permeability to protein, it is more important to 
understand the clinical meaning of Pcl than a theoretical measure. Secondly, urine protein 
loss, another route of protein loss that may affect plasma albumin, would ideally be 
measured. The difference between DM and IHD from the current observation could because 
of the excessive urine protein loss in DM that is not really related to endothelial permeability 
in ESRD. Thirdly, a validated correction factor is used to calculate total protein from serum 
albumin where total plasma protein is required to estimate Pcl. A direct measurement of 
plasma total protein was not available in this study as well as most of the other studies on 
peritoneal protein Pcl. It is possible that in extreme systemic inflammation, total serum 
protein may be underestimated and Pcl overestimated because of an uncoupling between 
serum albumin and total protein. Albumin is a negative acute-phase protein, and other 
proteins that are positive acute-phase proteins. The association between systemic 
inflammation and Pcl may have been amplified in that case. Fourthly, albumin, the 
predominant plasma and dialysate protein, may also pass through small pores 
(predominantly by convection). 155 Ideally, a series of proteins at different molecular weights 
should be measured to precisely dissect out the contribution of the relative pores, a 
procedure that is beyond the feasibility of a large prospective epidemiological study. Fifthly, 
multiple models were carried out in the study, but no correction for multiple comparisons 
was made, which may potentially increase the risk of type I error. The variables selected in 
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the model were based on scientifically plausible hypothesis rather than every possible 
combination, which help to limit the risk. 
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3.6 Conclusion 
Peritoneal Pcl is a function of PSTR, local membrane inflammation and comorbidity in 
patients commencing PD. The high peritoneal Pcl predicts worse outcome, which is a 
combination of hypoalbuminaemia and severity of comorbidity. It remains unclear as to 
whether this association is due to hypoalbuminaemia caused by reduced protein synthesis or 
due to systemic endothelial barrier dysfunction or both.  
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Longitudinal dissociation between small solute chapter 4.
transport and peritoneal protein clearance (Pcl) in 
peritoneal dialysis patients 
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4.1 Summary 
4.1.1 Purpose 
The purpose of the study is to clarify whether the peritoneal protein clearance (Pcl) - a 
measure of large pore, changes with time on PD or not. If so, it is to further investigate 
whether this change over time dissociated from the increase in PSTR. 
4.1.2 Methods 
Patients treated continuously for a minimum of four years were extracted from the 
longitudinal prospective Stoke PD Study. All patients in this cohort commencing PD since 
2000 had daily Pcl measured at baseline and 6 monthly intervals, along with peritoneal small 
solute transport rate (PSTR), ultrafiltration capacity, residual renal function (RRF), comorbid 
conditions and peritonitis events. Multi-level multi-variate analysis was used to determine 
associations with Pcl over time taking account of within subject correlations. 
4.1.3 Results 
Of the 279 incident patients, 49 had been on PD for more than 4 years, for whom there were 
335 full data sets within the 48 months of follow-up. At baseline Pcl correlated with PSTR 
whereas over time there was progressive uncoupling of this relationship with increasing PSTR 
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and stable Pcl. Multi-variate analysis found that age, PSTR, daily ultrafiltration and sodium 
removal were significant predictors of Pcl when controlled for gender, comorbidity, glucose 
exposure and RRF. However, the strength of the relationship between PSTR and Pcl was less 
with time on treatment in keeping with their progressive dissociation. Peritonitis was 
associated with increased PSTR but a similar pattern of uncoupling.  
4.1.4 Conclusion 
There is an uncoupling of the small (PSTR) and large (Pcl) pore pathways with time on PD 
which would be in keeping with a switch from local inflammation early on to progressive 
fibrosis combined with increased vascular surface area. Measuring longitudinal changes Pcl 
may complement membrane function tests monitoring progressive injury.   
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4.2 Introduction 
PD leads to changes in membrane morphology99 and function95, 98 over time which in a 
proportion of patients causes ultrafiltration failure and likely predisposes to the much rarer 
complication of encapsulating peritoneal sclerosis. Of the functional changes, increasing 
peritoneal small solute transport rate (PSTR) and a reduction in osmotic conductance 
(reduced ultrafiltration capacity independent of osmotic gradient) are well established84, 95. 
Longitudinal changes in Pcl, predominantly a reflection of hydrostatic pressure driven leak of 
plasma proteins through the large pore pathway, are less clear. Cross sectional and 
longitudinal studies 69, 72 have suggested this does not increase with time on treatment but it 
is not clear if this represents a real difference from PSTR, partly because Pcl has been found 
to be associated with age and comorbidity and in some studies is an independent predictor 
of survival61, 70-73 leading to informative censoring in cohort studies.  
Pcl (large pores) and PSTR (small pores) are known to be correlated at the start of PD 
treatment and there are at least two reasons for this. First, given that both pore systems are 
located in the capillary vessel wall it is likely that there will be considerable anatomical 
coupling. Second, as intra-peritoneal production of the pro-inflammatory cytokine IL-6 is 
correlated with and likely a key determinant of PSTR, local inflammation would be expected 
to cause increased numbers of large pores per unit of capillary length. If the increase in PSTR 
occurring with time on treatment is a function of increasing intra-peritoneal inflammation 
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then a parallel increase in Pcl would be anticipated. The purpose of this analysis was to test 
this hypothesis in a cohort of patients treated continuously over four years to avoid the 
influence of informative censoring by patients discontinuing treatment early with 
disproportionately increased Pcl due to the associations with age and comorbidity. 
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4.3 Methods 
4.3.1 Study design and patient population  
The Stoke PD study is a long term single centre, longitudinal, prospective observational 
cohort of consecutive new patients commencing PD. Since April 2000, peritoneal protein 
losses were measured 6-monthly as part of routinely collected data that includes 
demography, comorbidity, membrane function (peritoneal equilibration test to include PSTR 
and ultrafiltration capacity), RRF, dialysis prescription, clearances, achieved ultrafiltration and 
sodium removal. Data is collected and stored on a validated database (PDDB) and since 
2002 all patients have given their informed consent as one of the recruiting centres for the 
GLOBAL Fluid Study (MREC:02/9/14). The database was interrogated in July 2011 to identify 
all patients in whom there were at least four years of continuous data for the purpose of this 
analysis. During this period the majority of patients (>95%) used conventional glucose fluids 
(Dianeal) with an increasing proportion using icodextrin (Extraneal). 
4.3.2 Measurement of membrane function and Pcl 
Peritoneal equilibration tests were used to measure PSTR (dialysate:plasma creatinine ratio) 
and the UF capacity at 4 hours as previously described. The peritoneal dialysate protein loss 
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was measured by the Biuret method from the collection of 24-hour peritoneal dialysate 
effluent.  
Plasma albumin levels had been measured using the bromocresol green method before 22th 
Aug 2007 and was switched to bromocresol purple method afterward. An average difference 
of 5.5g/L between the results of the two methods had been established 149 and this 
conversion factor was applied. Peritoneal Pcl was calculated using a validated formula: 24 
hour dialysate protein loss / (serum albumin/0.4783), and expressed as mL/day. 
4.3.3 Average glucose exposure 
Peritoneal average glucose exposure was calculated by summing the total glucose exposure 
in each exchange and divided by total volume. For example, a patient using 2*2L exchanges 
of 1.36% glucose, 1*2L exchanges of 2.27% glucose and icodextrin 2L overnight, the average 
glucose exposure would be (1.36%*4+2.27%*2)/8=1.25%. 
4.3.4 Comorbidity and demography 
Demography, primary renal disease and comorbidity were recorded at the start of PD. 
Comorbidity was defined as described previously. Briefly, 7 comorbid domains were 
considered, including non-cutaneous malignancy, ischemic heart disease (IHD), peripheral 
vascular disease (PVD), left ventricular dysfunction (LVD), diabetes mellitus (DM), systemic 
 145 
 
 
collagen vascular disease, and any other condition thought to reduce life expectancy. The 
comorbidity score for each patient was defined as the number of these domains affected. 
The comorbidity grade was then derived from the comorbidity score. Grade 0 (low risk) was a 
zero score, grade 1 (medium risk) was a score of 1-2, and grade 2 (high risk) a cumulative 
score of ≥ 3. 
4.3.5 Statistical analysis 
Continuous data are expressed as means (SD) or medians (interquartile range) according to 
the distribution. For multivariate models non-parametric data were log or square root 
transformed to fit a normal distribution. Between-group comparisons used the 2-tailed 
unpaired t-test, the Mann-Whitney U test, one way ANOVA, independent samples Kruskal 
Wallis test or the χ-squared test depending on the data type, the number of groups and the 
distribution.  For single-level analysis data was annualised such that if there was more than 
one set of measurements available the mean was taken for further analysis to limit bias.  
Multi-level mixed linear model was applied to determine associations with Pcl and performed 
using MLwin software (Version 2.22, Centre for multilevel modelling University of Bristol). 
Repeat observations, e.g. membrane characteristics (level 1) were nested within individuals 
(level 2). To investigate the long term change of peritoneal membrane, those who were on 
PD for more than 4 years were extracted from the database. To restrict the survivor’s bias, 
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only the first 4 years data from these patients were further analyzed. The dependent variable 
was the daily protein Pcl and the independent covariates were included in the multivariate 
model if either they were significantly related to either the dependent variable on the uni-
level bivariate correlation or they were plausible explanatory variables according to theoretic 
model or other studies. Constant covariates, such as gender and comorbidity at baseline 
were level 2 variables. The intercept was set as random in level 2 to allow for between 
patient differences. The continuous variables were centered on the mean to facilitate the 
clinical interpretation of the model.  
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4.4 Results 
4.4.1 Patient demography and baseline membrane function 
1176 sets of membrane function tests and Pcl measurement in 280 patients were available 
for analysis (see Figure 4-1) from which 335 sets of data in 49 patients for whom four years of 
continuous data were available were extracted for further analysis. 175 of the 335 
observations were in APD and 190 were on icodextrin.   
Figure 4-1 Data selection process  
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The demographic details of the sub-cohort selected for this study are displayed in Table 4-1 
and split according to ever or never having peritonitis during the observation period. There 
was no significant difference between the two groups in terms of demographics or 
membrane function. Of the 25 patients who had peritonitis, 11 of them had one episode, 8 of 
them had two episodes and 6 three or more episodes of peritonitis.  
Table 4-1 Demography of the sub-cohort selected for this study 
  sub-cohort (n=49) 
Whole cohort 
(n=280) 
  
without 
peritonitis (n=24) 
With peritonitis 
(n=25) 
P 
value
a
 
combined 
(n=49)   
Gender (f/m) 11/13 10/15 0.68 21/28 120/160 
Diabetic (%) 29.2 32 0.83 30.6 29.6 
IHD (%) 12. 5 16 0.73 14.3 21.1 
LVD (%) 4.2 4 0.98 4.1 7.5 
comorbidity grade 
(low/medium/high) 11/12/1 9/14/2 0.71 20/26/3 107/146/27 
age (years) 52±17 49±19 0.51 51±18 55.3±16.5 
total time on PD 
(mo) 67±17 66±14 0.82 67±15 30.9±22 
survival time since 
PD start (mo) 85±21 80±21 0.39 83±21 56.2±35.1 
baseline PSTR 0.64±0.15 0.69±0.11 0.21 0.66±0.13 0.68±0.13 
baseline albumin 
(g/L) 32.2±3.5 30.9±4.5 0.28 31.5±4.1 30.7±4.8 
a, unpaired t test 
IHD, ischemic heart disease; LVD, left ventricular dysfunction; PSTR, peritoneal solute 
transport rate; PD, peritonea dialysis  
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4.4.2 Longitudinal relationship between Pcl and PSTR 
The changes in PSTR and Pcl with time on treatment are shown in Figure 4-2; PSTR increases 
over time (baseline, 0.66±0.13, 1st year, 0.66±0.13, 2nd year, 0.70±0.11, 3rd year, 0.71±0.12, to 
4th year, 0.74±0.12, P<0.01) whereas Pcl tends to decrease indicating a progressive 
dissociation of these aspects of membrane function. The mean values of Pcl and PSTR were 
showed in Figure 4-2. The plasma albumin was stable over the time; baseline: 31.7±3.9g/L, 
Year 1: 31.0±4.2g/L, Year 2: 31.7±3.4g/L, Year 3: 31.9±2.7g/L, Year 4: 32.1±2.9g/L, 
respectively.  
The relationship between PSTR and Pcl also weakened over time as shown by the changing 
slope and significance of the regression line, especially after baseline (Figure 4-2).  The 
Pearson correlation coefficient (R) at baseline was: 0.612 (P<0.01), Year 1: 0.28 (P=0.104), 
Year 2: 0.245 (P=0.113), Year 3: 0.27 (P=0.063), Year 4: 0.282 (P=0.052), respectively.  
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Figure 4-2 peritoneal protein clearance (Pcl) is positively related to PSTR and this 
relationship changes with time on PD 
 
• The significant linear regression between Pcl and PSTR in different time point is 
showed as dash line. 
• The actual mean value (SE bars) for protein clearance (Pcl) and PSTR at each time 
point are shown superimposed upon the linear regression.  
• Pcl is positively related to PSTR throughout the therapy.  
• However, the slope of the relationship between PSTR and Pcl got smaller with 
time on PD. 
 
 151 
 
 
4.4.3 Multivariate analysis of the determinants of PCl 
Table 4-2 summarizes the initial multi-level mixed linear models constructed to investigate 
the relationship between Pcl and PSTR. Their positive association persists after adjustment 
for comorbidity score, gender, age, urine volume and membrane UF capacity, but the time 
on therapy interaction shows that this is weakened as demonstrated by the significant 
negative  coefficient. Addition of glucose exposure and use of icodextrin to the model 
(Table 4-2 right) had little overall effect. As there were only a few patients on dry day regime 
in this cohort (11 of 335 data sets), no sub-analysis on this group was undertaken.  
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Table 4-2 Multi-level mixed linear model of daily Pcl (square root transformed)-base 
model and model with added glucose effect 
 Base model with glucose effect 
 
β 
standard 
error 
P 
value β 
standard 
error 
P 
value 
constant 9.57 0.3 <0.01 9.44 0.34 <0.01 
PSTR (for each 0.1 increase) 0.39 0.11 <0.01 0.43 0.11 <0.01 
comorbidity score (for each 1 unit 
increase)  -0.13 0.2 NS -0.18 0.21 NS 
gender (if female) -0.52 0.38 NS -0.37 0.4 NS 
age (year) 0.016 0.011 NS 0.019 0.011 0.1 
UF capacity on PET (for each 100ml 
increase)  0.04 0.03 NS 0.04 0.04 NS 
urine volume (for each 1000ml 
increase) 0.2 0.1 NS 0.2 0.2 NS 
PSTR *PD duration (2nd compared with 
1st year for each 0.1 increase in PSTR) -0.23 0.14 NS -0.25 0.14 0.08 
PSTR *PD duration (3rd compared with 
1st year for each 0.1 increase in PSTR) -0.35 0.14 <0.01 -0.37 0.14 <0.01 
PSTR *PD duration (4th compared with 
1st year for each 0.1 increase in PSTR) -0.30 0.14 <0.05 -0.27 0.15 0.07 
ICO usage (compared with not use) 
   
0.007 0.019 NS 
medium glucose exposure (compared 
with low glucose exposure) (n=51) 
   
0.02 0.02 NS 
high glucose exposure (compared with 
low glucose exposure) (n=13) 
   
0.03 0.03 NS 
PSTR, peritoneal solute transport rate; UF, ultrafiltration; PET, Peritoneal equilibration tests; ICO, 
icodextrin; PD, peritoneal dialysis 
medium glucose exposure, daily average glucose exposure 1.36%-2.27% 
high glucose exposure, daily average glucose exposure >=2.27% 
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4.4.4 The effect of accounting for UF and sodium removal 
One potential confounder of this analysis could be the increased requirement over time to 
obtain more ultrafiltration as a consequence of loss in RRF. Because albumin is able to pass 
through small pores, increased ultrafiltration rates have the potential to increase the 
convective removal of albumin and thus increase Pcl. Furthermore, although peritoneal UF 
and sodium removal are two highly correlated variables,  (r=0.875, P<0.01), by introducing 
them separately or together in the model it is possible to explore the effect of ultrafiltration 
via the small pores (sodium coupled) or aquaporins (uncoupled).  
Table 4-3 summarises this showing that when either UF or sodium are included separately 
that Pcl is positively associated with increased fluid or sodium removal. Included together the 
relationship remains positive with sodium removal (small pore coupled ultrafiltration) but 
associated negatively with ultrafiltration. For all these more complex models the time 
dependent relationship between Pcl and PSTR remains unaffected.  
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Table 4-3 Multi-level mixed linear model of daily Pcl (square root transformed)-
investigate the UF and sodium removal effect 
 
with daily sodium loss with daily UF with UF and sodium loss 
 
β SE P value β SE P value β SE P value 
Constant 9.56 0.33 <0.01 9.54 0.34 <0.01 9.29 0.32 <0.01 
PSTR (for each 0.1 
increase) 0.47 0.11 <0.01 0.46 0.11 <0.01 0.40 0.10 <0.01 
comorbidity score (for 
each 1 unit increase)  -0.13 0.2  NS -0.16 0.21  NS -0.14 0.19  NS 
gender (if female) -0.18 0.38  NS -0.31 0.4  NS -0.14 0.37  NS 
age (year) 0.02 0.01 0.09 0.02 0.01  NS 0.02 0.01 <0.05 
UF capacity on PET (for 
each 100ml increase)  0.04 0.04  NS 0.04 0.04  NS 0.05 0.03  NS 
urine volume (for each 
1000ml increase) 0.4 0.2 <0.05 0.32 0.16 <0.05 0.2 0.2  NS 
PSTR*PD duration (2
nd
 
compared with 1
st
 year 
for each 0.1 increase in 
PSTR) -0.31 0.14 <0.05 -0.28 0.14 0.05 -0.28 0.13 <0.05 
PSTR *PD duration (3
rd
 
compared with 1
st
 year 
for each 0.1 increase in 
PSTR) -0.41 0.13 <0.01 -0.40 0.14 <0.01 -0.37 0.13 <0.01 
PSTR *PD duration (4
th
 
compared with 1
st
 year 
for each 0.1 increase in 
PSTR) -0.31 0.15 <0.05 -0.28 0.15 0.06 -0.32 0.14 <0.05 
ICO usage (compared 
with not use) -0.03 0.02  NS -0.01 0.02  NS -0.03 0.21  NS 
medium glucose 
(compared with low 
glucose) (n=51) 0.02 0.02  NS 0.02 0.02  NS 0.36 0.19 0.052 
high glucose (n=13) -0.01 0.03  NS 0.009 0.04  NS 0.1 0.33  NS 
daily UF (for each 100ml 
increase)       0.00032 0.00016 <0.05 -0.15 0.03 <0.01 
daily sodium loss from 
dialysate (mmol) 0.006 0.001 <0.01       0.02 0.00 <0.01 
PSTR, peritoneal solute transport rate; UF, ultrafiltration; PET, Peritoneal equilibration tests; ICO, 
icodextrin; PD, peritoneal dialysis 
medium glucose exposure, daily average glucose exposure 1.36%-2.27% 
high glucose exposure, daily average glucose exposure >=2.27% 
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4.4.5 The effect of peritonitis  
The longitudinal relationship between Pcl and PSTR in patients who did or did not have 
peritonitis is shown in Figure 4-3. The pattern of dissociation was seen in both patient groups 
but PSTR tended to increase more significantly in those who had peritonitis, especially at 
Year 4. Multi-level modeling by peritonitis subgroup (see Table 4-4) did not alter the 
previously described associations except for revealing a significant relationship between Pcl 
and membrane UF capacity in the peritonitis positive group. 
Figure 4-3 The uncoupling in both with and without peritonitis cohorts. The dissociation 
between PSTR and Pcl exists in both patients with and without peritonitis. The PSTR 
tends to increase more significantly in those with peritonitis.  
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Table 4-4 Multi-level mixed linear model of daily Pcl (square root transformed) subgroup 
analysis to investigate peritonitis effect 
  without peritonitis (n=171) with peritonitis (n=164) 
  β 
standard 
error 
P 
value β 
standard 
error 
P 
value 
constant 9.36 0.38 <0.01 9.35 0.51 <0.01 
PSTR (for each 0.1 increase) 0.38 0.14 <0.01 0.43 0.17 <0.01 
comorbidity score (for each 1 unit 
increase)  -0.12 0.28  NS -0.28 0.28  NS 
gender (if female) -0.54 0.43  NS 0.3 0.6  NS 
age (year) 0.02 0.01  NS 0.03 0.02 0.06 
UF capacity on PET (for each 100ml 
increase)  0.01 0.05  NS 0.12 0.05 <0.01 
urine volume (for each 1000ml 
increase) 0.3 0.2  NS -0.2 0.2  NS 
PSTR *PD duration (2
nd
 compared 
with 1
st
 year for each 0.1 increase in 
PSTR) -0.19 0.16  NS -0.46 0.23 <0.05 
PSTR *PD duration (3
rd
 compared 
with 1
st
 year for each 0.1 increase in 
PSTR) -0.27 0.16  NS -0.54 0.21 <0.05 
PSTR *PD duration (4
th
 compared 
with 1
st
 year for each 0.1 increase in 
PSTR) -0.44 0.19 <0.01 -0.29 0.22  NS 
ICO usage (compared with not used) -0.14 0.31  NS 0.1 0.27  NS 
medium glucose exposure 
(compared with low glucose 
exposure) (n=51) 0.38 0.28  NS 0.42 0.25  NS 
high glucose exposure (compared 
with low glucose exposure) (n=13) -0.08 0.54  NS 0.26 0.42  NS 
daily UF (for each 100ml increase) -0.11 0.04 <0.01 -0.21 0.05 <0.01 
daily sodium loss from dialysate 
(mmol) 0.01 0.00 <0.01 0.02 0.00 <0.01 
PSTR, peritoneal solute transport rate; UF, ultrafiltration; PET, Peritoneal equilibration tests; ICO, 
icodextrin; PD, peritoneal dialysis 
medium glucose exposure, daily average glucose exposure 1.36%-2.27% 
high glucose exposure, daily average glucose exposure >=2.27% 
 
 157 
 
 
4.5 Discussion 
The intention of this analysis was to determine as cleanly as possible whether longitudinal 
peritoneal Pcl is coupled to changes in PSTR by studying a continuously treated cohort of 
patients, uncontaminated by drop-out and adjusted for known clinical and theoretical factors 
that could influence the association. We demonstrated unequivocally for the first time that 
these two measures of membrane function dissociate over time and that this is independent 
of other predictors of Pcl (age, sodium coupled/small pore ultrafiltration) or known drivers of 
membrane change such as glucose exposure and peritonitis.  
The uncoupling of Pcl and PSTR was due to a rise in the PSTR that was not matched by an 
increase Pcl in line with the relationship seen between these two measures at baseline. 
Increasing PSTR with time on PD is well established and from a theoretical perspective could 
be due either to an increase in the anatomical membrane in contact with dialysate, an 
increase in the density of perfused capillaries (to include neoangiogenesis) or an increase in 
capillary perfusion rate or any combination of the above.  There are good reasons to believe 
that the clinical variability in PSTR at the start of PD is in large part due to local membrane 
inflammation and the strong relationship with Pcl at baseline observed in this study supports 
this. If this had been purely an anatomical coupling this should have remained the case 
throughout the study whereas in fact an increase in small pore area with a relative decline in 
the large pore area is observed. This relative reduction in large pore area could reflect a 
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number of processes including a resolution of the early inflammatory state of the membrane 
following the start of PD – several studies have also shown that depending on when the 
initial membrane function tests are done there is also a fall in PSTR in the months after PD is 
established before the longer term increase. 156-158 Alternatively it could mean that newly 
formed vessels are abnormally under-represented with large pores (surprising as new vessel 
formation in diabetic nephropathy is usually associated with increased protein extravasation) 
or that interstitial and peri-vascular fibrosis, known to occur in PD, is impeding large pore 
leak or even formation of what considered to be transient structures. Distinguishing these 
mechanisms is beyond the capacity of this study but it is possible that further development 
of the three pore membrane/fibre-matrix model, which offered a potential explanation of 
the observed “uncoupling” of small solute transport (PS) and UF coefficient (LpS) seen in 
long-term PD84 might provide mechanistic insights. Measuring Pcl in the clinic is relatively 
easy and may provide an additional method of identifying membrane injury.  
Known drivers of membrane injury, namely glucose and/or glucose degradation products 
(>95% of patients in thus study were treated with conventional glucose solutions) and 
peritonitis did not appear to have a marked effect on the progressive uncoupling of PSTR and 
Pcl. There is more than a suggestion that in the peritonitis group membrane changes were 
overall more severe over time, especially the increase in PSTR, and in the multivariate 
analysis of the peritonitis subgroups there was an association between membrane UF 
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capacity as well as PSTR in those patients who had infections. Cause and effect cannot be 
inferred from this type of analysis but this would be in line with more severe membrane 
injury causing reduced osmotic conductance and Pcl through more severe fibrosis. 
The failure in this study to see a relationship between Pcl and comorbidity on multivariate 
analysis deserves comment. There are a number of explanations. First there was a 
relationship to increasing age as described previously61, 72 and this could account for some 
hidden association with comorbid disease. Second this is a selected patient cohort and more 
serious comorbidity – or specific types such as peripheral vascular disease – were under-
represented. Finally only 49 patients were included which may have led to type 2 statistical 
error in the level 2 component of the mixed-linear model. 
It was important to correct for other known theoretical determinants of Pcl that might 
change with time on PD. Albumin, by far the most abundant protein lost in PD effluent, is of a 
size that can potentially pass through small as well as large pores. Small pore albumin flux is 
driven by convection rather than hydrostatic pressure. To determine the contribution of 
achieved ultrafiltration (small pore convection) to Pcl we included this in the model where it 
associated with Pcl independent of PSTR without affecting the time on treatment interaction. 
By including sodium removal which removed predominantly via small pore convection in the 
model the prediction that Pcl is partly determined by this pathway is confirmed. 
 160 
 
 
As already eluded to this study has a number of limitations. Although our primary hypothesis 
was refuted it is observational and generates more questions than it answers especially with 
respect to cause and effect. In dealing with the concern related to informative censoring we 
had to define a selected patient group so generalisability should be considered carefully. This 
is a problem that all long-term studies of PD patients suffer from which are by their nature 
selective and in this sense the present study is no exception and the characteristics of the 
population studied are typical. For some of the covariates measured, e.g. glucose exposure 
there may not have been sufficient variability in the population to have sufficient power to 
detect an effect (only 13 observations used a high glucose regime (mean 
concentration >2.27%) in our study. The method we used to estimate Pcl is inversely 
dependent on plasma albumin which in turn co-varies with comorbidity which partly explains 
the relationship observed in cohort studies between Pcl and survival. This is unlikely to be a 
confounder in the present analysis both due to lack of drop-out and the fact that throughout 
the study the plasma albumin was very stable. Finally, a serial of models were carried out in 
the study, but no correction for multiple comparisons was made, which may potentially 
increase the risk of type I error. The variables were selected carefully based on scientifically 
plausible hypothesis rather than every possible combination, which should help to restrict 
the risk. 
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4.6 Conclusion 
There is an uncoupling of the small (PSTR) and large (Pcl) pore pathways with time on PD 
which would be in keeping with a switch from local inflammation early on to progressive 
fibrosis combined with increased vascular surface area. Measuring longitudinal changes Pcl 
may complement membrane function tests monitoring progressive injury. 
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Understanding the ultrafiltration obtained with chapter 5.
icodextrin-from theory to bedside 
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5.1 Summary 
5.1.1 Purpose 
The purpose of the study is to determine whether the ultrafiltration (UF) obtained with 
icodextrin changes with time on PD.  If so, it is to further investigate whether this change 
over time dissociated from the increase in peritoneal small solute transport rate (PSTR). It is 
also to test with clinically derived data which other factors are important in determining 
variations in the UF achieved with icodextrin as predicted from theoretical modelling and 
thus give a practical explanation of UF obtained with icodextrin for clinical use. 
5.1.2 Methods 
Net UF volumes obtained during long dwells were recorded as well as membrane 
characteristics and clinical factors every 6 monthly. Multi-level analysis was used to identify 
the predictor of UF by taking account of within subject correlations. The long dwell with 
icodextrin was analyzed for primary purpose. The long dwell with glucose solutions were also 
analyzed to enable comparisons with icodextrin to provide both historical and contemporary 
controls. 
 164 
 
 
5.1.3 Results 
2509 long-dwell observations from 613 patients in total were included in the analysis, 690 
dwells in 202 patients using icodextrin, 849 dwells in 318 patients using glucose in the 
icodextrin-contemporary cohort (after 1998) and 970 dwells in 297 patients prior to 
icodextrin availability (before 1998). Among the 690 icodextrin dwells, 280 were using CAPD 
(typically 9 hours overnight dwell), 289 were on APD with day fill (typically 15 hours), and 121 
were on APD with a short day fill (typically 9 hours day time dwell). In multi-level mixed linear 
modelling, prolonged time on PD therapy was related with less UF by icodextrin and this was 
dissociated from the effect of increase in PSTR. The UF negatively correlated to serum 
albumin, PSTR, UF capacity (UF in PET) and BMI were positively contributed to UF by 
icodextrin. CAPD was associated with  more UF compared with APD using icodextrin or 
glucose for the long dwells, regardless of dwell length (9 hours or 15 hours). High input 
volume (2.5L) was related to less UF compared with 2L in both icodextrin and glucose long 
dwells after 1998.  
5.1.4 Conclusion 
Prolonged time on PD decreases UF obtained with icodextrin. It is uncoupled from the effect 
of increase in PSTR. It would be in keeping with a progressive fibrosis combined with 
increased in small pore area. Better UF capacity indicates more UF by icodextrin. The factors 
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which are likely to affect the oncotic pressure gradient, hydrostatic pressure gradient or 
icodextrin metabolites concentration (plasma albumin, input volume, patient position, BMI 
and gender) are more important than the dwell length in explaining UF variability. To achieve 
better UF obtained with icodextrin, dialysis prescriptions exert high intra peritoneal pressure 
should be avoided and prolonged dwell length may not be helpful. 
 166 
 
 
5.2 Introduction 
Growing evidence has shown that peritoneal dialysis (PD) leads to morphological and 
functional changes in peritoneal membrane over time. Of the functional changes, the 
“uncoupling” between small solute transport rate (PSTR) and UF capacity has been well 
established and successfully modeled by an extension of the three pore membrane to 
include a fiber matrix layer that mimics membrane fibrosis. 84, 95, 103 The work in Chapter 4 
further showed there is a progressive uncoupling of the small pore (PSTR) and large pore (Pcl) 
pathways with time on PD. This would be in keeping with a switch from local inflammation 
early on to progressive fibrosis in which transcapillary protein leak is impaired combined with 
increased vascular surface area. 
In severe fibrosis, there is “uncoupling” of PSTR from the peritoneal UF coefficient (LpS) or 
more precisely, the peritoneal osmotic conductance to glucose (LpSσg). 
103 It is not clear 
whether this aspect of membrane function (LpSσ) can be demonstrated with a non-glucose 
containing dialysis fluid.  
Icodextrin was intentionally chosen in this study. On one hand, it is now widely used 
nowadays especially when having difficulties with fluid balance. It has been regarded as a 
standard strategy for patients with high PSTR who tend to achieve less UF with glucose 
solution. On the other hand, the mechanism of action of icodextrin as a dialysis fluid is quite 
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different from glucose. Icodextrin achieves UF through oncotic rather than osmotic pressure 
(it is isotonic with plasma) and this occurs via the small pore system only while glucose 
solutions obtain UF through both small pore and ultra-small pores (aquaporins).  
The purpose of the study is to  
(1) Determine whether the UF obtained with icodextrin – which only occurs via the small 
pore pathway - changes with time on PD. 
(2)  If so, it is to further investigate whether this change over time dissociated from the 
increase in PSTR, and thus independent of the change in small pore area.  
(3) to test with clinically derived data which other factors are important in determining 
variations in the UF achieved with icodextrin as predicted from theoretical modelling and 
thus  
(4) give a practical explanation of UF obtained with icodextrin for clinical use. 
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5.3 Methods 
5.3.1 Study design and patient population  
This was a retrospective analysis of a single centre, longitudinal, observational cohort study 
in which data were prospectively collected from 1990 until censored in Oct 2010. Peritoneal 
membrane function using peritoneal equilibration test (PET) and dialysis adequacy were 
routinely measured within the first one or two months of treatment, and then usually at 6 
monthly interval unless prevented by acute illness or subject availability. The PD prescription, 
UF of each exchange and urine volume on the day of dialysis adequacy test was recorded.  
Baseline data including demography, primary renal disease and comorbidity, were recorded 
as when they started PD. Data was collected and stored on a validated database (PDDB).    
The long dwells (the longest exchange of the day and no less than 7 hours) was analyzed in 
this study; typically this was the night dwell in continuous ambulatory peritoneal dialysis 
(CAPD) and the day dwell in automated peritoneal dialysis (APD), the main difference 
reflecting the posture of the patient during this period. The long dwell with icodextrin was 
analyzed as the primary purpose of the study. The long dwell with glucose based solution 
was also analyzed to compare with icodextrin because there was a major change in clinical 
policy in June 1998 (see detail below) and because of the potential selective bias related to 
this, the pre-1998 and post- 1998 observation groups were analyzed separately.  
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Before June 1998 the vast majority of the patients were treated with CAPD and glucose 
based solutions. The description of the Stoke cohort before 1998, survival analysis and 
longitudinal membrane change are described and published previously. 98 The handful 
exceptions, i.e. those not on CAPD and glucose based solutions before 1998 were excluded 
from the analysis due to the fact that they were highly selected patients. The clinical policy 
changed since then. In brief, an increasing proportion of patients were treated with APD, 
particularly when anuric and with difficulties in achieving a creatinine clearance target of 
60L/week/1.73m2, as described in the European Automated Peritoneal Dialysis Outcome 
Study.60 Patient choice, mainly related to their life style, was also taken into account in the 
modality use (APD or CAPD). Icodextrin was more likely to be used in patients with higher 
PSTR especially when combined with clinical difficulties of fluid management. No more than 
one bag of icodextrin was used per day.  
5.3.2 Characteristics of long dwell in different modalities  
Three PD modalities with long dwell were applied in our unit:  
(1) APD with day fill, short exchanges at night and the long dwell was in day time, 
typically 15 hours. 
(2) APD with short day fill, short exchanges at night and the long dwell was in day time 
installed in the morning and drained out at about 4pm, typically 9 hours, followed or 
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not followed by a medium length extra day dwell. This modality was used in patient 
with difficulties in achieving clearance target even when on APD with day fill or 
reabsorbing fluid with prolonged dwell length. 
(3) CAPD, medium dwells in day time and the long dwell at night, typically 9 hours.  
5.3.3 UF volume measurement and membrane function test 
For APD, the UF volume was measured by the APD device. Net UF volume from CAPD was 
accessed by weighing the drainage bag, converting the weight into volume by multiplying the 
specific gravity of 1g/ml and subtracted the expected input volume accounting for the 
average ‘overfill’, which had consistently been measured at 200mls in Stoke 159. 
We estimated PSTR, through measuring dialysate:plasma ratio of creatinine (D/P creatinine)  at 
the end of a standard 2L, 2.27%, 4 hour dwell in peritoneal equilibration test (PET). Net UF 
from this standard dwell was used as a measure of UF capacity. (Without subtract for overfill) 
5.3.4 Comorbidity 
Comorbidity was documented as described previously 160. Briefly, 7 comorbid domains were 
considered, including non-cutaneous malignancy, ischemic heart disease (IHD), peripheral 
vascular disease (PVD), left ventricular dysfunction (LVD), diabetes mellitus (DM), systemic 
collagen vascular disease, and any other condition known to reduce life expectancy. The 
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comorbidity score for each patient was defined as the number of these domains affected. 
The comorbidity grade was then derived from the comorbidity score. Grade 0 (low risk) was a 
zero score, grade 1 (medium risk) was a score of 1-2, and grade 2 (high risk) a cumulative 
score of ≥ 3. 
5.3.5 Analytical methods 
Plasma and dialysate concentrations of creatinine, glucose and plasma albumin were 
measured by the central lab in the hospital. Plasma albumin levels had been measured using 
the bromocresol green method before 22th Aug 2007 and was switched to bromocresol 
purple method afterward. An average difference of 5.5g/L between the results of the two 
methods had been established by Clase et al and the convert equation derived from them 
was used to adjust the data 149.  
5.3.6 Statistical analysis 
All data were expressed as means (±SD) unless the distribution was not normal, in which case 
medians (interquartile range) were shown. Between-group comparisons used the 2-tailed 
unpaired t-test, the Mann-Whitney U test, one way ANOVA, independent samples Kruskal 
Wallis test or the chi-squared test depending on the data type, the number of groups and the 
distribution.  Pearson and Spearman correlation were used for bivariate correlation 
according to the distribution. The majority of the input volumes were 1500ml, 2000ml and 
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2500ml, with a dozen of exceptions in total, ranging from 500ml to 3000ml. The input 
volume was re-coded into category variable using the following rules: ≤1750ml→1500ml, 
1750ml to 2250ml→2000ml, >2250ml→2500ml. 
Multi-level mixed linear model was applied in the study. Repeat observations (level 1) were 
nested within individuals (level 2). The dependent variable was the UF volume obtained from 
the long dwell and the independent variables were included in the multivariate model either 
if they were significantly related to the dependent variables on the uni-level bivariate 
correlation or they were plausible explanatory variables according to the 3-pore membrane 
model or known predictors in other studies. Variables that remain constant within patients, 
such as gender and comorbidity at baseline were put in level 2, whereas those that change 
within patients over time such as age, time on therapy, membrane characteristics, et al were 
treated as level 1. The intercept was set as random in level 2 to allow the between patient 
difference and the other explanatory variables were fixed coefficients. The continuous 
variables were centered on the mean in the model to facilitate the clinical interpretation. The 
multi-level modelling were performed using MLwin software (Version 2.22, Centre for 
multilevel modelling University of Bristol)  
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5.4 Results 
5.4.1 The patient and membrane characteristics according to 
different observation groups 
2509 long-dwell observations from 613 patients in total were in the analysis, 690 dwells in 
202 patients using icodextrin, 849 dwells in 318 patients using glucose in the icodextrin-
contemporary cohort (after 1998) and 970 dwells in 297 patients prior to icodextrin 
availability (before 1998).  see Figure 5-1 and Figure 5-2.  The medium number of 
observations per individual was 3, (range 1 to 21).  
Figure 5-1 dialysate regime for long dwells over the years 
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Figure 5-2 sub cohort for statistical analysis according to era and dialysate regime 
 
 
The patient and membrane characteristics in the different observation groups were shown in 
Table 5-1. These reflect the historical change of our PD cohort and clinical practice. In brief, 
there was more diabetes after 1998 and with higher BMI. The residual renal function, 
represented by urine volume, was higher after 1998 and patients were on the PD therapy for 
a longer time. After 1998, patients selectively moved to icodextrin or glucose long dwells 
according to the new clinical policy described before. As a result, the icodextrin observation 
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group had higher PSTR, less good UF capacity on PET, less urine output, were on PD for 
longer time, more likely diabetic and with heavier comorbidity burden.  
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Table 5-1 Patient characteristics, membrane characteristics and PD prescription in the 
three observational groups, 1. glucose before 1998, 2. glucose after 1998 and 3. 
icodextrin (after 1998) 
 Glucose 
before 1998 
n=970 
Glucose after 
1998 + 
icodextrin 
(after 1998) 
n=1539 
P 
value
a,
c
 
Glucose after 
1998 
n=849 
Icodextrin 
(after 1998) 
n=690 
P 
value
b,
c
 
age (year) 56.4±16.1 56.2±16.0 NS 55.4±16.5 57.1±15.5 <0.05 
gender (M/F)% 53.0/47.0 53.8/46.2 NS 49.8/50.2 58.7/41.3 <0.01 
BMI (kg/m
2
) 25.3±4.9 26.7±5.2 <0.01 25.8±4.9 27.7±5.4 <0.01 
time on therapy (mo) 15(6-31) 19(7-37) <0.01 14(3-34) 24(13-40) <0.01 
urine volume (ml) 350(0-930) 703(197-
1335) 
<0.01 940(319-
1572) 
529.5(62-
1000) 
<0.01 
Long dwell input 
volume % (N) 
1500ml 
2000ml 
2500ml 
 
 
18.5 (179) 
73.3 (711) 
8.2 (80) 
 
 
20.1(309) 
70.3 (1082) 
9.6 (148) 
NS  
 
13.4 (114) 
78.7 (668) 
7.9 (67) 
 
 
28.3 (195) 
60.0 (414) 
11.7 (81) 
<0.01 
PSTR 0.61±0.11 0.68±0.14 <0.01 0.63±0.12 0.74±0.13 <0.01 
UF capacity on PET (ml) 419±235 423±233 NS 451±226 388±236 <0.01 
albumin (g/L) 30.5(27.5-
34.5) 
31.5(28-33.5) NS 30.7±4.7 30.8±4.4 NS 
comorbidity 
grade(Low/Medium/High
) 
44.9/47.6/7.
4 
43.7/46.9/9.
4 
NS 50.4/41.3/8.
2 
35.5/53.8/10.
7 
<0.01 
DM (%) 13.6 23.2 <0.01 17.0 39.7 <0.01 
Dialysate type % (N) 
Icodextrin 
1.36% Glucose 
2.27% Glucose 
3.86% Glucose 
 
0 
66.7 (647) 
8.0 (78) 
25.3 (245) 
 
44.8 (690) 
30.0 (461) 
19.0 (293) 
6.2 (95) 
n/a  
0 
54.3 (461) 
34.5 (293) 
11.2 (95) 
 
100 (690) 
0 
0 
0 
n/a 
Modality (N) 
CAPD 
APD with day fill 
APD with short day fill 
 
970 
0 
0 
 
1012 
378 
149 
n/a  
732 
89 
28 
 
280 
289 
121 
<0.01 
a, Glucose before 1998 vs Glucose after 1998 and icodextrin; b, Glucose after 1998 vs 
Icodextrin 
c, unpaired t-test and one way ANOVA for continuous normal distributed variable, Mann-
Whitney U test and independent samples Kruskal Wallis test for non-normal distributed 
variables, chi-squared test for category variables 
NS, not significant; n/a, not applicable; BMI, body mass index; UF, ultrafiltration; PET, 
Peritoneal equilibration test; DM, diabetes 
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5.4.2 Comparison of patient and membrane characteristics 
between PD modalities within observation groups 
The patient and membrane characteristics of the different modalities within icodextrin and 
glucose after 1998 observation groups are displayed in Table 5-2. There were fewer patients 
on CAPD in the icodextrin observation group compared with glucose observation group 
(P<0.01). In both observation groups, CAPD patients were older. The APD with short day fill 
group was characterized as having less urine output, on PD for longer time, and higher PSTR.  
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Table 5-2 Comparison of the patient and membrane characteristics between different PD modalities within icodextrin 
(after 1998) and glucose after 1998 observation groups 
 
Icodextrin (after 1998) 
N=690 
Glucose after 1998 
N=849 
 
 
CAPD 
(n=280) 
APD with day fill 
(n=289) 
APD with 
short day fill 
(n=121) 
P value
a
 
CAPD 
(n=732) 
APD with day fill 
(n=89) 
APD with short 
day fill 
(n=28) 
P value
a
 
age (year) 59.7±13.9 54.4±17.6 57.6±12.3 <0.01 56.5±16.2 48.8±16.3 48.3±16.7 <0.01 
gender (M/F)% 62.9/37.1 50.9/49.1 67.8/32.2 <0.01 49.5/50.5 52.8/47.2 50.0/50.0 0.84 
BMI (kg/m
2
) 27.3±5.6 27.8±5.7 28.4±4.0 0.18 25.9±5.0 24.9±4.6 26.6±3.9 0.13 
time on therapy (mo) 21.5(12-37.5) 24(13-39) 33(20-49) <0.01 13(2-34) 15(6-33) 24(17-45) <0.01 
urine volume (ml) 659(254.5-1131.5) 597(152-1036) 0(0-372) <0.01 1006(395-1610.5) 819(180-1632) 0(0-140) <0.01 
input volume % (N) 
1500ml 
2000ml 
2500ml 
3.9 (11) 
78.9 (221) 
17.1 (48) 
56.1 (162) 
38.4 (111) 
5.5 (16) 
18.2 (22) 
67.8 (82) 
14.0 (27) 
<0.01 
10.1 (74) 
82.8 (606) 
7.1 (52) 
42.7 (38) 
50.6 (45) 
6.7 (6) 
7.1 (2) 
60.7 (17) 
32.1 (9) 
<0.01 
PSTR 0.74±0.11 0.74±0.14 0.77±0.14 0.053 0.63±0.12 0.66±0.12 0.68±0.11 <0.01 
UF capacity on PET (ml) 432±244 380±219 309±236 <0.01 451±216 465±285 397±263 0.38 
albumin (g/L) 31.5(29-34) 31(27.5-33.5) 31(28.5-33.5) 0.07 31.5(27.5-33.5) 30.5(28-33) 30.5(26-36) 0.72 
comorbidity grade 
(Low/Medium/High) % 
28.9/61.8/9.3 38.4/48.8/12.8 43.8/47.1/9.1 <0.01 51.2/39.8/9.0 42.7/52.8/4.5 53.6/46.4/0.0 <0.01 
DM (%) 47.5 37.0 28.1 <0.01 16.4 15.7 3.6 0.19 
a one way ANOVA for continuous normal distributed variable, independent samples Kruskal Wallis test for non-normal distributed 
variables, chi-squared test for category variables 
BMI, body mass index; UF, ultrafiltration; PET, Peritoneal equilibration test; DM, diabetes 
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5.4.3 The multi-level mixed linear model for long-dwell UF 
according to type of dialysate 
The long-dwell UF was different between gender, diabetic status, input volume, comorbidity 
grade and PD modality in at least one of the three observation groups. Time on therapy, BMI, 
UF capacity (on PET), PSTR, albumin and urine volume were significantly related to long-dwell 
UF on uni-level bivariate analysis in one or more observation groups. The detailed between 
group differences and uni-level bivariate correlations for the UF volume by observation 
groups is available in Table 5-3. These variables were included in multi-level mixed linear 
model, see Table 5-4.  
Gender, time on PD, PD modality (APD, no matter whole day fill or short day fill, compared 
with CAPD), input volume, BMI, PSTR, UF capacity on PET and plasma albumin were 
independent explanatory variables of UF obtained by icodextrin. These explanatory variables 
explained 21% of the whole variability of UF in icodextrin dwells. Within the unexplained 
variance, 31% was due to the between patient difference and 69% by within patient 
difference.  
In contrast to the icodextrin dwell, for the glucose long dwell (after 1998), urine volume was 
an independent covariate (β=-0.14, P<0.01), while the independent correlation between BMI, 
time on PD and UF by icodextrin was absent. The correlation between long dwell UF and 
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PSTR was negative for the glucose dwell and positive for icodextrin dwell. Lower plasma 
albumin independently correlated with more UF by icodextrin whereas the relationship was 
the opposite for glucose. Diabetic status did not have an impact on UF using icodextrin, while 
it correlated to more UF in glucose dwell. 34% of the variance of UF by glucose was explained 
by the explanatory variables in the model. The glucose concentration on its own explained 15% 
of the whole variance. 27% of the unexplained variance came from between patient 
difference and 73% was within patient difference. 
Comparing the two glucose observation groups, before and after 1998, urine volume was an 
independent covariate in both observation groups. Gender, input volume, albumin and 
diabetic status were not independent covariates previously, but were more recently. Glucose 
concentration accounted for much more total variance of UF (24% vs 15%) before than after 
1998. (Table 5-4)  
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Table 5-3 between group difference and uni-level bivariate correlation of the UF volume  
    
Glucose before 1998  
n=970  
Glucose after 1998  
n=849  
Icodextrin (after 1998)  
n=690  
    mean±SD 
P 
valuea mean±SD 
P 
valuea mean±SD 
P 
valuea 
Gender Female -23.4±361.1 NS 10.8±382.7 NS 317.9±268.9 <0.01 
Male -43.7±418.1   3.5±342.8   416.5±322.5   
DM or not non-DM -33.9±384.7 NS -6.2±349.2 <0.05 342.4±295.2 <0.01 
DM -36.0±438.7   72.6±420.4   426.4±313.7   
input 
volume 
1500ml -58.9±293.6 NS -203.4±337.3 <0.01 283.7±268.9 <0.01 
2000ml -34.3±405.8   35.5±343.5   432.6±311.7   
2500ml 22.8±456.7   83.2±465.3   307.0±288.2   
comorbidity 
grade 
low -11.9±412.4 <0.05 12.9±360.1 NS 338.7±253.1 NS 
medium -66.0±370.8   3.7±372.4   393.4±336.6   
high 35.0±388.3   -10.4±338.1   410.1±288.8   
PD modality CAPD -34.2±392.3 n/a 30.6±354.8 <0.01 489.9±271.5 <0.01 
APD with 
day fill     -186.0±359.2   287.8±291.4   
APD with 
short day 
fill      8.9±419.0   322.0±328.2   
    
correlation 
coeffecientb   
correlation 
coeffecient   
correlation 
coeffecientb   
age (year)  0.01 0.78 0.04 0.26 0.04 0.27 
time on therapy (mo)  0.09 0.01 0.04 0.21 -0.10 0.01 
BMI (kg/m2)  0.04 0.24 0.06 0.08 0.15 <0.01 
Weight (kg)  0.03 0.36 0.06 0.10 0.14 <0.01 
UF capacity on PET (ml)  0.09 <0.01 0.14 <0.01 0.13 <0.01 
PSTR  -0.11 <0.01 -0.15 <0.01 0.17 <0.01 
albumin (g/L)  0.02 0.58 0.03 0.39 -0.15 <0.01 
urine volume (ml)  -0.23 <0.01 -0.35 <0.01 0.12 <0.01 
BMI, body mass index; UF, ultrafiltration; PET, Peritoneal equilibration test; DM, diabetes 
a, unpaired t-test or one way ANOVA according to number of groups 
b, Pearson correlation  
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 Table 5-4 Multi-level mixed linear model for long dwell UF obtained by icodextrin or 
glucose based dialysate (before and after 1998 separately)  
 
Glucose before 1998 
n=970 
Glucose after 1998 n=849 
Icodextrin (after 1998) 
n=690  
   β  SE  P value  β  SE  P value  β  SE  P value  
constant  -159.2  26.6  <0.01  108.8 34.6 <0.01  472.7 32.8  <0.01  
Gender (if female)  -11.3  28.8    NS -67.5  28.0  <0.05  -81.4  30.9  <0.01  
time on PD (for each 
month)  
0.73  0.61   NS 0.80  0.52   NS -1.17  0.54  <0.05  
Urine Volume (for each 
ml)  
-0.08  0.02  <0.01  -0.14  0.02  <0.01  -0.02  0.02   NS 
APD with short day fill 
(compared with CAPD)  
         -191.9  59.3  <0.01  -160.2  37.0  <0.01  
APD with day fill 
(compare with CAPD)  
         -174.1  37.4  <0.01  -165.6  30.8  <0.01  
input volume 1500ml 
(compared with 2000ml)  
-32.8  35.8   NS -42.5  39.4   NS 16.1  33.9   NS 
input volume 2500ml 
(compared with 2000ml)  
-8.0  38.5   NS -142.3  43.3  <0.01  -110.7  41.6  <0.05  
BMI (for each 1kg/m
2
 
increase)  
-5.1  2.9   NS 5.1  2.8   NS 11.4  2.7  <0.01  
PSTR (for each 0.1 
increase)  
-85.1  11.7  <0.01  -57.35  9.71  <0.01  34.5  8.56  <0.01  
UF capacity on PET (for 
each ml increase)  
0.12  0.05  <0.05  0.10  0.05  <0.05  0.10  0.04  <0.05  
Albumin (for each 1g/L 
increase)  
1.1  2.2   NS 5.7  2.3  <0.05  -10.3  2.5  <0.01  
Diabetes (if yes)  -27.3  39.1   NS 75.3  34.2  <0.05  4.7  31.9   NS 
2.27% Glucose (compared 
with 1.36% Glucose)  
238.2 39.3 <0.01  130.7  25.9  <0.01   NS       
3.86% Glucose (compared 
with 1.36% Glucose)  
520.5  26.4  <0.01  402.4  37.6  <0.01   NS       
Explained variance by the 
whole model (%) 
36 
  
34 
  
21 
  
Proportion of whole 
variance explained by 
glucose concentration (%) 
24 
  
15 
  
NA 
  
Residual variance 
accounted by 
between/within patient 
difference (%) 
25/75 
  
27/73 
  
31/69 
  
 BMI, body mass index; UF, ultrafiltration; PET, Peritoneal equilibration test; DM, diabetes 
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5.5 Discussion 
This is the first study demonstrated that over time there is less UF obtained using  icodextrin 
in long term PD patients despite the fact that they tend to have a higher PSTR (small pore 
area). It is also the first study to give such a practical and comprehensive description of 
factors associated with the variability in UF achieved with icodextrin in a clinical setting. It 
also provides useful information for the clinician by providing evidence on which to base 
prescription guidance to get the best UF using icodextrin.  
5.5.1 The changing membrane  
In response to the original research question, the most important findings of this study was 
the impact of time on therapy and UF capacity in PET on achieved UF obtained with 
icodextrin; both point to membrane fibrosis and reduced osmotic conductance for glucose.  
It is likely that one component of the osmotic conductance (LpSσg), namely the liquid 
membrane permeability (Lp) also affects fluid transport obtained with icodextrin (in effect, 
LpSσg is proportional to LpSσico, although σ is of course very different as will be fluid 
reabsorption kinetics). It is therefore possible that the observation that UF with icodextrin 
declined with time on treatment, despite the increase in PSTR, reflects a reduction in LpSσico 
due to reduced Lp as observed in severe type 2 UF failure, usually present after prolonged PD 
use 161. This is thought to be associated with the development of fibrosis 162  and the cause 
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the “uncoupling” of PSTR from the peritoneal UF coefficient (LpS) or more precisely, the 
peritoneal osmotic conductance to glucose (LpSσg) 
103.  
This study confirmed the previous finding that fast transporters achieve a better UF than 
slower transporters 163, 164 and also gave a practical estimate of the size of this effect. A 
patient with PSTR of 0.9 would be expected to have about 100ml more UF than a patient 
with PSTR 0.6. According to the three pore model, icodextrin draws UF almost exclusively 
through small pores. High transport status measured by PET corresponds to a bigger effective 
membrane area and therefore more small pores.      
5.5.2 Osmotic pressure gradient  
The present study was the first clinical study to show that patients with lower albumin levels, 
who tend in general to have more difficulties in fluid management, have, as predicted by 
modelling, more UF when using icodextrin compared with those with normal albumin levels. 
It fits with the clinical observation that patients with poor fluid status gained more UF from 
icodextrin 165. According to the three-pore model, icodextrin exerts its main effect by creating 
colloid osmotic pressure. The computer-simulation based on the three-pore model predicts 
that plasma colloid osmotic pressure has a major impact on UF in icodextrin dwells 166. Most 
of the colloid osmotic pressure is attributable to serum albumin due to its predominant 
amount in circulation and small molecular weight. A study in a mixed group of healthy 
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individuals and hospital or clinic patients with various diseases showed a strong correlation 
between albumin concentration and colloid osmotic pressure, r=0.882 167. The reason that 
previous studies did not find this relationship between UF and albumin is likely due to the 
high day to day variance in both UF and albumin concentrations. The large sample size and 
use of a multi-level analytic approach as used here are needed to show this relationship.  
The advantage of using icodextrin in diabetes has been noticed and emphasized since it was 
first established due to its metabolic benefit. Several studies also proved its efficiency in fluid 
management in dietetic patients 168, 169. Ahmad, et al, further reported the observation that 
icodextrin actually produce higher UF in diabetic than in non-diabetic patients 170. Our study 
proved their observation in uni-variate analysis. However, when accounting for the other 
variables in the multi-variate model, especially albumin and transport status, the difference 
between diabetic and non-diabetic disappear. 
5.5.3 The effect of dwell volume 
The observation that a large input volume was related to less UF is different from the 
computer stimulation based on the three pore model which predicts similar or, if anything, 
more UF in large input dwells (2.5L or 3L) 171.  The effect of large input volume in the clinical 
setting is complicated. Apart from the fact that osmotic pressure maintains longer with large 
input volume, although this effect is much more predominant in glucose dwells, it increases 
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the effective membrane area on one hand, and increases intra-peritoneal hydrostatic 
pressure on the other. According to the present study, it seems that the effect of the longer 
maintained osmotic pressure and increased efficient membrane area, which potentially 
increase UF, was over-ridden by the high intra-peritoneal hydrostatic pressure. Input volume 
has a major impact on intraperitoneal pressure. An elevated intra-peritoneal hydrostatic 
pressure would favour fluid reabsorption by whatever route (transcapillary or lymphatic). 
From computer stimulations, we know that an increased rate of macromolecular clearance 
out of the peritoneal cavity could be related to a decreased UF by icodextrin. There is also 
clinical data showed the significant effect of hydrostatic pressure on UF with glucose 
exchanges 172. A study in children confirmed the negative relationship between intra-
peritoneal pressure and net UF achieved by glucose in four hour dwells but found no such 
relationship in icodextrin 173. However, these results should be interpreted with caution, 
especially when extrapolating to long dwells and adults, as observations were limited to 4-
hour dwells and it is known that children achieve less UF with icodextrin than seen in adult 
174  
5.5.4 The UF difference between APD and CAPD 
Another important finding of this study was that CAPD achieves more UF than APD in long 
dwells, regardless icodextrin or glucose solution. The difference in intraperitoneal pressure 
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between supine and up-right may contribute some of the difference between APD and CAPD 
long dwells as mentioned before.  
But it may not be the only explanation. It is difficult to compare daily achieved UF with APD 
versus CAPD as it very much depends on the prescription. However, on the one hand, it is 
widely accepted that CAPD is as good as APD in terms of preserving residual renal function, if 
not better. On the other hand, higher daily UF in CAPD has been noticed in several studies 175-
177. Neglecting overfills used to be a reason for overestimating UF in CAPD, but awareness of 
this is now established. 159, 178, 179.  There are still studies like the present one which had 
clearly accounted for overfill yet still find a difference in UF between APD and CAPD. A follow 
up study in incident patients  showed UF was consistently lower in incident APD patients 
than in their counterparts undergoing CAPD. Again, unexpectedly, the residual renal function 
declined faster in the APD group rather than the CAPD group in that study. None of the 
studies so far, including the present study, have taken into account the difference between 
volumetric measurement versus weighing of dialysis fluid in assessing the amount of UF. In 
fact, specific gravity of drained dialysate is greater than 1.0, so using the equivalent values 
(1g=1ml) in CAPD patients will overestimate UF, whereas it is measured as true volume by 
the APD device. According to the average specific gravity of drained icodextrin (1.026g/ml) 
measured in limited number of samples, there is an about 60 ml over estimation of UF in 
CAPD in a single icodextrin dwell (2L) with 0.4L UF. (More detailed calculation see appendix) 
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5.5.5 The effect of dwell length 
UF using icodextrin is expected to increase in a linear fashion for at least until 17 hours 
according to the computer stimulation base on the “standard” set of parameters of the 
three-pore model 171. This analysis suggests that UF from 15 hour dwells is no more than 9 
hours dwells on average To address this problem Jeloka at al. designed a study to discover 
the relationship between UF and dwell length 180 in icodextrin in which Dwell length was 
increased by one hour every week, from 10 to 14 hours. In keeping with the present 
observation they found there was no significant increase in UF beyond 10 hours on average 
but discovered a number of  divergent UF patterns, with the peak being achieved at different 
times in different subjects. By resetting the parameters in three pore model it is possible to 
partially explain this variability 166. It is clinically useful to be aware that prolonged dwell time 
does not always lead to better UF using icodextrin.    
5.5.6 Effects of the Icodextrin metabolite distribution volume 
Another finding of this study that had not been reported before was the positive relationship 
between UF and BMI, as well as the gender difference in icodextrin UF. Combined with the 
previous observations that body weight, or more precisely the volume of distribution was the 
only important predictor of plasma icodextrin metabolite concentrations in both long term 
patients 181  and in a single exchange kinetics study 182, it raises the possibility that the effects 
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of BMI and gender are a function of plasma icodextrin metabolite concentrations which then 
affect achieved UF. It is known that icodextrin use increases the plasma icodextrin metabolite 
concentrations and the icodextrin metabolites increase plasma osmolality 183-185. Computer 
simulations indicate that the osmolar effect of icodextrin metabolites might oppose 
peritoneal UF 171 and fit with the known phenomenon that patients naïve to icodextrin get 
more UF than those on long term use. However, the hypothesis that plasma icodextrin 
metabolites may negatively correlate with UF has not been validated in clinical studies so far. 
A study done by Ota et al. in 18 patients demonstrated 5 mOsm/L increase in plasma 
osmolality due to circulating icodextrin metabolites, but the plasma icodextrin metabolite 
level did not have statistically significant influence on net UF 185. Taking the relatively small 
impact of the osmolar effect on UF within the deviation of plasma icodextrin metabolite in 
PD population, a much bigger sample size such as achieved with the present study would be 
needed to pick up a the clinically and statistically significant effect on UF. The technical 
difficulty and expense in measuring icodextrin metabolites make this difficult to carry out 
such a big study.     
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Table 5-5 the potential linkage between clinical observation and theoretic parameters 
   Clinical phenomenon  Theoretic  parameters 
icodextrin  PSTR↑, UF ↑  
Membrane area (S)  
glucose PSTR↑, UF ↓  
icodextrin  
Time on therapy ↑, UF ↓  
Hydraulic permeability (Lp) 
reflection coefficient (σ)  
UF capacity in PET ↑ , UF ↑  
glucose 
Time on therapy ↑, UF ↔ 
UF capacity in PET ↑ , UF ↑  
icodextrin 
Big input volume (2500ml), UF ↓ 
hydrostatic pressure gradient  
APD less than CAPD in UF 
glucose  
Big input volume (2500ml), UF ↓ 
APD less than CAPD in UF 
icodextrin 
Female less than male in UF 
Icodextrin metabolite concentration  BMI↑ , UF ↑ 
glucose NA 
icodextrin albumin ↓, UF ↑  Colloid osmotic pressure  gradient   
glucose Glucose concentration crystalloid osmotic pressure  gradient   
icodextrin  9h vs 15h similar 
a
 
Dwell length  
glucose 9h vs 15h similar 
a
 
icodextrin urine volume ↑, UF ↔  
Others: urine volume  
glucose urine volume ↑, UF ↓ 
b
 
icodextrin nil  
Others: comorbidity (diabetes)  
glucose nil 
c
 
The selective biases had to bear in mind when interpreting the result.  
a, UF in 15 hours dwells was no more than 9 hours, but it could be less. Because one of the reasons to 
switch from 15 hours to 9 hours dwells was unsatisfied UF. 
b, more urine volume related to less UF in glucose dwells. It was likely that those with less UF would be 
kept on glucose solution only when they had enough urine volumes, otherwise they would have been 
switched to icodextrin solution or HD.  
c, diabetic status was related to more UF in glucose dwells after 1998. Similar argument as b. 
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5.5.7 Limitations 
This study had a number of limitations. First, it was not a randomized controlled trial and the 
selective biases clearly existed in response to the changing prescription policy over 20 years. 
These selective biases have to be borne in mind when interpreting the result, especially for 
glucose dwells. For example, more urine volume was related to less UF in glucose dwells in 
this study. It was likely that those with less UF would be kept on glucose solution only when 
they had enough urine volumes, otherwise they would have been switched to using the 
icodextrin solution or HD. Similar arguments may also be applied for the finding that there 
was no impact of time on therapy in glucose dwells and that diabetic status predicts more UF 
after 1998. The lack of difference between 9 hour and 15 hour dwells by glucose based 
solution may again due to the intended switch from long dwells to shorter dwells in patients 
who were not obtaining enough UF. Secondly, due to the observational nature of the study, 
the selective biases also came from the disproportional drop out of patients due to technique 
failure or death. However, the negative correlation between time on PD and UF using 
icodextrin was not likely to come from this informative censoring as it is unlikely that patients 
achieving better UF from icodextrin would leave the therapy earlier. Thirdly, the interaction 
effect between input volume, glucose concentration and PD modality (CAPD/APD) could not 
been further studied because of the small number of observations in some break down 
categories. Fourthly, only linear relationships was analysed in detail in the present study, 
 192 
 
 
whereas more complex non-linear relationship may exist as seen in the study by Jeloka180. 
Fifthly, no correction for multiple comparisons was made in the study which may potentially 
increase the risk of type I error. The variables selected in the model were based on 
scientifically plausible hypothesis rather than every possible combination, which should limit 
the risk. Finally, none of the theoretical parameters were directly measured in the study (e.g. 
plasma oncotic pressure), but rather clinically measured surrogates were used (e.g. plasma 
albumin). 
 193 
 
 
5.6 Conclusion 
1. Prolonged time on PD decreases UF obtained with icodextrin. 
2. It is uncoupled from the effect of increase in PSTR. It would be in keeping with a 
progressive fibrosis combined with increased in small pore area.  
3. Better UF capacity indicates more UF by icodextrin. The factors which are likely to 
affect the oncotic pressure gradient, hydrostatic pressure gradient or icodextrin 
metabolites concentration (plasma albumin, input volume, patient position, BMI and 
gender) are more important than the dwell length in explaining UF variability.  
4. To achieve better UF obtained with icodextrin, dialysis prescriptions excert high intra 
peritoneal pressure should be avoided and prolonged dwell length may not be helpful. 
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What is the relationship between soluble chapter 6.
biomarkers of inflammation and endothelial damage, 
systemic transcapillary albumin leak and 
hypoalbuminaemia in PD patients? 
(the main body of this chapter has published on Nephrol Dial Transplant 2012; 27:4437-4445) 
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6.1 Summary 
6.1.1 Purpose 
Inflammation, hypoalbuminaemia and Pcl are important predictors of survival in patients 
treated with PD.  We hypothesised that the common link is abnormal endothelial barrier 
function. To test this, we explored associations between hypoalbuminaemia, systemic 
albumin leak and soluble markers of systemic inflammation and endothelial injury. 
6.1.2 Methods 
This was a cross-sectional study of 41 prevalent PD patients. Endothelial barrier function was 
measured as transcapillary escape rate of 125-I albumin (TERalb). 17 plasma biomarkers 
including pro-inflammatory cytokines, endothelial biomarkers and MMPs, were measured. 
Hierarchical clustering analysis (HCA) and principal component analysis (PCA) were used in 
this hypothesis generating exploratory study. 
6.1.3 Results 
The mean TERalb was 13.7±8.9 (%/h), higher than in non-uremic subjects 8.22±5.8 (%/h). 
Three patient clusters were defined from HCA according to their biomarker patterns. Cluster 
1 was characterized by inflammation, hypoalbuminaemia, over hydration and intermediate 
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TERalb. Cluster 2 was non-inflamed, preserved muscle mass and more normal TERalb. Cluster 3 
had highest TERalb, platelet activation, preserved plasma albumin and intermediate hs-CRP 
levels. Two principal components (PCs) were identified from the biomarker matrix, PC1, 
indicating platelet activation and PC2, pro-inflammatory. TERalb was positively related to PC1 
but not PC2. Diabetes and ischemic heart disease were associated with PC1 and PC2 
respectively. 
6.1.4 Conclusions 
This exploratory analysis indicates that endothelial barrier function is decreased in PD 
patients and is associated with diabetic status and markers of platelet activation more than 
inflammation. In contrast, hypoalbuminaemia is associated more with inflammation and 
atherosclerotic disease indicating a more complex relationship between systemic endothelial 
barrier function, inflammation and hypoalbuminaemia which requires further validation.  
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6.2 Introduction 
As demonstrated in Chapter 3, Pcl predicts survival of PD patients independent of PSTR and 
peritoneal membrane inflammation, and its relationship to comorbidity and survival is 
complex. The association between Pcl and survival is likely to be a combination of 
hypoalbuminaemia and high vascular permeability due to endothelial dysfunction associated 
with systemic vascular injury. Inflammation and hypoalbuminaemia are both important 
predictors of survival in patients treated with dialysis for advanced renal failure 53, 186, 187. 
Indeed it may represent the link between increased systemic and/or peritoneal protein leak, 
inflammation, hypoalbuminaemia and worse survival through its association with reduced 
capillary barrier function. (See Figure 6-1) 
 To investigate this relationship between the systemic transcapillary escape rate of albumin 
(TERalb), as an indicator of endothelial barrier function, a panel of biomarkers of endothelial 
dysfunction and associated clinical phenotypes. Hierarchical clustering (HC) and principle 
component analysis (PCA) were used to generate patient groups from the patterns of 
biomarkers observed and then subsequently compared their clinical phenotypes so as to 
avoid any preconceived assumptions.  
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Figure 6-1Simplified linear hypothesis linking comorbidity to hypoalbuminaemia invoking 
reduced endothelial barrier function as the central unifying mechanism 
  
Figure 6-2 Modified relationship between comorbidity, inflammation, systemic protein leak 
and hypoalbuminaemia in the light of current findings. 
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6.3 Materials and Methods 
6.3.1 Study design and patient population 
This was a cross sectional study of prevalent PD patients in a single centre. Sequential 
patients were approached to participate and studied while undergoing their routine 6-
monthly assessments of peritoneal membrane function and dialysis adequacy tests, provided 
they were not acutely ill or within 1 month of peritonitis. The study was peer reviewed and 
approved by the local ethics committee and all patients signed the consent form.  
6.3.2 TERalb and plasma volume 
After a bolus intravenous injection of 10ml 0.185MBq 125I-human serum albumin (HSA), 
blood samples were taken at 10, 20, and 30 min at a remote venous site. The isotopic 
concentration in each case was plotted against time on a semi-logarithmic scale and the best 
linear fit line was performed from these points. TERalb, expressed as percentage loss per hour 
(%/h) was estimated from the disappearance rate of the 125I HSA from the gradient of this 
line. The plasma volume was calculated by extrapolating the line to time zero. The method 
was also applied for clinical purposes as the measurement of plasma volume in the 
normalisation of red cell mass and diagnosis of primary polycythaemia. These patients who 
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were mainly referred from haematologist during the time of this study served as non-uremic 
contemporaneous ‘in house’ controls.   
6.3.3 Biomarker measurement 
The plasma sample for biomarker analysis was collected just before 125I HSA injection on the 
study day and stored at -20°C. A panel of 17 biomarkers, which are involved in inflammation, 
endothelial function and tissue remodelling processes, [interleukin-6 (IL-6), tumour necrosis 
factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin-1 beta (IL-1β), interleukin-10 (IL-
10), monocyte chemotactic protein-1 (MCP-1), inter-cellular adhesion molecule 1 (ICAM-1), 
vascular cell adhesion protein 1 (VCAM-1), E-selectin, P-selectin, CD40 ligand (CD40-L), 
vascular endothelial growth factor (VEGF), matrix metalloproteinase-1 (MMP-1), matrix 
metalloproteinase-2 (MMP-2), matrix metalloproteinase-3 (MMP-3), matrix 
metalloproteinase-8 (MMP-8), matrix metalloproteinase-9 (MMP-9)], was measured on a 
Luminex suspension array system (BioPlex 200TM platform, Bio-Rad Laboratories, Hemel 
Hempstead, Hertfordshire, UK) using commercially available multi-analyte cytokine kits 
(Milliplex MAP, Millipore (UK) Ltd, Walford, Hertfordshire, UK) or Fluorokine multi-analyte 
profiling kits for MMPs (R&D Systems, Abingdon, UK). Assays were carried out according to 
the manufacturer’s instructions. A brief description of the biomarkers measured was 
summarised in Table 6-1.  
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Table 6-1 A brief summarize of the biomarkers measured in the study 15, 188 
biomarkers  Main sources Main biological function 
CD 40 ligand Activated 
platelets 
Bound to CD40, promotes leukocyte recruitment and 
transmigration on endothelial cells. Enhances plaque 
thrombogenicity through mediating tissue factor 
expression. 
Platelet factor 
4 
Activated 
platelets 
Promotes blood coagulation and leukocyte attraction 
P-selectin Activated 
platelets, 
endothelial cells 
Mediates endothelial cell/platelet-leukocyte interaction 
E-selectin Endothelial cells Promotes leukocyte rolling 
VEGF Endothelial cells, 
leukocytes, 
activated 
platelets 
prime regulator of angiogenesis and contributes to vascular 
permeability, regulated by growth factors and cytokines 
ICAM-1 Endothelial cells, 
leukocytes 
Promotes leukocyte adherence and migration 
VCAM-1 Endothelial cells Promotes leukocyte adherence  
IL-6 Endothelial cells, 
macrophages  
Stimulate acute phase proteins and antibody production, 
activate cytotoxic lymphacytes 
TNF-α macrophages Promotes expression of adhesion molecules and 
inflammatory cell recruitment 
IFN-γ leukocytes Immunoregulatory cytokine 
IL-10 leukocytes Down-regulation of adhesion molecules and 
proinflammatory cytokines 
IL-1β macrophages Promotes expression of adhesion molecules and 
inflammatory cell recruitment 
MCP-1 Endothelial cells  Recruits monocytes to sites of vascular injury or 
inflammation. Contributes to thrombin generation and 
thrombus formation. 
MMPs macrophages Tissue remodeling, contribute to plaque instability 
VEGF, vascular endothelial growth factor; ICAM-1, inter-cellular adhesion molecule 1; VCAM-1, vascular cell 
adhesion protein 1; IL , interleukin; TNF-α, tumour necrosis factor-alpha; IFN-γ, interferon-gamma; MCP-1, 
monocyte chemotactic protein-1; MMP, matrix metalloproteinase  
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6.3.4 Body composition, solute clearance, membrane function 
and blood biochemistry 
Estimated total body water (TBW) and extra-cellular water (ECW) were evaluated by 
bioimpedance (BIA, multi-frequency Xitron Hydra device, Model 4200, Xitron Technologies, 
San Diego, CA). ECW/TBW was calculated and took as a measure of hydration status.189, 190  
At the same time, absolute TBW was measured by deuterium (D2O) dilution technique. The 
detailed methodologies have been described previously 191. In brief, a baseline and an 
equilibrated blood samples were taken before and 2.5 hours after an oral dose of 99.8% D2O 
(Cambridge Isotope Laboratories, USA). The difference between the headspace HDO 
abundance of the two samples, measured by flowing afterglow mass spectrometry (FA-MS), 
was used to determine TBWD after accounting for equilibration with dialysate and 4% D 
exchange with H in body proteins. The difference between BIA estimated (TBWBIA) and D 
dilution measured TBW (TBWD) reflects tissue over hydration 
144, 191.  
The dialysis dose and residual renal function were calculated as the weekly Kt/Vurea from the 
24-hour urinary and dialysate clearance by direct measurement of urea in urine and dialysate. 
Peritoneal dialysate protein loss was measured from the collection of 24-hour dialysate 
effluent. A validated equation was used for the calculation of protein clearance, (Pcl), =24 
hour dialysate protein loss/(serum albumin/0.4783). 
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Solute transport was measured by standard 4-hour PET test with 2.27% glucose 
concentration 2-L exchange. The dialysate:plasma ratio of creatinine at the completion of the 
4-hour dwell period (D/P creatinine) was used to estimate PSTR.  
Plasma albumin was estimated using the bromocresol purple colorimetric method, 
peritoneal dialysate and urine protein by the Biuret method. C-reactive protein was 
measured using a latex enhanced immunoturbidimetric method.  
6.3.5  Statistical analysis 
One way ANOVA and unpaired t test were used to examine differences in normally 
distributed continuous data among groups, chi-square for categorical data. Univariate 
correlations were examined by Pearson correlation coefficient. Variables not normally 
distributed were log2 transformed for further analysis. Significance was considered at P 
values <0.05. Statistical analyses were performed using IBM SPSS Statistics version 19 except 
for the HCA. 
6.3.5.1 Hierarchical cluster analysis (HCA) 
The biomarker levels were first converted to Log2 and expressed relative to the mean value 
for normalization. These measurements were used to generate heat map using Genesis 
software (version 1.7.2, Alexander Sturn, Institute for Genomics and Bioinformatics, Graz 
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University of Technology). The Genesis programme uses a two-dimensional HC method, using 
the average linkage clustering agglomerative rule that enables groups of variables with 
similar expression levels to be clustered together as well as grouping together patient 
samples with similar expression patterns.  
6.3.5.2 Principal component analysis (PCA) 
To decrease the dimensionality of the biomarker data set while retaining as much of the 
variance as possible, an exploratory PCA was employed. Principal components (PCs) were 
extracted using varimax rotation, with the factor selection based on an eigen value cut-off of 
1.0. Because of limitations of the sample size, 8 biomarkers only were processed in the final 
analysis. These biomarkers were selected from the first two PCs, which contributed the most 
variance of the whole matrix. Those biomarker variables not normally distributed after log 
transformation were converted to binary data.  
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6.4 Results  
A total of 41 prevalent patients (M/F 22/19, mean age 61±17 years, median time on PD 20 (9-
33) months, diabetics 29%) were studied. The TERalb was higher in the PD patients 13.74±8.8 
(%/h) than the non-uremic comparator group 8.22±5.8 (%/h) (n=13, P<0.05).  
Three clusters and one outlier were defined from the HCA (Figure 6-3). Patient characteristics, 
peritoneal membrane function and TERalb (Table 6-2) and absolute biomarker concentrations 
(Table 6-3) are shown by cluster. Cluster 1 was characterized by an inflammatory profile, 
associated with higher hs-CRP, lower albumin, intermediate TERalb and over hydration 
indicated by higher ECW/TBW BIA  and the big discrepancy between measured TBW (TBWD) 
and estimated (TBWBIA) – a more sophisticated measure of over hydration. (Figure 6-4, Figure 
6-5) Cluster 2 was non-inflamed according to the lowest CRP levels, had the lowest TERalb and 
the most normal body composition as evidenced by the highest body water by body weight 
but good agreement between D dilution and BIA measures, indicating well preserved muscle 
mass but least over hydration. Cluster 3 was characterised by biomarkers consistent with 
platelet activation, had the highest TERalb but only moderate CRP levels, less inflammation 
and less over hydration than Cluster 1 patients.  
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Figure 6-3 Plasma concentration profiles of 17 biomarkers in 41 patients expressed as a 
hierarchical clustering analysis (HCA) heat map.  
Plasma concentrations of biomarker close to, higher and lower than the mean values are 
represented by black, red and green colours, respectively. Three patient clusters, Cluster 
1 (blue bar), Cluster 2 (green bar), Cluster 3 (red bar) and one outlier are generated by 
HCA. 
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Table 6-2Characteristics of the three patient clusters derived from hierarchical clustering 
analysis 
 Cluster 1 
(n=17) 
Cluster 2 
(N=9) 
Cluster 3 
(n=14) 
Single 
Outlier 
TERalb (%/h) 13.88±9.23 9.12±5.29
a 17.29±9.11 3 
Age (yr) 62.1±17.2 61.4±19.2 60.3±15.7 60 
Gender (M%) 65 56 36 M 
BMI (kg/m2) 26.1±5.7 25.8±3.9 28.3±5.1 25.1 
PD duration (mo) 22.9±20.3 27.6±21.0 26.8±21.2 10.5 
PSTR  0.81±0.13 0.78±0.12 0.74±0.17 0.7 
Albumin (g/L)  29.1±4.9b 31.3±3.3 33.2±4.1 33 
CRP(mg/L) 14.3(4.8-21)c 1.5(0.6-4) 4.6(0.8-9.5) 16.8 
Peritoneal Pcl (ml/day) 95.6±48.3 67.3±21.7 69.0±24.7 64.04 
Daily peritoneal protein loss 
(g/24h) 
6.3±3.2 4.9±1.6 5.0±1.8 4.28 
Urine protein loss (g/24h) 0.58±0.5 0.88±0.85 0.74±0.51 1.12 
Total daily protein loss 
(g/24h) 
7.11±3.00 6.06±2.06 6.02±2.07 5.4 
Urine volume (ml) 709±631 1128±626 1059±759 997 
Adjusted PV (ml/m2) 1439±300 1441±173 1446±197 2158 
TBWD/Weight 0.51±0.04 0.53±0.07
a 0.47±0.06 0.52 
TBWBIA/Weight 0.45±0.05 0.53±0.08
c,d 0.45±0.06 0.56 
TBWD/Weight - 
TBWBIA/Weight 
0.049±0.041 0.006±0.025e 0.023±0.055 -0.046 
ECW/TBW BIA 0.50±0.04 0.47±0.03
f 0.48±0.04 0.44 
Ever smoked (%) 44 22 23 yes 
IHD (%) 41 22 29 No 
Diabetes (%) 17 22 50 No 
a, Cluster 2 vs Cluster 3, P<0.05; b, Cluster 1 vs Cluster 3, P<0.05; c, Cluster 1 vs Cluster 2, P<0.01; d, Cluster 
2 vs Cluster 3, P<0.01; e, Cluster 1 vs Cluster 2, P<0.05; f, Cluster 1 vs Cluster 2, P=0.085. (one way ANOVA 
post hoc test (Fisher's least significant difference (LSD))  
TERalb , transcapillary escape rate of albumin; Pcl, protein clearance; BMI, body mass index; Adjusted PV, 
plasma volume adjusted by body surface area; TBWD/Weight, Total body water (TBW) normalized to body 
weight as determined from deuterium (D) dilution; TBWBIA/Weight, Total body water (TBW) normalized 
to body weight as estimated by BIA; IHD, ischemia heart disease. 
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Table 6-3 biomarker concentration of the three patient clusters derived from hierarchical 
clustering analysis 
  cluster 1 cluster 2 cluster 3 single outlier P value a  
ICAM-1 (ug/ml) 0.49±0.09 0.4±0.07 0.34±0.08 0.41 <0.01 
VCAM-1 (ug/ml) 0.83±0.18 0.74±0.16 0.72±0.2 0.52  NS 
E-Selectin (ng/ml) 68.21±31.07 44.16±18.08 56.23±27.51 26.13  NS 
P-Selectin (ng/ml) 94.63±31.68 79.94±27.23 126.52±46.95 48.53 <0.05 
MMP-1 (pg/ml) 33.4(15-104.8) 10.1(1-60.8) 345(35.9-821.8) 1 <0.05 
MMP-2 (ug/ml) 0.24(0.17-0.28) 0.76(0.34-1) 0.29(0.23-0.44) 0.24 P=0.081 
MMP-3 (ng/ml) 11.5±5 22.76±12.76 13.52±4.49 9.04 <0.01 
MMP-8 (ng/ml) 3.69±1.66 2.26±0.8 2.04±1.15 0.33 <0.01 
MMP-9  (ng/ml) 67.66±38.23 55.54±26.02 53.13±30.4 30.7  NS 
IFN gamma 
(pg/ml) 1.4(0-4.6) 0.5(0-1.4) 1.7(1.1-2.3) 2.1  NS 
IL-1beta (pg/ml) 0.1(0.1-0.1) 0.1(0.1-0.1) 0.4(0.1-4.1) 0.1 <0.01 
IL-6 (pg/ml) 5.4(3-11.4) 2.2(1-4.2) 3.5(2.8-5.1) 8.7 <0.05 
IL-10 (pg/ml) 2.7±2 1.4±1.9 4.5±4 1.4 <0.05 
MCP-1 (pg/ml) 357.8±156.9 377.5±175.2 417.1±131.2 61.7  NS 
CD40L (ng/ml) 3.1±2.3 4.16±2.58 7.85±2.61 1.16 <0.01 
TNF alpha 
(pg/ml) 12.1±4.9 6.4±4 8.9±3 19.5 <0.01 
VEGF (pg/ml) 3(3-3) 3(3-3) 50.9(3-135.7) 3 <0.01 
a, one way ANOVA for continuous normal distributed variable, independent samples 
Kruskal Wallis test for non-normal distributed variables 
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Figure 6-4 ECW/TBW (estimated by BIA) grouped by clusters determined by hierarchical clustering 
analysis (HCA).  
ECW/TBW (estimated by BIA) is positively associated with over hydration and related to 
outcome. 190 Cluster 2 patients show relatively lower ECW/TBW compared with Cluster 1 
and the variance between patients is less. 
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Figure 6-5  Total body water (TBW) normalized to body weight as determined from 
deuterium (D2O) dilution (TBWD/Weight) (blue) and estimated by BIA 
(TBWBIA/Weight) (green) grouped by clusters determined by hierarchical clustering 
analysis (HCA).  
Excess TBW determined from BIA compared with D dilution is associated with over 
hydration 144, 191. Cluster 2 patients show good agreement between the methods and have 
the highest normalised body water indicating their well preserved muscle mass. Patients 
in Cluster 1 and to a lesser extent Cluster 3 have higher measured body water than 
estimated by BIA indicating their over hydration. 
 
The PCA was first carried out in the whole panel of the 17 biomarkers. Seven principal 
components (PCs) were identified, explaining 74.9% of the total variance, Figure 6-6. The 
eight biomarkers that composed the two strongest PCs, contributing the majority of the 
variance, were selected for the final PCA and are shown with their eigen values (> 1) in Figure 
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6-7. The first PC (PC1-platelet activation) was composed mainly of MMP-1, P-selectin, CD40L 
and VEGF. The second PC (PC2 pro-inflammation) featured an inverse relationship between 
MMP-3, and positive association with IFN-γ, TNF-α and VCAM-1. This component showed a 
positive relationship with CRP (r=0.31, P=0.047) and was negatively correlated with plasma 
albumin (r=-0.50, P=0.001).  
Figure 6-6 Principal component analysis (PCA) from the whole panel of the 17 
biomarkers  
Eigen values and percentage contributing to the total sample variance of each of the 7 
principal components (PCs) is presented. Individual composition feature is showed along 
with their rotated loading coefficients, a measure of the importance of each biomarker to 
the factor, displayed as a bar chart.  
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Figure 6-7 Principal component analysis (PCA) from reduced number of biomarkers 
The 8 biomarkers that compose the two strongest principal components (PCs), 
contributing the majority of the total sample variance are selected for the final PCA. The 
composition of the 2 PCs derived from the final model is displayed along with their 
rotated loading coefficients expressed as a bar chart. 
 
The relationship between the HCA and PCA is shown graphically in Figure 6-8. It can be seen 
that despite differing dimensions that these two analytical techniques give patterns that are 
in agreement. Patients with different comorbidities also showed differences in PCs such that 
patients with IHD and DM have different, albeit overlapping patterns of biomarkers (Figure 
6-9). Diabetes had higher PC1, while PC2 was higher in ischemic heart disease (IHD). 
Peripheral vascular disease (PVD) showed no difference in PC1 and PC2, (Table 6-4).   
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Figure 6-8 Combined graphical representation of the hierarchical clustering analysis 
(HCA) (centroid plot) and principal component analysis (PCA) (dimensionless weighted 
scores). 
There is good agreement between the methods showing association between cluster 3 
and increased platelet activation, cluster 1 with inflammation and cluster 2 with the 
absence of markers of endothelial dysfunction. 
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Figure 6-9 Combined graphical representation of PC scores and comorbidity; heart disease 
(IHD) and diabetes (DM) are clustered according to their different pattern of PC scores. 
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Table 6-4 Principal components (PCs) in different comorbidity status 
 IHD (n=13) Non-IHD 
(n=28) 
P 
valuea 
DM (n=12) Non-DM 
(n=29) 
P valuea PVD (n=12) Non-PVD 
(n=29) 
P 
valuea 
PC1 -0.01±0.80 0.01±1.09 0.951 0.62±0.94 -0.26±0.92 0.009** -0.01±0.76 0.01±1.10 0.96 
PC2 0.51±0.89 -0.23±0.51 0.025* -0.19±0.97 0.08±1.02 0.436 -0.06±0.85 0.02±1.07 0.814 
PC, principal component; IHD, ischemia heart disease; DM, diabetes mellitus; PVD, Peripheral vascular disease 
a, Unpaired t-test 
*, P<0.05 
**, P<0.01 
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To further explore the relationship between clinical factors and biomarker profiles with our 
primary endpoint, TERalb, univariate regression analysis was undertaken. None of the clinical 
measures, including demographics, membrane function, PD duration, CRP or systemic 
dynamic factors (pulse pressure, mean blood pressure), showed significant correlation to 
TERalb whereas the biomarker derived PC1 score (platelet activation) showed a positive 
relationship (r=0.33 P=0.03). (Table 6-5) Multivariate analysis found this relationship to be 
independent of age, gender and PD duration.  
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Table 6-5 Univariate correlation of transcapillary albumin escape rate (TERalb) 
 Correlation coefficient P valuea 
Age (yr) -0.21 0.19 
BMI (kg/m2) -0.09 0.57 
PD duration (mo) 0.26 0.11 
Pulse pressure (mmHg) 0.10 0.54 
Albumin (g/L)  -0.09 0.56 
Log2CRP(mg/L) -0.04 0.81 
PSTR 0.12 0.46 
UF capacity (ml) -0.03 0.88 
Daily peritoneal protein loss (g/24h) 0.23 0.16 
Peritoneal Pcl (ml/day)  0.15 0.36 
urine protein loss (g/24h) -0.16 0.34 
Total protein loss (g/24h) 0.20 0.23 
Urine volume (ml) -0.22 0.17 
Gender   0.1 
Ever smoking   0.28 
IHD   0.39 
Diabetes   0.19 
PVD   0.71 
Principal Component 1 0.33 0.03* 
Principal Component 2 0.07 0.69 
Pcl, protein clearance; IHD, ischemia heart disease; PVD, Peripheral vascular disease; 
BMI, body mass index; PSTR, peritoneal solute transport rate 
a, Pearson or Spearman correlation for continuous variables as appropriate according to 
distribution and unpaired t test for between group difference 
*, P<0.05 
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6.5 Discussion 
This is the first study to measure systemic endothelial barrier function in patients with 
chronic kidney disease (CKD) stage 5 and relate this to a wide panel of circulating biomarkers 
of inflammation and endothelial dysfunction. It confirms that endothelial barrier function is 
abnormally decreased and suggests that this is not solely related to inflammation but more 
so to platelet activation in this clinically stable cross-sectional cohort.   Furthermore, patients 
with IHD and DM have different, albeit overlapping patterns of biomarkers, although both 
exhibit endothelial dysfunction.  
The TERalb is a widely accepted measurement of endothelial barrier function, first described 
as early as 1973 192, 193. TERalb is increased in several conditions associated with endothelial 
dysfunction such as diabetes, hypertension and atherosclerosis 29-32 and also sepsis where it 
is clearly associated with marked inflammation. However endothelial barrier function has 
been less well investigated in end stage renal disease. This study found that mean TERalb is 
higher in CKD stage 5 patients than in non-uremic controls that likely had other pathologies 
as they were undergoing investigation for polycythemia. A previous study of 29 non-diabetic 
CKD patients (GFR (11-44)ml/min*1.73m2) whose other markers of endothelial function (e.g. 
von Willebrand factor) were normal unless subjects were current smokers 194 showed no 
difference between CKD patients and normal controls. This suggests that severe renal failure 
is associated with more severe endothelial dysfunction and is in broad agreement with other 
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rather small previously published studies in dialysis patients. TERalb was increased in 11 
diabetics treated with PD (but not in non-diabetics) 195 and 9 pre-dialysis haemodialysis 
patients 196. This is supported by in vivo experiments in which human uremic plasma 
increased frog mesenteric micro- vascular permeability to both water and protein, 197 
subsequently confirmed in other studies.  22 One of the strengths of our study, which 
demonstrated a relatively high median TERalb was that we recruited sequential patients 
undergoing routine assessment of their therapy with <5% of patients declining investigation, 
so reducing selection bias.   
Although a relationship between TERalb and blood pressure was seen in some early studies in 
hypertension patients 192, 198, 199 we did not observe this to be the case in this cross-sectional 
study. The relationship may be more complex in this dialysis cohort with multiple 
comorbidities and concomitant medication. A study comparing TERalb according to the 
angiotensin-converting enzyme (ACE) gene polymorphism in essential hypertension showed 
that ACE D/D homozygosity, which is associated with high risk of atherosclerotic vascular 
disease is related to higher TERalb despite identical 24 hour blood pressure readings 
33. 
Furthermore, endothelial function can be influenced by medications used in the patients 
with related effect on TERalb. High-dose simvastatin reduces low-density lipoprotein 
cholesterol by 39%, and is reported to normalize TERalb 
34. No clear relationship between 
medications and TERalb were observed in this study. 
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The measurement of a wide range of biomarkers combined with hierarchical cluster and PCA 
allowed us to investigate the overall pattern of their association with endothelial barrier 
dysfunction. It is important to note that these analyses are exploratory in nature but allow 
the generation of hypotheses for further testing. Using this approach we were able to 
identify three main patient clusters and there was good agreement between these and the 
two main components identified through PCA; additional PCs were identified that warrant 
further investigation in a larger validation cohort but were excluded from further analysis 
here to avoid type 1 statistical error. The advantage to this approach is that while biomarkers 
are likely to correlate to each other as they all reflect endothelial function it enables 
identification of possible multiple biomarker functions or different metabolic or signalling 
pathways involved in endothelial dysfunction. For example, CD40L is expressed in lymph cells, 
epithelial cells, fibroblasts, endothelial cells and platelets in response to pro-inflammatory 
cytokines, platelet activators and nitric oxide signalling.  After combining with CD40, it 
subsequently up-regulates the pro-inflammatory and pro-atherogenic genes 17  Although 
results from our PCA should be taken as exploratory, we find that PC1 (HC3 phenotype) is 
composed primarily of MMP-1, P-selectin, CD40L and VEGF,  all of which are released in 
significant amounts from platelets, and reflect platelet activation 200. PC2, composed by IFN-γ, 
TNF-α and VCAM-1 and negatively contributed by MMP-3, is mainly involved in pro-
inflammatory pathways and defined the inflamed, overhydrated and hypoalbuminaemia HC1 
phenotype.  HC2 was a relatively healthy phenotype with most normal body composition and 
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least abnormal TERalb. PC1 and PC2 could explain a significant proportion (34.3%) of the 
variance in the whole biomarker matrix. 
One important finding of this study is demonstration that the link between platelet activation 
and increased endothelial permeability may not be just through inflammation. The links 
between inflammation as a trigger for platelet activation in vascular lesions and between 
inflammation, atherosclerosis and endothelial dysfunction in uraemia are well established 201. 
These pathways may however act either independently or sequentially; activated platelets 
can induce secretion of chemokines for monocyte recruitment 128 whereas single microvessel 
perfusion with TNF- alone, without platelet activation, does not alter the endothelial 
permeability129. In an aseptic animal injury model, systemic depletion of neutrophils with 
antibody failed to prevent the increase in vascular permeability, whereas antiplatelet pre-
treatment reduced this by 25% 130. These findings suggest that platelet activation may have a 
critical role in endothelial hyper permeability that may not necessarily be through 
inflammation, especially in the low grade inflammatory status seen in uremia.  
This study found that DM and IHD tend to cluster with different patterns of biomarkers 
associated with endothelial dysfunction and in keeping with other studies, we found that 
diabetics more commonly display an increase in platelet reactivity. 202  Worse cardiovascular 
outcomes in diabetics may reflect inadequate responses to anti-platelet therapy 203. Another 
important finding of this study is that the systemic leak of albumin from the circulation to 
 222 
 
 
extravascular space is not correlated to hypoalbuminaemia and thus unlikely to be causally 
related. It is well established that the single strongest predictor of plasma albumin 
concentration in PD patients is the daily peritoneal protein loss 66, 204, in turn strongly 
correlated to the rate of PSTR, an indicator of the effective vascular area in contact with 
dialysate. There is, however, residual variability in peritoneal protein losses that has now 
been shown in several studies to be an independent predictor of patient survival61, 72. This 
link between peritoneal Pcl and survival can at least in part be explained by an association 
with increasing age and cardiovascular comorbidity, raising the possibility that some of the 
variability may reflect endothelial dysfunction. We did not see any clear relationship between 
systemic protein leak and peritoneal protein losses in this study probably because the latter 
is dominated by effective peritoneal vascular area in contact with dialysate. It is also possible, 
given that this was a study of prevalent patients, that some had acquired membrane changes 
that could influence protein losses. The reason that plasma albumin is more strongly 
associated with peritoneal protein losses than with systemic leak is that the former 
represents net daily losses (typically 5-10 g/day) whereas the latter reflects the re-circulation 
between intra and extra-vascular pools of up to 10 times this amount daily. Net plasma 
albumin concentration will also be determined by the balance of synthesis and catabolism, 
and the former in relatively fit PD patients has been shown to be increased above normal.66 
The patients with the lowest albumin in this study were those with inflammation compared 
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to markers of platelet activation, in keeping with previous observations that 
hypoalbuminaemia in inflamed patients is associated with reduced synthesis.  
This study has a number of limitations. First, the number of patients would ideally be larger 
to enable a more extensive correlation of the PCA with clinical phenotype. Despite this, it 
remains the largest study of TERalb in dialysis patients to date and the numbers were limited 
by the ethical permission which was primarily obtained to measure plasma volume in an 
adequately powered study of fluid status and hypoalbuminaemia 191. Secondly, the 
biomarker patterns identified, while good evidence that the relationship in more complex 
that originally envisaged can only be considered as hypothesis generating at this stage. 
Further validation in a larger patient cohort of selected biomarkers is planned. Thirdly, we did 
not have ethics permission to study normal subjects, so limiting our comparison to a non-
uremic control group under clinical investigation, which might be expected to have worse 
endothelial function than normal subjects 205. As acknowledged above, the cross-sectional 
design means that there may be confounding of the data by factors known and unknown 
that change with time on treatment. 
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6.6 Conclusion 
In conclusion, this study elaborates a more complex relationship between abnormal 
endothelial dysfunction and clinical phenotype in patients on PD, emphasising the 
importance of platelet activation as well as inflammation (Figure 6-1, Figure 6-2). In addition, 
it further clarifies our understanding of the mechanisms of hypoalbuminaemia, an important 
predictor of survival in patients on PD. It remains unclear how this endothelial dysfunction in 
relation to hydration status. This would be discussed in Chapter 7. 
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What is the relationship between soluble endothelial chapter 7.
biomarker patterns, hydration status and 
hypoalbuminaemia in PD patients? 
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7.1 Summary 
7.1.1 Purpose 
In the previous pilot study, we demonstrated that the systemic endothelial barrier function 
was decreased in PD patients, especially diabetics. But it was not associated with 
hypoalbuminaemia or overhydration. To independently validate this and further investigate 
the determinate of fluid redistribution in PD patients, we explored the associations between 
hypoalbuminaemia, endothelial biomarkers and hydration status in a multi-centre cohort.  
7.1.2 Method 
This was a multi-centre cross sectional study of 149 prevalent PD patients. Hydration status 
was measured as ECW/TBW by a single frequency (50Hz) BIA device. A panel of 14 plasma 
endothelial biomarkers were measured. The selection of the biomarkers in the current study 
was mainly based on the pilot study (chapter 6) with further emphasis on platelet activation, 
which was found to relate to systemic endothelial permeability. Principal component analysis 
(PCA) was again used to identify the patterns in endothelial dysfunction. 
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7.1.3 Results 
Five principal components (PCs) were identified from the biomarker matrix. PC1, mainly 
composed of PF 4, P-selectin, MMP-1 and CD40L, indicating platelet activation, was related 
to diabetes. PC2, featured a positive association with VEGF, IFN-γ, TNF-α and IL-6, prone to 
pro-inflammatory, tended to be related to ischaemic heart disease (IHD). The combination of 
the PCs and the association to comorbidities were consistent with the pilot study. ECW/TBW 
was higher in patients who were female, with severe comorbidities and increase with age. It 
was negatively related to albumin and positively to PC 4 (adhesion molecular) in univariate 
analysis, while gender, comorbidity and albumin remained significant in multivariate model.  
7.1.4 Conclusion 
Platelet activation and inflammation are the two important processes contribute to 
endothelial dysfunction in PD patients. Endothelial dysfunction in different comorbidity is not 
universal but with different predominant mechanism, so that specific strategy may be 
applied.  Hydration status is related plasma albumin and it may through its colloid effect. 
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7.2 Introduction 
In the previous pilot study, we demonstrated that the systemic endothelial barrier function 
was decreased in PD patients, especially diabetics. But it was not associated with 
hypoalbuminaemia or overhydration.206 It indicates that reduced endothelial barrier function 
resulted in a higher albumin turnover rate between intravascular and extravascular space but 
does not directly cause low albumin levels in the blood stream.  
On the other hand, fluid redistribution plays an important role in overhydration in PD 
patients. 191 In patients with hypoalbuminaemia, there was tissue overhydration even 
without an increase in plasma volume. The attempt to normalize the hydration status in 
hypoalbuminamic patients may lead to hypovolemia and in the risk of loss of residual renal 
function. It is not clear whether this fluid redistribution is a direct result of 
hypoalbuminaemia or the change of endothelial permeability.  
Bioimpedance (BIA) is simple to perform and gives highly reproducible measurements of two 
components of body composition: TBW and ECW. Intervention studies have demonstrated its 
ability to identify changes in fluid status in response to changes in therapy189. ECW:TBW ratio 
is a powerful predictor of patient survival190 and accepted as a measure of hydration status. 
The purpose of this study was to independently validate the previous finding in the pilot 
study and further investigate the determinate of fluid redistribution. We explore the 
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associations between hypoalbuminaemia, endothelial biomarkers and hydration status in a 
multi-centre cohort.  
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7.3 Methods 
7.3.1 Study design and patient population 
This was a multi-centre cross sectional study of prevalent PD patients. The patient population 
was part of the BIA study (Developing Bioimpedance (BIA) as a tool for fluid management in 
Peritoneal Dialysis Patients: A validation Study ClinicalTrials.gov NO: NCT00801112.) See 
appendix for the detailed BIA study design. There were three UK centres in the BIA study, the 
University Hospital of North Staffordshire, St. James’s University Hospital and Sheffield 
Kidney Institute, Northern General Hospital. The patients were more than 16 years old and 
had been stably established on PD for more than 3 months Patients with acute inflammation, 
e.g. peritonitis within one month were excluded. Clinically determined optimal fluid status 
was achieved on the sampling day. If not, extra effort would be taken to achieve optimal fluid 
status before taking the sample and BIA measurement. The patient was excluded from the 
study if clinical optimal fluid status could not be achieved. Clinical optimal fluid status was 
defined as the minimal body weight that patient can achieve without adverse effect, eg, 
hypotension. 
The clinical characteristics, including membrane function, PD regime, biochemistry profiles 
and comorbidity were collected locally. The plasma samples for CRP and biomarker 
measurement were mostly collected on the same day of BIA measurement and stored in the 
local centre before sent to the central lab (Stoke). The local storage temperature was -20°C. 
The storage duration was 652.4±105.3, 404.3±120 and 294.4±69.1 (P<0.01) days, for Stoke, 
Sheffield and Leeds, respectively. Apart from the clinical recorded albumin, it was also 
measured centrally in the stored samples. 
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7.3.2 Clinical characteristics  
Comorbidity was recorded at the time of enrollment by local consultant. Stoke comorbidity 
score were used in the study. In brief, 7 comorbid comorbidity domains were considered, 
including non-cutaneous malignancy, ischemic heart disease (IHD), peripheral vascular 
disease (PVD), left ventricular dysfunction (LVD), diabetes mellitus (DM), systemic collagen 
vascular disease, and any other condition thought to reduce life expectancy.  The 
comorbidity score was the number of these domains affected. The comorbidity grade was 
then derived from the comorbidity score. Grade 0 (low risk) was a zero score, grade 1 
(medium risk) was a score of 1-2, and grade 2 (high risk) a cumulative score of ≥ 3. 
Membrane function was evaluated by standard peritoneal equilibration test (2.27% PET) in 
all three centres. The clinical routine biochemistry profiles were measured locally as part of 
clinical practice. The sampling date of the biochemistry profile including albumin may or may 
not be on the same day as BIA measurement or samples for biomarker. The interval in 
between was less than one month.  
Plasma albumin was measured by the Bromocreosol Purple colorimetric method in Stoke 
during the study period. It had been using Bromocreosol Green colorimetric method in 
Sheffield before switch to Bromocreosol Purple colorimetric method at Feb 2011. 
Bromocreosol Green colorimetric method was used in Leeds over the study period. An 
average difference of 5.5g/L between the results of the two methods had been established 
by Clase et al and the converting equation derived from their work was used to adjust the 
data to Bromocreosol Purple colorimetric method.149 
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7.3.3 BIA measurement 
BIA parameters were measured by a single frequency (50Hz) BIA device (Akern BIA 101 
Anniversary) in the study. The total body resistance and reactance were measured according 
to the operation manual for further calculation of total body water (TBW) and extra-cellular 
water (ECW). (See appendix for calculation detail) 
7.3.4 Biomarker measurement 
A panel of 14 endothelial biomarkers, which involved in inflammation, platelet activation and 
tissue remodelling processes, were measured in the study.  It was mainly based on the pilot 
study with further emphasis on platelet activation, which was found to relate to systemic 
endothelial permeability in the pilot study.Luminex suspension array system (Bio-Rad) was 
used to measure interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α), interferon-
gamma (IFN-γ), CD40 ligand (CD40-L) and vascular endothelial growth factor (VEGF) (Human 
cytokine/chemokine MAP multiplex kit (Millipore corporation, USA)); inter-cellular adhesion 
molecule 1 (ICAM-1), vascular cell adhesion protein 1 (VCAM-1), E-selectin and P-selectin 
(Human adhesion molecule Fluorokine MAP multiplex kit (R&D Systems, Minneapolis, USA)); 
matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-3 (MMP-3) (Human MMP 
Fluorokine MAP multiplex kit (R&D Systems, Minneapolis, USA). ELISA was applied to 
measure matrix metalloproteinase-8 (MMP-8), matrix metalloproteinase-9 (MMP-9) and 
platelet factor 4 (Duoset Human ELISA kits (R&D Systems, Minneapolis, USA). Assays were 
carried out according to the manufacturer’s instructions. Albumin and CRP were also 
centrally measured in Stoke.  
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7.3.5 Statistical analysis 
Continuous data were expressed as mean values ± SD or median (inter quartile range), as 
appropriate. One way ANOVA was used to examine differences in normal distributed 
continuous data, and chi-square for categorical data. For those not normal distributed, 
Kruskal Wallis H test was applied to test the difference between groups. Unpaired t test were 
applied to compare difference between two independent samples. The univariate correlation 
was examined by Pearson correlation coefficient or Spearman correlation coefficient as 
appropriate according to distribution. Multi-level analysis was applied for the multivariate 
analysis and the constant in the model was allowed to be different between centre to 
account for centre effect.  
To decrease the dimensionality of the biomarker data set and retain as much of the variance 
as possible, an exploratory PCA was employed. Principal components (PCs) were extracted 
using varimax rotation, with the factor selection based on an Eigen value cut-off of 1.0.  
Significance was considered at P values <0.05. Multi-variant analysis was done by MLwin. 
Other statistical analyses were performed using IBM SPSS Statistics version 20. 
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7.4 Results 
7.4.1 Demography, patient characteristics and hydration status  
A total of 149 prevalent patients (f/m 61/88, mean age 58.59±14.76 years, median time on 
PD 23 (8-36) months, diabetics 37/149) in three centres were studied. (Table 7-1) There were 
significant centre differences in residual renal function and hydration status. The PSTR, PET 
UF and the use of bio-compatible solutions were also different. The distribution of 
comorbidity did not reach statistical significant difference among centres.  
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Table 7-1 Demography, patient characteristics and hydration status by centre 
  Stoke (n=57) 
Sheffield 
(n=40) Leeds (n=52) 
p 
value
a
 
Total 
(n=149) 
gender (f/m) 21/36 20/20 19/33 .345 60/89 
IHD (N/Y) 46/11 34/6 45/7 .685 125/24 
PVD (N/Y) 48/9 36/4 45/7 .705 129/20 
DM (N/Y) 47/10 28/12 37/15 .255 112/37 
comorbidity grade 
(low/medium/high) 23/29/5 20/16/4 15/35/2 
.112 
58/80/11 
age (year) 58.21±15.81 59.4±13.77 58.38±14.56 .920 58.59±14.76 
urine volume (ml) 
1194.5(739-
1829) 
1398(786-
2077.5) 
635.5(207.5-
1063) 
<0.001 940(531-
1683) 
PD duration (mo) 23(5-44) 22(9.5-32) 24.5(9-40) .527 23(8-36) 
DPCr 0.66±0.12 0.76±0.13 0.7±0.09 .001 0.69±0.12 
PET UF (ml) 322.7±207 53.9±207.5 144.9±260.2 <0.001 205.1±250.7 
use of biocompitible solution 3/57 23/40 4/52 <0.001 30/149 
albumin (g/L) Cotemporary local 
adjusted method 32.5±4.6 33.1±3.7 34.5±3.4 
.043 
33.4±4.1 
albumin (g/L) Stored central 
measurement 26.7±4 32.7±4.4 30.5±3.5 
<0.001 
29.6±4.6 
Hgb (g/dl) 11.7±1.4 11.8±0.9 11.4±1.6 .354 11.6±1.4 
Height (cm) 169.26±9.72 168.83±9.87 166.33±10.44 
.275 168.12±10.0
4 
weight (kg) 79.95±17.13 77.95±16.65 72.53±17 .069 76.81±17.16 
TBW (L) 41.83±7.73 43.33±9.32 39.21±7.88 .055 41.29±8.33 
ECW (L) 19.14±3.77 20.14±4.21 16.34±4 <0.001 18.41±4.25 
ECW/TBW 0.46±0.06 0.47±0.05 0.42±0.08 .001 0.45±0.07 
TBW/weight 0.53±0.07 0.56±0.08 0.55±0.07 .216 0.54±0.07 
H
2
/R (cm
2
/Ω) 58.18±12.02 62.38±15.14 54.51±12.49 
.019 
58±13.34 
H
2
/Xc (cm
2
/Ω) 
567.32±152.8
2 
613.38±170.9
5 
462.05±152.8
1 
<0.001 542.47±168.
56 
 IHD, ischemia heart disease; PVD, peripheral vascular disease  
TBW, Total body water; ECW, extracellular water 
a. One way ANOVA for normal distributed continuous data and Kruskal Wallis H test for those not normal 
distributed. Chi-square for categorical data 
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7.4.2 Albumin measurement 
As stated in the methods section there were two sets of albumin measurements. One was 
the clinical locally measured albumin, adjusted according to the different methodologies. The 
other was the stored central measurement. Both were significantly different among centres. 
(Table 7-1) The blood taken for central measurement was the same for the biomarker assays, 
including CRP, obtained on the same day as BIA measurement and within one month of the 
local albumin measurement. The correlation between the two albumin measurements was 
0.648 (p<0.001) (Figure 7-1)  
Figure 7-1 The correlation between the two sets of albumin measurement 
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7.4.3 Endothelial biomarkers 
There were 12 patients who did not have biomarker profiles measured due to the sample 
availability or poor quality. One patient was confirmed to have acute inflammation at 
sampling so was excluded from the PC analysis.  
The correlation between CRP and endothelial biomarkers are shown in Table 7-2. Five 
principal components (PCs) were identified, explaining 68.3% of the total variance. (Figure 
7-2) The first PC (PC1-platelet activation) was composed mainly of PF 4, P-selectin, MMP-1 
and CD40L. The second PC (PC2 pro-inflammation) featured a positive association with VEGF, 
IFN-γ, TNF-α and IL-6. The third PC (PC3-MMPs) was mainly the combination of MMP 8 and 
MMP 9. PC 4 (–adhesion) was contributed mostly by the two adhesion molecular VACM-1 
and ICAM-1. PC 5 was negatively related to MMP-3, and positively to E-selectin. The 
combination of the PCs was rather similar to the pilot study. (Figure 6-6, Figure 6-7)  
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Table 7-2 CRP and biomarkers matrix 
  CRP  IFN-γ IL-6 
CD4
0L TNFα VEGF 
ICAM
-1 VCAM 
E-
Selecti
n  
P-
Selecti
n 
MMP-
1 
MMP-
3 
MMP-
8 
MMP-
9 PF-4 
CRP  r 
a
 1.000 -.040 .195 .171 .160 -.068 .169 .107 .045 .135 .034 .020 .315 .108 .061 
P value   .641 .021 .044 .059 .423 .042 .200 .587 .105 .688 .811 <0.01 .193 .463 
IFN-γ r   1.000 .468 .463 .341 .618 .064 -.057 .023 .458 .339 .050 .025 -.061 .572 
P value     <0.01 <0.0
1 
<0.01 <0.01 .458 .510 .786 <0.01 <0.01 .558 .773 .477 <0.01 
IL-6 r     1.000 .364 .395 .418 .114 .108 .158 .413 .268 .035 .112 .083 .331 
P value       <0.0
1 
<0.01 <0.01 .184 .207 .064 <0.01 .001 .681 .189 .333 <0.01 
CD40
L 
r       1.000 .316 .313 .088 -.126 .083 .669 .488 .089 .295 .065 .784 
P value         <0.01 <0.01 .305 .141 .335 <0.01 <0.01 .298 <0.01 .448 <0.01 
TNFα r         1.000 .488 .117 .256 .105 .163 -.116 -.150 .076 .136 .151 
P value           <0.01 .171 .002 .221 .056 .174 .079 .375 .110 .077 
VEGF r           1.000 .068 .089 .026 .266 .155 -.135 .021 .073 .348 
P value             .427 .301 .762 .002 .070 .116 .803 .391 .000 
ICAM
-1 
r             1.000 .356 .257 .357 .117 .088 .044 .246 .064 
P value               <0.01 .002 .000 .161 .292 .601 .003 .444 
VCA
M 
r               1.000 -.075 .019 .027 .084 .089 .070 -.129 
P value                 .367 .818 .747 .315 .285 .403 .120 
E-
Select
in  
r                 1.000 .310 .009 -.170 .117 .239 .080 
P value                   <0.01 .913 .041 .159 .004 .338 
P-
Select
r                   1.000 .572 .196 .213 .033 .771 
P value                     <0.01 .018 .010 .694 <0.01 
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in 
MMP
-1 
r                     1.000 .218 .084 -.060 .623 
P value                       .008 .313 .476 <0.01 
MMP
-3 
r                       1.000 .107 -.072 .116 
P value                         .200 .391 .164 
MMP
-8 
r                         1.000 .446 .132 
P value                           <0.01 .113 
MMP
-9 
r                           1.000 -.083 
P value                             .321 
PF4 r                             1.000 
P value                               
a, Spearman correlation,  
IL-6,interleukin-6, TNF-α, tumour necrosis factor-alpha, IFN-γ, interferon-gamma, CD40-L, CD40 ligand and VEGF, 
vascular endothelial growth factor; ICAM-1, inter-cellular adhesion molecule 1, VCAM-1, vascular cell adhesion protein 
1, E-selectin and P-selectin; MMP, matrix metalloproteinase; PF4, platelet factor 4 
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Figure 7-2 Principal component matrix.  
Eigen values and percentage contributing to the total sample variance of each of the 5 
principal components (PCs) is presented. Individual composition feature is showed along 
with their rotated loading coefficients, a measure of the importance of each biomarker to 
the factor, displayed as a bar chart. 
 
The correlation between albumin and PCs tended to be stronger for the stored 
central measurement. There was a positive relationship between PC 1 and albumin 
(stored central measurement) and generally negatively related to all the other PCs. 
There was no significant correlation between albumin (contemporary local adjusted 
method) and PCs, apart from PC4. (Table 7-3)  
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Table 7-3 correlation between albumin, CRP and principal components (PCs) 
  
albumin (Stored central 
measurement) 
P 
value 
a 
albumin (Cotemporary Local 
adjusted method) 
P 
value 
a 
albumin (stored 
sample)     .648** 
<0.00
1 
PC1  .229** 0.007 .135 .138 
PC2 -.160 0.063 -.036 .692 
PC3  -.161 0.062 -.094 .302 
PC4  
-.297** 
<0.00
1 -.299** .001 
PC5  -.231** 0.007 .019 .837 
CRP  -.034 .685 -.060 .491 
PC, principal component 
a, Pearson correlation coefficient or Spearman correlation coefficient as appropriate according to 
distribution 
*, P<0.05 
**, P<0.01 
 
7.4.4 Biomarker pattern in different comorbidity 
Patients with different comorbidity (DM vs IHD) showed different, albeit overlapping 
biomarker patterns. Diabetes had higher PC1 (platelet activation), while PC2 (inflammation) 
tended to be higher in ischemic heart disease (IHD). (Table 7-4) It reproduced the biomarker 
pattern in different comorbidity found in the pilot study. (Figure 7-3) 
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Table 7-4 biomarker pattern in different comorbidities 
  None (N=90) DM (N=33) IHD, without DM (N=13) P valuea 
PC 1 -0.43(-0.89-0.45) 0.32(-0.52-1.1) -0.42(-0.68-0.48) .029 
PC 2 -0.29(-0.74-0.34) -0.34(-0.78-0.39) 0.12(-0.18-0.94) .202 
PC 3 -0.24(-0.47-0.21) -0.13(-0.5-0.13) -0.36(-0.57-0.47) .928 
PC 4 -0.01±1.05 0.03±0.95 0±0.85 .975 
PC 5 -0.03±0.93 0.21±1.05 -0.33±1.3 .230 
PC, principal component 
IHD, ischemia heart disease; DM, diabetes mellitus 
None - without DM or IHD 
DM – with DM, may or may not have IHD 
IHD without DM – IHD and without DM  
a, One way ANOVA for normal distributed continuous data and Kruskal Wallis H test for those not normal 
distributed 
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Figure 7-3 Combined graphical representation of PC scores and comorbidity; heart 
disease (IHD) and diabetes (DM) are clustered according to their different pattern of PC 
scores  
The data points represent the mean values (±SE) for the patient with (a) diabetes (DM), 
(b) ischemic heart disease (IHD) but without DM and (c) without DM or IHD. Diabetes 
has higher PC1 (platelet activation), while PC2 (inflammation) tends to be higher in 
ischemic heart disease (IHD). It reproduces the patterns found in the pilot study. 
 
7.4.5 Correlations to hydration status (ECW/TBW) 
ECW/TBW, as a measure of hydration status, was positively correlated to age and 
comorbidity grade. Female had a higher ECW/TBW as measured by BIA. Albumin was 
negatively correlated to ECW/TBW. (Figure 7-4, Figure 7-5) Among the PCs, PC 4 was 
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significantly correlated to ECW/TBW in univariate analysis. (Table 7-5) Gender, comorbidity 
status and albumin level remained significant (either contemporary local adjusted method or 
stored central measurement) in multivariate model. (Table 7-6) 
Figure 7-4 The relationship between albumin (stored central measurement) and 
hydration status, as measured by extracellular water (ECW)/total body water (TBW) 
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Figure 7-5 The relationship between albumin (cotemporary local adjusted method) and 
hydration status, as measured by extracellular water (ECW)/total body water (TBW) 
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Table 7-5 Univariate correlation between hydration status (ECW/TBW) and clinical 
characteristics and principal components (PCs) 
  ECW/TBW P value a 
gender (f/m) 0.47±0.07/0.43±0.07 .003 
comorbidity 
(low/medium/high) 0.43±0.06/0.45±0.07/0.50±0.09 .003 
age (year) .231** .005 
PSTR .130 .176 
Albumin (g/L) 
(Cotemporary Local 
adjusted method) 
-.274** 
.002 
Albumin (g/L) (Stored 
central measurement) 
-.204* 
.013 
PD duration (mo) 0.032 .699 
urine volume (ml) -0.1 .254 
Daily fluid removal (ml) -.126 .148 
PC1  -.058 .505 
PC2  .092 .289 
PC3  .077 .377 
PC4  .214* .013 
PC5  -.088 .313 
CRP (mg/l) .072 .392 
PC, principal component; PSTR, peritoneal solute transport rate 
a, Pearson correlation coefficient or Spearman correlation coefficient as appropriate 
according to distribution, t test or ANOVA to compare groups 
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Table 7-6 multivariate model for hydration status (ECW/TBW) 
  
albumin (Cotemporary Local 
adjusted method) 
albumin (Stored central 
measurement) 
ECW/TBW β  
standard 
error P value β  
standard 
error P value 
constant 0.45646 0.0095 <0.01 0.46071 0.01119 <0.01 
gender (if male) -0.02795 0.01011 <0.05 -0.03761 0.01017 <0.01 
comorbidity medium 
(compared with low) 0.0174 0.01086  NS 0.01616 0.01087  NS 
comorbidity high 
(compared with low) 0.08869 0.01893 <0.01 0.08002 0.01996 <0.01 
age (year) 0.00044 0.00035  NS 0.00059 0.00035  NS 
albumin (for each 1g/L 
increase) -0.00374 0.00124 <0.05 -0.00241 0.00126 0.055 
lgCRP (mg/l) 0.01102 0.01654  NS 0.00036 0.01511  NS 
PC1 -0.00554 0.00509  NS -0.00383 0.00558  NS 
PC2 0.00411 0.0048  NS 0.00068 0.00487  NS 
PC3 0.00593 0.00476  NS 0.00664 0.00495 NS  
PC4 0.00449 0.00535  NS 0.00742 0.00534  NS 
PC5 -0.00066 0.0052  NS -0.00632 0.00545 NS  
PC, principal component; PSTR, peritoneal solute transport rate; ECW, extracellar water; 
TBW, total body water 
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7.5 Discussion 
This study independently validated the previous finding in the pilot study that patients with 
IHD and DM had different, albeit overlapping patterns of soluble endothelial biomarkers, 
although both exhibit endothelial dysfunction. The reproducible combination of PCs 
indicated that inflammation and platelet activation were two independent although highly 
related processes in endothelial dysfunction. Hydration status (as measured by ECW/TBW) 
was negatively related to albumin, while its relationship to soluble endothelial biomarkers 
lost significance when controlled for albumin concentration. A plausible explanation for this 
is that the relationship between albumin and hydration status is through its colloid effect 
rather than as a surrogate of endothelial dysfunction.  
7.5.1 Reproducibility of PC combinations and biomarker 
patterns according to different comorbidities 
A large panel of endothelial biomarkers was measured in the study. The selection of the 
biomarkers was based on the pilot study with further emphasis on the platelet activation, the 
process identified from the pilot study to be related to endothelial permeability. Principle 
component analysis was applied again in this study to identify possible different pathway 
involved in endothelial dysfunction. The PCs identified from the current study had good 
agreement with the previous pilot study. 206 PC1- composed primarily of biomarkers highly 
 249 
 
 
related to platelet activation. These were platelet factor 4, P-selectin, MMP-1 and CD40L, all 
of which were released in significant amounts from platelets and/or reflect platelet 
activation. 188 PC2, composed of VEGF, IFN-γ, TNF-α and IL-6, was mainly involved in the pro-
inflammatory pathway. The main difference in the combination of PCs between the pilot 
study and the current study is VEGF, which was combined in PC 1, and now in PC 2. It may 
reflect the fact that VEGF, a central regulator of angiogenesis and well-known circulating 
permeability factor 207, is involved in both pathways. This reproducible combination of PCs 
reflected that inflammation and platelet activation are two important mechanisms in 
endothelial dysfunction in PD patients.  
PC1-platelet activation factor, was higher in DM. PC2-inflammation factor, tended to be 
higher in IHD. It again reproduced the previous finding in the pilot study. 206 It indicated that 
the mechanism of endothelial dysfunction underlying DM and IHD may be different. It is 
important to notice this as different treatment strategy may need to emphasize.  
7.5.2 Endothelial dysfunction, albumin and hydration status 
Plasma albumin is known to relate to hydration status in PD patients. 208, 209 A relationship is 
also found between hydration status and inflammation and other endothelial dysfunction 
evidence.209 In the current multi-variant analysis, albumin and comorbidity were the two 
independent variables related to hydration status as measured by ECW/TBW, while the 
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endothelial biomarker PCs lost significance in multi-variant analysis. Hydration status is not 
just the balance between fluid input and output but also a result of fluid re-distribution 
between different components in PD patients.191 As showed in the pilot study, endothelial 
permeability, measured by TERalb, was not related to hydration status.206 It is, therefore 
more likely that albumin determines hydration status through its colloid effects rather than 
as a surrogate of inflammation or endothelial injury. 
7.5.3 The centre effect 
A significant centre effect was noticed in the study. Leeds showed significantly lower residual 
renal function and lower ECW/TBW. As this is a cross sectional analysis, we were not in a 
position to investigate the causation. The plausible thought raised here would be that less 
good residual renal function was not necessarily related to worse hydration status in a 
selective cohort, while the possibility that patients has less residual function as a 
consequence of being less overhydrated needs to be considered. Consideration needs to be 
taken about the balance between residual renal function and hydration status. Taking the 
observation from the current study that overhydration was partially a result of 
hypoalbuminaemia, attempt to correct the hydration status in hypoalbuminaemic patient by 
increasing UF may not be effective and potentially put at  risk the loss of residual renal 
function. 
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For the centre differences in membrane function (PSTR and PET UF capacity), apart from the 
real physiological difference, variance for other reasons need to be considered. More 
patients were on bio-compatible solution in Sheffield, which is known to relate to less UF. 
Potentially, different method of measuring UF, plasma and dialysate creatinine may also 
contribute to the centre effect, e.g. overfill.  
7.5.4 Limitations 
This study has a number of limitations. Firstly, two different sets of albumin were measured 
in the study. The albumin) measured locally was done by different methods and the samples 
were not taken exactly on the same day of BIA measurement and the samples for biomarker 
measurement. On the other hand, the samples for albumin measured centrally were stored 
for significant period of time. The stability of albumin beyond 4 months is not clear.210 It may 
explain the absence of the classic inverse relationship between albumin and inflammation. 
Possibly due to the close relationship between albumin levels on two different days, within 
one month in apart, we were still able to pick the relationship between albumin and 
hydration status.  
Secondly, no direct measurement of osmotic pressure was taken due to clinical feasibility. 
Plasma albumin was measured as a surrogate. Thirdly, detailed fluid balance (fluid in and out) 
was not recorded. However, extra effort had been made to achieve clinical optimal fluid 
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status. The possibility of worse fluid status due to inappropriate dialysis regime or excess 
fluid intake was limited as much as we can. The majority of the variability of fluid status 
should come from the patient related factors. Fourthly, hydration status was measured as 
ECW/TBW by BIA. It is not able to differentiate worse fluid status and increased muscle mass 
by BIA measurement although the latter was much less likely in PD patients. Finally, the 
different biomarker pattern between DM and IHD observed in the current study was based 
on PD patients. It is not clear whether it can be generalized to non PD populations. Further 
studies in common populations need to be done. 
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7.6 Conclusion 
In conclusion, platelet activation and inflammation are the two important processes 
contribute to endothelial dysfunction in PD patients. Endothelial dysfunction in different 
comorbidity is not universal but with different predominant mechanism. Specific strategy 
may be applied accordingly.  Plasma albumin and hydration status are related and may 
through the colloid effect of albumin. 
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General discussion chapter 8.
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8.1 The journey of the project so far 
The observation that Pcl is related to patient survival in PD has been repeated in several 
cohorts. This key observation was the primary stimulus for the work presented in this thesis: 
the main purpose was to investigate the reasons why Pcl is related to survival. The centrally 
stated hypothesis was that peritoneal Pcl is linked to survival because it reflects a systemic 
abnormality of the capillary circulation, specifically at the level of the endothelium, rather 
than being evidence of local membrane injury. The latter is complex because membrane 
injury is believed to change with time on dialysis. A series of connected studies, using 
different methods and patients cohorts were undertaken to address this hypothesis from 
different perspectives. 
Chapter 3: Is peritoneal protein clearance (Pcl) related to comorbidity, local peritoneal 
membrane inflammation or both at the commencement of PD? Which of these are 
predictors of patient survival? 
It was demonstrated that Pcl is determined by both local and systemic factors. Locally, both 
membrane area, determined form the PSTR and local membrane inflammation as evidenced 
by intra-peritoneal IL-6 production, both have independent effects on Pcl. Given that 
capillary protein leak is one of the cardinal features of inflammation, this would suggest that 
for a given anatomical membrane area (small pores) there is a greater representation of 
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large pores. Systemically, comorbidity, which is not associated with local peritoneal 
inflammation, also affects Pcl and this is partly explained by the known association between 
hypoalbuminaemia and comorbidity, with plasma albumin acting as a ‘reverse’ acute phase 
protein. However, this association is different by type of comorbidity (eg. The effect of 
diabetic status on Pcl relies much on hypoalbuminaemia while to less extent for IHD.) 
The observation that Pcl predicts survival was again repeated in the current project providing 
further external validation of this association. It has been further clarified that this prediction 
is not due to the local factors, namely, PSTR or membrane inflammation. The predictive value 
of Pcl on survival is related to its relationship to hypoalbuminaemia and comorbidity. It is 
again complex and different by type of comorbidity. 
Neither the cross sectional associations nor the prediction of survival in the follow-up study 
of Pcl found in the incident cohort was found to exist in prevalent patients. This raises the 
possibility that the nature of Pcl in prevalent patients is different from incident patients. 
Chapter 4: Does peritoneal Pcl change with time on PD? If so, is this change over time 
coupled with the known increase in PSTR? 
From the longitudinal analysis of the Stoke cohort, it was shown that peritoneal Pcl was 
initially proportional to membrane area (PSTR) but that it decreased with time on PD 
treatment. In fact there is an uncoupling of the small pore (PSTR) and large pore (Pcl) 
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pathways with time on PD. This would be in keeping with a switch from local inflammation 
early on to progressive fibrosis in which transcapillary protein leak is impaired combined with 
increased vascular surface area.  
This is in keeping with other studies which have demonstrated the uncoupling between PET 
UF capacity and PSTR.95 This has also been successfully modeled by an extension of the three 
pore membrane to include a fiber matrix layer that mimics membrane fibrosis. 103 The 
current work gives the clinical evidence of synchronous similar effect of fibrosis on large pore 
flow and it would be of great interest to see if this is also predicted by this adapted 3-
pore/fibre matrix model.  
In severe fibrosis, there is “uncoupling” of PSTR from the peritoneal UF coefficient (LpS) or 
more precisely, the peritoneal osmotic conductance to glucose (LpSσg). The question arises 
as to whether this aspect of membrane function (LpSσ) can be demonstrated with a non-
glucose containing dialysis fluid, specifically icodextrin which achieves ultrafiltration through 
oncotic rather than osmotic pressure, but for which the liquid permeability component (Lp) 
of fluid conductance is similarly affected by fibrosis. This was the reason for exploring the 
determinants of UF using icodextrin and investigating whether this is also “uncoupled” from 
PSTR over time on PD, further validating the three pore membrane/fiber matrix hypothesis. 
Chapter 5: Does the ultrafiltration obtained with icodextrin – which only occurs via the 
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small pore pathway, change with time on PD? If so, is this change over time dissociated 
from the increase in PSTR? 
Again, using data collected prospectively for the longitudinal observations of patients in the 
Stoke cohort, it was demonstrated that prolonged time on PD decreases UF and it is 
uncoupled from the effect of increase in PSTR, which would otherwise be expected to 
improve the efficiency of this glucose polymer. As already argued, this would be in keeping 
with a progressive fibrosis combined with increased vascular surface area.  
The analysis while also confirming the expected impact of certain membrane characteristics 
on UF such as high PSTR and better UF capacity, also demonstrated that factors which are 
likely to affect the oncotic pressure gradient, hydrostatic pressure gradient or icodextrin 
metabolites concentration are more important than the dwell length in explaining UF 
variability.  
These observations fit with the theoretical modeling and have clear implications for dialysis 
prescription. 
Chapter 6: What is the relationship between soluble biomarkers of inflammation and 
endothelial damage, systemic transcapillary albumin leak and hypoalbuminaemia in PD 
patients? 
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As demonstrated in Chapter 3, Pcl predicts survival of PD patients independent of PSTR and 
peritoneal membrane inflammation and its relationship to comorbidity and survival is 
complex. The association between Pcl and survival is likely to be a combination of 
hypoalbuminaemia (to which it is mathematically coupled) and possibly high vascular 
permeability due to impaired endothelial barrier function associated with systemic vascular 
injury. To clarify the association between systemic vascular permeability, hypoalbuminaemia 
and comorbidity, this pilot biomarker study was conducted. 
It was demonstrated that endothelial permeability is increased in PD patients and it is 
different in different type of comorbidity and different patterns of biomarkers. DM is more 
related to increased endothelial permeability compared with IHD. DM tended to be 
associated with biomarkers known to represent platelet activation whereas cardiovascular 
comorbidity, especially ischemic heart disease associated with inflammation.  As this was an 
exploratory analysis, using pattern recognition methodology such as principle component 
analysis, it required further validation. 
Recent mechanistic studies have shown that hypoalbuminaemia and comorbidity are 
strongly related to overhydration in PD patients 191 and that this is because of increased 
extravascular tissue hydration presumed to be a consequence of reduced plasma oncotic 
pressure.  This pilot study also suggested that the increased endothelial permeability is not 
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associated with hypoalbuminaemia or over hydration. This raises the hypothesis that 
endothelial hyper-permeability is not the main cause of fluid redistribution in PD patients. 
Chapter 7: What is the relationship between soluble endothelial biomarker patterns, 
hydration status and hypoalbuminaemia in PD patients? 
The validation of the pilot study (Chapter 6) was undertaken in a different patient cohort – a 
multicentre centre clinical trial designed to investigate the value of bioimpedance in the 
management of fluid status in PD patients.  One of the reasons for selecting these patients 
on entry to the trial was the possibility of relating these biomarker and comorbidity patterns 
to hydration status.  
This study found that endothelial biomarker patterns associated with the different types of 
comorbidity were reproducible in this independent cohort. However the hydration status 
was related plasma albumin, age and comorbidity rather than any independent association 
with endothelial dysfunction suggesting that the association is mediated through its colloid 
effect.  
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8.2 Implications and Further thoughts 
8.2.1 Should we measure Pcl in clinical setting? 
Combined with PSTR, Pcl measurements could help to distinguish an anatomically large 
membrane from an inflamed membrane and/or systemic comorbidity, at least in incident 
patients. However, there is argument that the local inflamed membrane by itself may not 
necessary predict worse survival. (according to current project and unpublished data from 
the GLOBAL fluid study) By measuring Pcl is not able to separate the effect of local 
inflammation and systemic comorbidity. Longitudinal monitoring of Pcl may give information 
about membrane fibrosis. The drawback of this is that it would be difficult to interpret on 
individual level, as it is confounded by the change of comorbidity, plasma albumin level and 
membrane inflammation. It therefore seems that this is unlikely to become a routine method 
of assessing injury which might be achieved better by measuring specific biomarkers. 
8.2.2  Do we need a “Peritoneal Equilibration Test (PET)” for 
icodextrin? 
Currently, all membrane function tests are based on glucose solution. As showed in the 
present project, the UF achieved by icodextrin is related to the UF from a standard 4 hours 
2.27% dwell, but a lot more variance is beyond the UF capacity from a standard PET test. A 
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“PET” for icodextrin will give a better prediction of UF for icodextrin dwells, adding extra 
information about the peritoneal membrane.  
For the purpose of comparison, the changeable variables that may affect icodextrin UF as 
determined in the current project should be controlled, namely, the position of the patient, 
dwell length, input volume. The test should not be conducted until the circulation level of 
icodextrin metabolites is stable. Combine these, an overnight, 8 hours dwell with 2L input 
volume would likely to be the most practical “standard icodextrin dwell”. 
8.2.3 What determines the plasma albumin concentration in PD 
patient? What strategies would increase plasma albumin 
level? 
Albumin level is an important predictor of survival not just in PD population but also in a 
more general population. Factors that may contribute to albumin concentration include 
synthesis rate, catabolic rate, exogenous loss (predominantly to urine and peritoneal cavity in 
the case of PD), redistribution to the interstitial space and plasma volume.  
Albumin synthesis is controlled in part by nutrition. However, malnutrition alone does not 
usually cause hypoalbuminaemia, unless in extreme case. Patients with anorexia nervosa 
have essentially normal albumin level. Actually, inflammation plays a much more important 
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role in determining albumin levels, especially those with multiple chronic conditions, both by 
decreasing synthesis and increasing catabolic rate.  
Exogenous loss, predominantly to urine and the peritoneal cavity in PD, is the most 
important determinant of hypoalbuminaemia in PD patients. However, it has been shown in 
healthy PD patient, even in the ‘nephrotic’ range protein loss through peritoneal cavity, 
plasma albumin level would be maintained by increase synthesis and reduced catabolic rate. 
211 We now know from the current project, that the relationship between peritoneal protein 
loss and hypoalbuminaemia is more complex due to its link through comorbidity.  
From the present project, increased TERalb, which may indicate a high turnover rate with 
recirculation back to the plasma compartment via lymphatics, does not change plasma 
albumin level significantly. This is different from what is seen in acute sepsis, where albumin 
redistributes to extra-vascular space in short time period.  
However, plasma volume expansion in normal subject should not change plasma albumin 
level as seen when we move to high altitude. 212 However, there is paradoxical result in 
dialysis population. Plasma volume expansion was shown to be related to low albumin 
concentration in a HD cohort ,213 but not the case in another PD cohort. 191 Taking account of 
the current finding that plasma albumin level relates to hydration status of PD patient and it 
is independent to endothelial dysfunction, the cause and result relationship between plasma 
volume and albumin level needs to be reconsidered.  
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Taken together, the best ways to maintain plasma albumin level is either to suppress the 
factors that may reduce synthesis and increase catabolism, eg. Inflammation, or decrease 
exogenous protein loss, both from urine and peritoneal cavity. The former can be achieved 
with ACE inhibition and/or ARBs, whereas the latter would require an adaptation of the PD 
process in which dialysate is re-circulated after removal of fluid and toxic metabolites. 
Portable absorbent cartridges could be developed to do this. Of course, infection would be 
the main concern of this therapy. In principle, more ‘biocompatible’ dialysis solutions that 
attract less membrane inflammation may also help to reduce albumin loss from peritoneal 
cavity. However, so far, there is no such dialysis fluid showing convincing evidence of causing 
less membrane inflammation. 154  
8.2.4 What is the difference between IHD and DM? 
Another interesting finding from this thesis is the differences observed between DM and IHD. 
Firstly, IHD and DM have different impact on Pcl. Compared with IHD, Pcl in DM is more a 
function of hypoalbuminaemia, while DM patients are systemically leakier (higher TERalb). 
One possible explanation of these findings may due to the fact incident DM patient on PD 
have more protein loss from urine. Excessive urine protein loss is a clear source of 
hypoalbuminaemia. This hypoalbuminaemia would then relate to a higher Pcl than it would 
be expected from systemic vascular damage. Secondly, DM and IHD have different 
endothelial biomarker pattern, with DM more associated with endothelial barrier injury, IHD 
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more inflammatory. This is in keeping with the different response of therapy in DM patients 
compared with non-DM. This points to different therapeutic strategies needing to be 
developed according to the predominant pathology process that may be helpful in the future. 
All these findings are based on PD cohorts in the current study, the difference between DM 
and IHD need to be studied in common populations. 
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Appendix chapter 9.
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9.1 Measuring ultrafiltration (UF) -more complicated than I 
thought 
9.1.1 How do we measure UF in clinical practice and in 
research? 
To measure UF in PD is clearly extremely important for both clinical and research purpose. It 
is thought to be easy to measure. The detailed methodology of measuring UF is not even 
always mentioned in the literature. The ‘routine’ way is weighting the drainage bag and 
subtracting the labelled input volume in CAPD. In some carefully designed clinical trials, both 
drainage and input bags are weighted and UF are calculated as the difference between the 
two bags. The overfill issue has been raised for some years. 159, 178 Some studies start to 
account for overfill when measuring UF. For APD, the machine gives the UF reading based on 
volume measurement.  
9.1.2 The controversy findings around UF 
The UF difference between APD and CAPD is difficult to understand. It is widely accepted that 
CAPD is as good as APD in terms of preserving residual renal function, if not better. On the 
other hand, a favoured 24 hour UF in CAPD has been noticed in several studies 175-177. 
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Neglecting overfill used to be one of the reasons for over estimating UF in CAPD. However, 
there are studies like us which have clearly accounted for overfill still find difference in UF 
between APD and CAPD. A follow up study in incident patients 177 showed UF were 
consistently lower in incident APD patients than in their counterparts on CAPD. 
Controversially, the residual renal function declined faster in the APD group rather than the 
CAPD group in that study.  
9.1.3 The impact of specific gravity 
The fact that dialysate weight slightly heavier than water was believed to be neglectable by 
almost the whole PD society. We evaluated the impact of specific gravity in measuring UF 
volume in this study. 
The specific gravity in dialysate drainage was measured from sequential patients came for 
their routine dialysis clearance test. 9 drainage dialysate samples from different patients 
were collected. Three were from icodextrin long dwells, three were from 1.36% glucose 4 
hour dwells and the other three were from 2.27% glucose 4 hour dwells. Weight and volume 
were measured and specific gravity was calculated as weight/volume. Fresh dialysate and 
water were served as controls. The measurement was repeated for three times in each 
sample. (Table 9-1) 
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Table 9-1 specific gravity of different type of dialysate 
  Specific gravity 
(g/ml) 
mean±SD 
P valuea (compared 
with water) 
water  1.001±0.002  
icodextrin 
fresh 1.037±0.002 <0.01 
Long dwell drainage 1.026±0.006 <0.01 
Glucose (1.36%) 
fresh 1.017±0.002 <0.01 
4 hour drainage 1.021±0.001 <0.01 
Glucose (2.27%) 
fresh 1.017±0.001 <0.01 
4 hour drainage 1.011±0.003 0.016 
a, one sample t test 
Taking the average specific gravity from our measurement in limited number of samples, the 
potential over estimation of UF in CAPD in a single icodextrin dwell (2L) with 0.4L UF can be 
calculated as following. 
Reported UF (L, misleading by kg)  
= [2L (input volume) + 0.4L (UF)] * 1.026 (g/ml) - 2L (input volume)  
= 0.461(L, misleading by kg) (over estimate for 0.061L)  
The specific gravity should be different between patients and dwells and potentially depend 
on the UF and transport status. Our calculation should only be taken as a rough estimation. 
However, it is worth to keep in mind that for a patient with typical CAPD regime (eg. 1.36% 
glucose 4L+2.27% glucose 2L+Icodextrin 2L), the specific gravity issue may account for about 
100ml overestimation of UF.  
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9.1.4 Conclusions 
The specific gravity difference may lead to measureable overestimation of UF in CAPD. It is 
important to keep this in mind in both clinical and research setting. 
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9.2 What do we learn from the methodology upgrade of plasma 
creatinine measurement in a peritoneal dialysis centre? 
9.2.1 Background  
The difference of plasma creatinine measurement by different methodology has been 
noticed for some years in early stage chronic kidney disease (CKD), due to its critical impact 
on estimating glomerular filtration rate (GFR). The National Kidney Disease Education 
Program (NKDEP) of National Institutes of Health recommends that an estimated GFR should 
be calculated from plasma creatinine and reported to physicians to assist early identification 
of patients with renal disease. The NKDEP Laboratory Working Group has done a great 
amount of work to establish standardization and improve accuracy of plasma creatinine 
measurements in clinical laboratories worldwide. 214 
However, the variability of creatinine measurement in end stage renal disease (ESRD) has 
been regarded as neglectable for long time. It is somehow reasonable in the context of 
measuring estimated GFR. The estimated GFR is 7ml/min/1.73m2 for a 60 year old non 
African American male when plasma creatinine is 700umol/L and 6 ml/min/1.73m2 if the 
plasma creatinine is reported as 770umol/L according to the MDRD equation. 215 However, a 
variety of plasma creatinine from 100umol/L to 110umol/L is related to a 7ml/min/1.73m2 
difference in estimated GFR in a subject with same gender, race and age. 
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Presumably because of this, the available Standard Reference Materials (SRMs) of creatinine, 
which are supposed to be used to evaluate the accuracy of clinical methods and to validate 
working or secondary reference materials, are no more than 467.4umol/L. 216 In another 
word, the accuracy and commutability of the creatinine measurement in higher level can be 
unreliable. 
The local lab upgraded the creatinine measurement method during the project. This study 
was to investigate whether this change in creatinine measurement had any effect on 
dialysate/plasma (D/P) creatinine, the most important parameter in peritoneal dialysis (PD) 
patients for both clinical and research purpose.  
9.2.2 Methods 
9.2.2.1 The methodology change of plasma creatinine measurement in 
the clinical laboratory 
The clinical laboratory upgraded the methodology for plasma creatinine from the O’leary 
modified kinetic Jaffé method to creatininase based enzymatic method on 29th Oct 2008. 
Advia analyser (Siemens Healthcare Diagnostics Inc, Newbury, UK) was used both before and 
after. There was no change in dialysate creatinine measurement - Beckman Synchron 
reagents (Kinetic Jaffé method) on DxC800 analyser (Beckman Coulter UK Ltd, High Wycombe, 
UK).  
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9.2.2.2 Patient population 
It was a single centre retrospective observational study. The baseline demography, residual 
renal function, peritoneal solute clearance, and membrane function measured by peritoneal 
equilibration test (PET), were routinely recorded within the first one or two month of 
treatment, and then usually at 6 monthly intervals in all patients as part of the clinical routine 
in our centre. The patients who had creatinine measured both 12 months before and 12 
months after 29th Oct 2008 were included in the analysis. For the patients had more than one 
creatinine measurement during the 12 months, the one closest to the switch date was 
analysed.  
29-10-08 was the real switch time point. 29-10-07 and 29-10-09 were selected artificially to 
serve as controls. Paired creatinine results around 29th Oct 2007 and 29th Oct 2009 were 
selected in the same way as for 29-10-08. The three sub-cohorts were analysis in the study. 
The clinical policy did not change and no new dialysate was introduced into the centre during 
the study period of time. 
9.2.2.3 Statistical analysis 
Paired t-test was performed to compare the difference before and after the switch day. Delta 
of each pair of the data was calculated as a function of difference before and after the switch. 
The difference between different switch points, one real switch point and two artificial 
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switch points, was compared by one-way analysis of variance (ANOVA). Statistical analysis 
was performed using SPSS version 18 (Chicago, IL, USA).  
9.2.3 Results 
No significant difference in age, gender, PD duration and time interval between the two 
measurement dates was found in the three sub-cohorts. (Table 9-2) 
Table 9-2 demography of the three sub-cohorts around the different switch time point 
 29-10-07 (n=66) 29-10-08 (n=60) 29-10-09 (n=55) P valuea 
Age (years)b 56±17 59±16 61±16 NS 
Gender (M/F) 28/38 27/33 21/34 NS 
PD duration (mo) b 27±23 29±23 30±28 NS 
Interval between 
two measures 
(days) 
198±32 198±41 200±55 NS 
29-10-08 was the real switch time point. 29-10-07 and 29-10-09 were the two time 
points artificially selected to serve as controls. 
a, ANOVA or chi square P value 
b, PD duration and age were until the earlier measurement of creatinine within the 
comparison 
 
The increases of plasma creatinine before and after the two artificial switch time points were 
not significant (29-10-2007, from 657.5±248.2umol/L to 682.5±275.8umol/L, P=0.135; 29-10-
2009, from 688.0±289.4umol/L to 707.0±273.0umol/L, P=0.458). There was a significant 
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increase after the real switch time point, 29-10-2008, from 610.7±260.2umol/L to 
697.0±285.5umol/L (P<0.001).  
D/P creatinine was stable before and after the two artificially selected cut points (29-10-2007, 
before 0.79±0.15, after 0.81±0.14, P=0.282; 29-10-2009, before 0.66±0.12, after 0.67±0.13, 
P=0.734). If anything, there was a small increase of D/P creatinine in these two sub-cohorts. 
The average D/P creatinine levels significantly decreased from 0.78±0.13 to 0.72±0.12 after 
the lab switch the methodology (P<0.001). The difference of the delta D/P creatinine before 
and after the switch time points across the three sub-cohorts was shown in Figure 9-1.  
No statistics correlation was found between the delta of D/P creatinine and absolute D/P 
creatinine level. (Figure 9-2) A 0.06±0.02 mean decrease after the methodology switch was 
constant through the observed D/P creatinine range. 
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Figure 9-1 delta D/P creatinine before and after the switch time point, 29-10-2008, and 
the two artificially selected switch time points, 29-10-2007 and 29-10-2009 
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Figure 9-2 correlation between delta of D/P creatinine before and after the switch time 
points and absolute D/P creatinine 
There was no significant correlation between delta of D/P creatinine before and after the 
switch time points and absolute D/P creatinine. A 0.06±0.02 mean decrease after the 
methodology switch was constant through the observed D/P creatinine range. 
 
9.2.4 Discussion 
D/P creatinine at four hours is the most important parameter in managing PD patients. Firstly, 
it is related to survival. Patients with a high D/P creatinine at baseline have increased 
mortality and technique failure, at least historically.51, 55 Secondly, it gives the guidance for 
original dialysis regime, 217 although clinician would modify it according to clinical response. 
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Thirdly, it is also recommended to be used in monitoring patient longitudinally and in 
diagnosing ultrafiltration failure. 217  
9.2.4.1 The impact on longitudinal observation 
The first time we noticed the impact of this upgrade was during a longitudinal analysis of 
Stoke cohort. There was a significant decrease in D/P creatinine, since the end of 2008. It has 
been well described that the D/P creatinine ratio steadily increases during the year on the 
therapy. According to the previous study in our centre, the mean D/P creatinine was about 
0.65 in the incident PD cohort and gradually increased to 0.74 after spending seven years on 
the therapy. 95 For those two artificial cut points in the current analysis, D/P creatinine ratio 
was somehow increased but far from significant different in the 6 month interval. On the 
background of the slow creep of D/P creatinine, the drop of D/P creatinine, from 0.78±0.13 
to 0.72±0.12 before and after the methodology change was remarkable. It was not likely that 
any novel clinical revolution improved the membrane function dramatically.   
The methodologies of routine clinical measurements need to be upgraded from time to time 
with the development of laboratory technique. The new methods are generally more precise 
and reliable. But the commutability between the new and old methods should always be 
aware of by both clinicians and labs. 
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9.2.4.2 The impact on multi centre study 
The centre effect of membrane function has been noticed for long time, as we found in the 
current project. The reported proportions of high transporters range from about 17% 218 to 
approximately 50%.217, 219 Race, age, gender and diabetes mellitus or comorbidity burden, 
which have been proved to have effect on membrane function, are thought to contribute to 
centre effect. 160, 220, 221 However, the centre effect has never been fully understood. The 
different methodology of creatinine measurement might have a silent but important 
contributor to the centre effect.  
It would be technically difficult to compare the results from different centres because of the 
lack of the SRMs in high level. SRMs and a global traceable system would be the solution for 
this problem.  
9.2.4.3 The impact on the classification of PSTR   
The widely accepted classification of different PSTR is based on 4 hours D/P creatinine ratios 
as first described in 1987. 222 Twardowski et al did the study in 86 patients with 18 diabetic 
nephropathies. Mean, mean-1SD, mean+1SD levels of D/P creatinine were used as the cut off 
to divide the whole cohort into high (H), high average (HA), low average (LA), and low (L) 
peritoneal transporters. Mean, mean-1SD, mean+1SD levels of D/P creatinine in that specific 
cohort were 0.65, 0.50, and 0.80, the cut off points we are familiar nowadays. 
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The exact values are now used to classify transport status in different centres instead of 
using the centre specific means and mean+-SDs. There is advantage of this strategy. It 
facilitates the comparison between different cohorts. However, to use the same exact value 
as criteria we need to make sure that the D/P creatinine measurement is reliable and 
commutable, more specifically, commutable to Twardowski’s lab, in the first place. More 
precisely, it is to the lab 25 years ago. To set up a classic classification of PSTR, a standard 
methodology of D/P creatinine measurement is important. It should be traceable to different 
centres and traceable to future methodologies. 
9.2.5 Summary 
The methodology upgrade in plasma creatinine measurement had effect on dialysate/plasma 
(D/P) creatinine. It is important to aware of this and its further impact. Standardization in 
high range of plasma creatinine is needed. 
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9.3 Bioimpedance as a Tool for Fluid Management in Peritoneal 
Dialysis (PD) Patients-study protocol 
NCT00801112 http://clinicaltrials.gov 
9.3.1 Background 
Low peritoneal ultrafiltration, and by inference low sodium removal, is associated with worse 
outcomes in PD. Equally, excessive fluid removal is a risk factor for dehydration and loss of 
residual renal function. Current guidelines have advocated a daily UF volume of 1litre. 
However, their blunt application could lead to either inappropriate early loss of residual renal 
function or modality transfer. Body composition changes spontaneously with time on PD. 
Short term changes in hydration (specifically extracellular fluid volume, ECFv) combined with 
medium term changes in muscle and fat make it difficult for the clinician to be sure if fluid 
status is stable. There is a significant need for evidence on how to best manage fluid status in 
PD patients, both in terms of an appropriate clinical strategy and also a simple and 
reproducible tool to guide clinicians to apply the strategy. 
Bioimpedance (BIA) gives highly reproducible measurements of two components of body 
composition: it measures the resistance of the body to an electrical current, inversely 
proportional to the total amount of fluid in the body (total body water-TBW), and the storage 
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(reactance) of the current, proportional to the cell membrane mass, which then proportional 
to intracellular water (ICW). It is simple to perform. Intervention studies have demonstrated 
its ability to identify changes in fluid status in response to changes in therapy189 and the 
ECW:TBW ratio is a powerful predictor of patient survival.190 It is likely that BIA will become 
the standard tool to assist clinicians in assessing fluid status.  
We hypothesize that regular monitoring of BIA adds value to the management of fluid status 
in PD patients. 
9.3.2 Method 
9.3.2.1 Study design 
It is a prospective, randomized controlled trial. Following a 2-3 month run-in period, during 
which fluid status is optimized – (if necessary). Patients are then randomized 1:1 with 
stratification for centre and urine volume (anuric or non-anuric). BIA measurements are 
taken in both groups 3 monthly in the 12 months study period and in addition at any time of 
clinical need in active group. The BIA information will be available to the clinician and assist 
to set the dry weight in active group, while the clinicians will be blinded to the results in the 
control group. Figure 9-3  
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Figure 9-3 The BIA study design 
 
9.3.2.2 Study setting 
Three UK centres and one centre in Shanghai are involved in the study. They are University 
Hospital of North Staffordshire, St. James’s University Hospital, Sheffield Kidney Institute 
Northern General Hospital and Shanghai Renji Hospital. All of them are University hospitals 
with well established PD programmes. The planned recruiting patient number is more than 
half of their whole PD population.  
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The samples will be sent to University Hospital of North Staffordshire shortly after being 
collected for further analysis in the three UK centres. The samples in Shanghai Renji Hospital 
will be stored and analyzed locally. 
9.3.2.3 Patient population 
The patient who are more than 16 years old and has been stably established on PD for more 
than 3 months in the study centres are approaching for the study.  
9.3.2.3.1 Exclusion criteria: 
1. plan to discontinue PD within 6 months 
2. unable to give consent or refuse to take part in the study 
3. peritonitis in the last 30 days  
4. pregnancy 
5. implanted electronic devices 
9.3.2.3.2 Withdraw 
Patients permanently leave the PD therapy (transfer to haemodialysis, renal transplantation, 
spontaneous recovery of renal function), or loss to follow-up.  
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9.3.2.3.3 Sample size calculation 
We hypothesize that the control group will have a drift upward in ECW while the active group 
will remain stable (no change from baseline). Based on historical data, we expect the 
standard deviation of mean change from baseline is about 1.22 (this is the standard deviation 
of the differences in ECV over an 8 month period in a group of 27 patients). 38 patients per 
group will have adequate statistical power to detect a 0.8kg increase in control group, 
assuming type I error of 5% and 80% power. 42 patients in each group is planned to enroll 
with the assumption of 15% of dropout rate. 
9.3.2.4 BIA measurement 
The single frequency (50Hz) BIA device (Akern BIA 101 Anniversary) is used in the study. The 
total body resistance and reactance are measured according to the operating manual. The 
patient may with or without PD fluid in the peritoneal cavity when do the measurement but 
it should be consistent during the follow up. 
9.3.2.5 Interpretation of the BIA information 
In active group, hight2/resistance, inversely proportional to TBW, and hight2/reactance, 
inversely proportional to cell membrane mass, will be plotted. The baseline result from each 
patient will be used as reference for the individual patient. The follow up measurement will 
be plotted and chased up. No intention will be made to normalize the patient to their age 
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and gender matched ‘normal reference range’ from the general population. Generally 
speaking, prolonged vector length and increased phase angle indicate the increase of TBW 
and hydration status. (Figure 9-4) Both clinical and BIA information will be taken into account 
when making decision of target weight. When the BIA result is opposite to the clinical 
symptoms and signs, the clinician can make the decision whether go with the clinical or the 
BIA information. In control group, the BIA result will not be plotted out and the clinician will 
make the decision based on pure clinical information. 
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Figure 9-4 BIA vector 
 
9.3.2.6 Intervention 
The difference between the control and active group is at the stage of setting target weight. 
The BIA information is available to the clinician to help in setting target weight in active 
group while in control group the BIA information is not available to clinician.  
In terms of achieving target weight, it is left to the clinical team to use whatever tools at their 
disposal in both groups. These will include more intensive advice on dietary salt and fluid 
intake, increased use of hypertonic solutions, icodextrin, modality change (APD v. CAPD), or 
most likely a combination of these. It is also important to notice that the clinical fluid 
 288 
 
 
management policy in different centre can be different. (E.g. icodextrin and APD are not 
available in Shanghai) It will be documented and taken into account for secondary analysis. 
9.3.2.7 Outcome measures 
Primary outcome measure is ECW determined from BIA. 
Secondary outcome measures include 
1. Blood pressure control (BP measurement and medication); 
2. Residual renal function; 
3. Membrane function (Glucose exposure, PSTR, UF Capacity); 
4. Cardiac function; 
a. BNP (all centres) 
b. ECHO (limited centres) 
5. Total body water using gold standard methods (D2O dilution method) (limited 
centres); 
6. Incidence of adverse reaction. 
9.3.2.8 Sample handling and storage 
Blood samples will be collected and centrifuged at 3000rpm on site before being stored at -
20 degree until further analysis.  
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9.3.2.9 Data analysis plan 
Paired t-test will be used for the primary endpoint and secondary endpoint, comparing the 
results before and after treatment. Differences in proportions will be evaluated by chi-square 
of Fisher’s exact tests, as appropriate. Multi level regression model will be applied to control 
covariates. Repeated measures (level 1) will be nested within individual (level 2). The centre 
effect will also be addressed by using multi level strategy by nesting individual within centre 
(level 3). A further level will be considered regarding the big difference between Shanghai 
and the three UK centres (level 4). 
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9.4 How Akern BIA 101 Anniversary transform the resistance 
and reactance to TBW and ECW? 
9.4.1 Purpose 
To investigate how Akern BIA 101 Anniversary transform the resistance and 
reactance measurements to TBW and ECW.   
9.4.2 Methods 
172 sets of patient information (including gender, height and body weight) and 
resistance and reactance were put into the software of Akern BIA 101 Anniversary. 
The TBW and ECW output from the software were recorded. Based on reference, 223 
the first 100 records was used to generate a set of formulas to calculate TBW and 
ECW from height, body weight, gender and raw resistance and reactance readings. 
The formulas were then applied to calculate TBW and ECW for all records.  
9.4.3 Results 
The formulas generated were as following. 
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For TBW, If female, 
          
     
 
        
 
 
          
 
 
      
For TBW, if male  
          
     
 
        
 
 
          
 
 
      
For ECW 
    
   
            
                    
          
         
 
The correlations between the TBW and ECW derived from the Akern BIA Anniversary 
software and the TBW and ECW calculated from the formulas above were show in Figure 9-5 
and Figure 9-6. The difference between the two methods was not related to the absolute 
values Figure 9-7 and Figure 9-8.  
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Figure 9-5 the correlation between the TBW from the machine (derived from the Akern 
BIA Anniversary software) and the TBW calculated from the formula 
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Figure 9-6 the correlation between the ECW from the machine (derived from the Akern 
BIA Anniversary software) and the ECW calculated from the formula 
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Figure 9-7 the correlation between the difference of the calculated TBW from the formula 
and from the machine and the absolute value of TBW 
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Figure 9-8 the correlation between the difference of the calculated ECW from the formula 
and the ECW from the machine and the absolute value of ECW 
 
 
9.4.4 Conclusion 
The formulas generated in this analysis have good agreement with the manufacturer’s 
algorithms (Akern BIA 101 Anniversary BIA device). TBW and ECW output from the BIA device 
are calculated from resistance, reactance, height, weight and gender using universal 
algorithms, without accounting for age or comorbidities. 
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Abstract
Background. Inflammation, hypoalbuminaemia and peri-
toneal protein clearance are important predictors of survival
in patients treated with peritoneal dialysis (PD). We hy-
pothesized that the common link is abnormal endothelial
barrier function. To test this, we explored associations be-
tween hypoalbuminaemia, systemic albumin leak and solu-
ble markers of systemic inflammation and endothelial
injury.
Methods. This was a cross-sectional study of 41 prevalent
PD patients. Endothelial barrier function was measured as
transcapillary escape rate of 125I albumin [transcapillary
escape rate of albumin (TERalb)]. Seventeen plasma bio-
markers including pro-inflammatory cytokines, endothelial
biomarkers and metalloproteinases were measured. Hier-
archical clustering analysis (HCA) and principal compo-
nent analysis (PCA) were used to explore the hypothesis.
Results. The mean TERalb was 13.7 6 8.9 (%/h), higher
than in non-uraemic subjects 8.22 6 5.8 (%/h). Three pa-
tient clusters were defined from HCA according to their
biomarker patterns. Cluster 1 was characterized by inflam-
mation, hypoalbuminaemia, overhydration and intermedi-
ate TERalb. Cluster 2 was non-inflamed, preserved muscle
mass and more normal TERalb. Cluster 3 had highest
TERalb, platelet activation, preserved plasma albumin and
intermediate high-sensitivity C-reactive protein levels.
Two principal components (PCs) were identified from the
biomarker matrix, PC1, indicating platelet activation and
PC2, pro-inflammatory. TERalb was positively related to
PC1 but not PC2. Diabetes and ischaemic heart disease
were associated with PC1 and PC2, respectively.
Conclusions. This exploratory analysis indicates that en-
dothelial barrier function is decreased in PD patients and is
associated with diabetic status and markers of platelet
activation more than inflammation. In contrast, hypoalbu-
minaemia is associated more with inflammation and
atherosclerotic disease indicating a more complex rela-
tionship between systemic endothelial barrier function,
inflammation and hypoalbuminaemia which requires
further validation.
Keywords: biomarker pattern; body composition; inflammation; platelet
activation; transcapillary escape rate
Introduction
Inflammation and hypoalbuminaemia are both important
predictors of survival in patients treated with dialysis for
advanced renal failure [1–3]. Endothelial dysfunction is a
feature of uraemia [4], also present in complicated diabetes
and cardiovascular co-morbidities that commonly occur in
these patients. Indeed, it may represent the link between
increased systemic and/or peritoneal protein leak, inflam-
mation, hypoalbuminaemia and worse survival through its
association with reduced capillary barrier function [5] (see
Figure 1a). However, the picture is further complicated in
peritoneal dialysis (PD) patients by the important daily
losses of protein from the peritoneal cavity which likely
explains why for a given degree of hypoalbuminaemia,
survival in PD patients is superior to those on haemodial-
ysis [1]. The observation that peritoneal protein clearance
(the main determinant of absolute protein losses) predicts
survival independent of effective peritoneal surface area
[5–7] led us to test the hypothesis that the underlying com-
mon factor is impaired systemic endothelial barrier function.
To do this, we explored the relationship between the
systemic transcapillary escape rate of albumin (TERalb) as
an indicator of endothelial barrier function, a panel of bio-
markers of endothelial dysfunction and associated clinical
phenotypes. We used the techniques of hierarchical cluster-
ing (HC) and principal component analysis (PCA) to gen-
erate patient groups from the patterns of biomarkers
observed and then subsequently compared their clinical
phenotypes so as to avoid any pre-conceived assumptions.
Materials and methods
Study design and patient population
This was a cross-sectional study of prevalent PD patients in a single centre.
Sequential patients were approached to participate and studied while
undergoing their routine 6-monthly assessments of peritoneal membrane
 The Author 2012. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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function and dialysis adequacy tests, provided they were not acutely ill or
within 1 month of peritonitis. The study was peer reviewed and approved
by the local ethics committee and all patients signed the consent form.
TERalb and plasma volume
After a bolus intravenous injection of 10 mL 0.185 MBq 125I-human
serum albumin (HSA), blood samples were taken at 10, 20 and 30 min
at a remote venous site. The isotopic concentration in each case was
plotted against time on a semi-logarithmic scale and the best linear fit line
was performed from these points. TERalb, expressed as percentage loss per
hour (%/h) was estimated from the disappearance rate of the 125I HSA
from the gradient of this line. The plasma volume was calculated by
extrapolating the line to time zero. The method was also applied for
clinical purposes as the measurement of plasma volume in the normal-
ization of red cell mass and diagnosis of primary polycythaemia. These
patients who were mainly referred from haematologists during the time of
this study served as non-uraemic contemporaneous ‘in-house’ controls.
Biomarker measurement
The plasma sample for biomarker analysis was collected just before 125I
HSA injection on the study day and stored at 20C. A panel of 17
biomarkers, which are involved in inflammation, endothelial function
and tissue remodelling processes, [interleukin-6 (IL-6), tumour necrosis
factor-alpha (TNF-a), interferon-gamma (IFN-c), IL-1b, IL-10, monocyte
chemotactic protein-1, inter-cellular adhesion molecule 1, vascular cell
adhesion protein 1 (VCAM-1), E-selectin, P-selectin, CD40 ligand
(CD40L), vascular endothelial growth factor (VEGF), matrix metallopro-
teinase (MMP)-1, MMP-2, MMP-3, MMP-8, MMP-9], was measured on a
Luminex suspension array system (Bio-Plex 200TM platform; Bio-Rad
Laboratories, Hemel Hempstead, Hertfordshire, UK) using commercially
available multi-analyte cytokine kits [MILLIPLEX MAP; Millipore (UK)
Ltd, Walford, Hertfordshire, UK] or Fluorokine multi-analyte profiling
kits for MMPs (R&D Systems, Abingdon, UK). Assays were carried out
according to the manufacturer’s instructions.
Body composition, solute clearance, membrane function and blood
biochemistry
Estimated total body water (TBW) and extra-cellular water were evaluated
by bioimpedance (BIA, multi-frequency Xitron Hydra device, Model
4200; Xitron Technologies, San Diego, CA). At the same time, absolute
TBW was measured by deuterium (D2O) dilution technique. The detailed
methodologies have been described previously [8]. In brief, baseline and
equilibrated blood samples were taken before and 2.5 h after an oral dose
of 99.8% D2O (Cambridge Isotope Laboratories). The difference between
the headspace HDO abundance of the two samples, measured by flowing-
afterglow mass spectrometry, was used to determine TBWD after account-
ing for equilibration with dialysate and 4% D exchange with H in body
proteins. The difference between BIA estimated (TBWBIA) and D dilution
measured TBW (TBWD) reflects tissue overhydration [8, 9].
The dialysis dose and residual renal function were calculated as the
weekly Kt/Vurea from the 24-h urinary and dialysate clearance by direct
measurement of urea in urine and dialysate. Peritoneal dialysate protein
loss was measured from the collection of 24-h dialysate effluent. A vali-
dated equation was used for the calculation of protein clearance, (Pcl), ¼
24-h dialysate protein loss/(serum albumin/0.4783).
Solute transport was measured by standard 4-h peritoneal equilibrium
test with 2.27% glucose concentration 2-L exchange. The dialysate:plasma
ratio of creatinine at the completion of the 4-h dwell period (D/P
creatinine) was used to estimate low-molecular-weight solute transport.
Plasma albumin was estimated using the bromocresol purple colorimetric
method, peritoneal dialysate and urine protein by the biuret method.
C-reactive protein (CRP) was measured using a latex enhanced immuno-
turbidimetric method.
Statistical analysis
One-way analysis of variance and unpaired t-test were used to examine
differences in normally distributed continuous data among groups, chi-
square for categorical data. Univariate correlations were examined by
Pearson correlation coefficient. Variables not normally distributed were
log2 transformed for further analysis. Significance was considered at
P-values <0.05. Statistical analyses were performed using IBM SPSS
Statistics version 19 except for the HC analysis (HCA).
Hierarchical cluster analysis
The biomarker levels were first converted to Log2 and expressed relative to
the mean value for normalization. These measurements were used to gen-
erate heat map (Figure 2) using Genesis software (version 1.7.2, Alexander
Sturn; Institute for Genomics and Bioinformatics, Graz University of
Technology). The Genesis programme uses a two-dimensional HC
method, using the average linkage clustering agglomerative rule that en-
ables groups of variables with similar expression levels to be clustered
together as well as grouping together patient samples with similar expres-
sion patterns.
Principal component analysis
To decrease the dimensionality of the biomarker data set while retaining as
much of the variance as possible, an exploratory PCA was employed.
Principal components (PCs) were extracted using varimax rotation, with
the factor selection based on an eigen value cut-off of 1.0. Because of
limitations of the sample size, eight biomarkers only were processed in the
final analysis. These biomarkers were selected from the first two PCs,
which contributed the most variance of the whole matrix. Those biomarker
variables not normally distributed after log transformation were converted
to binary data.
Results
A total of 41 prevalent patients (M/F 22/19, mean age 61
17 years, median time on PD 20 [9–33] months, diabetics
Fig. 1. (a) Simplified linear hypothesis linking co-morbidity to hypoalbuminaemia invoking reduced endothelial barrier function as the central unifying
mechanism. (b) Modified relationship between co-morbidity, inflammation, systemic protein leak and hypoalbuminaemia in the light of current findings.
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29%) were studied. The TERalb was higher in the PD pa-
tients 13.74  8.8 (%/h) than the non-uraemic comparator
group 8.22  5.8 (%/h) (n ¼ 13, P < 0.05).
Three clusters and one outlier were defined from
the HCA (Figure 2). Patient characteristics, peritoneal
membrane function and TERalb (Table 1) and absolute
biomarker concentrations (Table 2) are shown by cluster.
Cluster 1 was characterized by an inflammatory profile,
associated with higher high-sensitivity CRP, lower albu-
min, intermediate TERalb and overhydration indicated by
the big discrepancy between measured TBW (TBWD)
and estimated (TBWBIA). Cluster 2 was non-inflamed
according to the lowest CRP levels, had the lowest TERalb
and the most normal body composition as evidenced by the
highest body water by body weight but good agreement
between D dilution and BIA measures, indicating well-
preserved muscle mass but least overhydration. Cluster 3
was characterized by biomarkers consistent with platelet
activation, had the highest TERalb but only moderate
CRP levels, less inflammation and less overhydration than
Cluster 1 patients.
The PCA was first carried out in the whole panel of the
17 biomarkers. Seven PCs were identified, explaining 74.9%
of the total variance, Figure 3a. The eight biomarkers that
composed the two strongest PCs, contributing the majority
of the variance, were selected for the final PCA and are
shown with their eigen values (>1) in Figure 3b. The first
PC (PC1-platelet activation) was composed mainly of
MMP-1, P-selectin, CD40L and VEGF. The second PC
(PC2 pro-inflammation) featured an inverse relationship
between MMP-3 and positive association with IFN-c,
TNF-a and VCAM-1. This component showed a positive
relationship with CRP (r ¼ 0.31, P ¼ 0.047) and was
negatively correlated with plasma albumin (r ¼ 0.50,
P ¼ 0.001).
The relationship between the HCA and PCA is shown
graphically in Figure 4a. It can be seen that despite differ-
ing dimensions that these two analytical techniques give
patterns that are in agreement. Patients with different
co-morbidities also showed differences in PCs such that
patients with ischaemic heart disease (IHD) and diabetes
mellitus (DM) have different, albeit overlapping, patterns
of biomarkers (Figure 4b). Diabetes had higher PC1, while
PC2 was higher in IHD (Table 3).
To further explore the relationship between clinical fac-
tors and biomarker profiles with our primary end point,
Fig. 2. Plasma concentration profiles of 17 biomarkers in 41 patients expressed as a HCA heat map. Plasma concentrations of biomarker close to higher
and lower than the mean values are represented by black, red and green colours, respectively. Three patient clusters, Cluster 1 (blue bar), Cluster 2 (green
bar), Cluster 3 (red bar) and one outlier are generated by HCA.
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TERalb, univariate regression analysis was undertaken.
None of the clinical measures, including demographics,
membrane function, PD duration, CRP or systemic dy-
namic factors (pulse pressure, mean blood pressure),
showed significant correlation to TERalb whereas the bio-
marker derived PC1 score (platelet activation) showed a
positive relationship (r ¼ 0.33 P ¼ 0.03) (Table 4). Multi-
variate analysis found this relationship to be independent of
age, gender and PD duration.
Discussion
This is the first study to measure systemic endothelial bar-
rier function in patients with chronic kidney disease (CKD)
Stage 5 and relate this to a wide panel of circulating bio-
markers of inflammation and endothelial dysfunction. It
confirms that endothelial barrier function is abnormally
decreased and suggests that this is not solely related to
inflammation but more so to platelet activation in this
Table 1. Characteristics of the three patient clusters derived from HCAa
Cluster 1 (n ¼ 17) Cluster 2 (n ¼ 9) Cluster 3 (n ¼ 14) Single outlier
TERalb (%/h) 13.88 6 9.23 9.12 6 5.29
b 17.29 6 9.11 3
Age (years) 62.1 6 17.2 61.4 6 19.2 60.3 6 15.7 60
Gender (M, %) 65 56 36 M
BMI (kg/m2) 26.1 6 5.7 25.8 6 3.9 28.3 6 5.1 25.1
PD duration (months) 22.9 6 20.3 27.6 6 21.0 26.8 6 21.2 10.5
Solute transport (4 h D/P creatinine ratio) 0.81 6 0.13 0.78 6 0.12 0.74 6 0.17 0.7
Albumin (g/L) 29.1 6 4.9c 31.3 6 3.3 33.2 6 4.1 33
CRP (mg/L) 14.3 (4.8–21)d 1.5 (0.6–4) 4.6 (0.8–9.5) 16.8
Peritoneal Pcl (mL/day) 95.6 6 48.3 67.3 6 21.7 69.0 6 24.7 64.04
Peritoneal protein loss (g/24 h) 6.3 6 3.2 4.9 6 1.6 5.0 6 1.8 4.28
Urine protein loss (g/24 h) 0.58 6 0.5 0.88 6 0.85 0.74 6 0.51 1.12
Total protein loss (g/24 h) 7.11 6 3.00 6.06 6 2.06 6.02 6 2.07 5.4
Urine volume (mL) 709 6 631 1128 6 626 1059 6 759 997
Adjusted PV (mL/m2) 1439 6 300 1441 6 173 1446 6 197 2158
TBWD/Weight 0.51 6 0.04 0.53 6 0.07
b 0.47 6 0.06 0.52
TBWBIA/Weight 0.45 6 0.05 0.53 6 0.08
d,e 0.45 6 0.06 0.56
TBWD/Weight  TBWBIA/Weight 0.049 6 0.041 0.006 6 0.025f 0.023 6 0.055 0.046
Ever smoked (%) 44 22 23 Yes
IHD (%) 41 22 29 No
Diabetes (%) 17 22 50 No
aAdjusted PV, plasma volume adjusted by body surface area; BMI, body mass index; Pcl, protein clearance corrected for dialysis regime (modality, dry
day and overfill); TBWD/Weight, TBW normalized to body weight as determined from deuterium (D) dilution; TBWBIA/Weight, TBW normalized to
body weight as estimated by BIA. Clusters 1, 2 and 3 were compared using one-way analysis of variance (ANOVA) and when significant the post hoc
between group differences are shown.
bCluster 2 versus Cluster 3, P < 0.05.
cCluster 1 versus Cluster 3, P < 0.05.
dCluster 1 versus Cluster 2, P < 0.01.
eCluster 2 versus Cluster 3, P < 0.01.
fCluster 1 versus Cluster 2, P < 0.05 (ANOVA).
Table 2. Mean/median biomarker concentrations of the three patient clusters derived from HCAa
Cluster 1 (n ¼ 17) Cluster 2 (N ¼ 9) Cluster 3 (n ¼ 14) Single outlier P-value (ANOVA)
ICAM-1 (lg/mL) 0.49 6 0.09 0.4 6 0.07 0.34 6 0.08 0.41 <0.01
VCAM-1 (lg/mL) 0.83 6 0.18 0.74 6 0.16 0.72 6 0.2 0.52 NS
E-selectin (ng/mL) 68.21 6 31.07 44.16 6 18.08 56.23 6 27.51 26.13 NS
P-selectin (ng/mL) 94.63 6 31.68 79.94 6 27.23 126.52 6 46.95 48.53 <0.05
MMP-1 (pg/mL) 33.4 (15–104.8) 10.1 (1–60.8) 345 (35.9–821.8) 1 <0.05
MMP-2 (lg/mL) 0.24 (0.17–0.28) 0.76 (0.34–1) 0.29 (0.23–0.44) 0.24 0.081
MMP-3 (ng/mL) 11.5 6 5 22.76 6 12.76 13.52 6 4.49 9.04 <0.01
MMP-8 (ng/mL) 3.69 6 1.66 2.26 6 0.8 2.04 6 1.15 0.33 <0.01
MMP-9 (ng/mL) 67.66 6 38.23 55.54 6 26.02 53.13 6 30.4 30.7 NS
IFN gamma (pg/mL) 1.4 (0–4.6) 0.5 (0–1.4) 1.7 (1.1–2.3) 2.1 NS
IL-1b (pg/mL) 0.1 (0.1–0.1) 0.1 (0.1–0.1) 0.4 (0.1–4.1) 0.1 <0.01
IL-6 (pg/mL) 5.4 (3–11.4) 2.2 (1–4.2) 3.5 (2.8–5.1) 8.7 <0.05
IL-10 (pg/mL) 2.7 6 2 1.4 6 1.9 4.5 6 4 1.4 <0.05
MCP-1 (pg/mL) 357.8 6 156.9 377.5 6 175.2 417.1 6 131.2 61.7 NS
CD40L (ng/mL) 3.1 6 2.3 4.16 6 2.58 7.85 6 2.61 1.16 <0.01
TNF-a (pg/mL) 12.1 6 4.9 6.4 6 4 8.9 6 3 19.5 <0.01
VEGF (pg/mL) 3 (3–3) 3 (3–3) 50.9 (3–135.7) 3 <0.01
aANOVA, analysis of variance; ICAM-1, inter-cellular adhesion molecule 1; NS, non significant.
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clinically stable cross-sectional cohort. Furthermore, pa-
tients with IHD and DM have different, albeit overlapping,
patterns of biomarkers, although both exhibit endothelial
dysfunction (Figure 4b).
The TERalb is a widely accepted measurement of endo-
thelial barrier function, first described as early as 1973
[10, 11]. TERalb is increased in several conditions associ-
ated with endothelial dysfunction such as diabetes, hyper-
tension and atherosclerosis [12–15] and also sepsis where it
is clearly associated with marked inflammation. However,
endothelial barrier function has been less well investigated
in end-stage renal disease. This study found that mean
TERalb is higher in CKD Stage 5 patients than in non-
uraemic controls who likely had other pathologies as they
were undergoing investigation for polycythaemia. A pre-
vious study of 29 non-diabetic CKD patients (glomerular
filtration rate 11–44 mL/min/1.73 m2) whose other markers
of endothelial function (e.g. von Willebrand factor) were
normal unless subjects were current smokers [16] showed
no difference between CKD patients and normal controls.
This suggests that severe renal failure is associated with
more severe endothelial dysfunction and is in broad agree-
ment with other rather small previously published studies
in dialysis patients. TERalb was increased in 11 diabetics
treated with PD (but not in non-diabetics) [17] and 9 pre-
dialysis haemodialysis patients [18]. This is supported
by in vivo experiments in which human uraemic plasma
increased frog mesenteric micro- vascular permeability to
both water and protein, [19] subsequently confirmed in
other studies. [20] One of the strengths of our study, which
demonstrated a relatively high median TERalb, was that we
recruited sequential patients undergoing routine assessment
of their therapy with <5% of patients declining investiga-
tion, so reducing selection bias.
Although a relationship between TERalb and blood pres-
sure was seen in some early studies in hypertensive patients,
we did not observe this to be the case in this cross-sectional
study. The relationship may be more complex in this dialysis
cohort with multiple co-morbidities and concomitant
medication. A study comparing TERalb according to the
angiotensin-converting enzyme (ACE) gene polymorphism
in essential hypertension showed that ACE D/D homozygo-
sis, which is associated with high risk of atherosclerotic
vascular disease, is related to higher TERalb despite identical
24-h blood pressure readings [23]. Furthermore, endothelial
function can be influenced by medications used in the pa-
tients with related effect on TERalb. High-dose simvastatin
reduces low-density lipoprotein cholesterol by 39% and is
reported to normalize TERalb [24]. No clear relationship
between medications and TERalb was observed in this study.
The measurement of a wide range of biomarkers com-
bined with hierarchical cluster and PCA allowed us to
investigate the overall pattern of their association with endo-
thelial barrier dysfunction. Using this approach, we were
able to identify three main patient clusters and there was
good agreement between these and the two main
Fig. 3. (a) PCA from the whole panel of the 17 biomarkers eigen values and percentage contributing to the total sample variance of each of the seven PCs
is presented. Individual composition feature is showed along with their rotated loading coefficients, a measure of the importance of each biomarker to
the factor, displayed as a bar chart. (b) PCA from reduced number of biomarkers. The eight biomarkers that compose the two strongest PCs, contributing
the majority of the total sample variance are selected for the final PCA. The composition of the 2 PCs derived from the final model is displayed along with
their rotated loading coefficients expressed as a bar chart.
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Fig. 4. (a) Combined graphical representation of the HCA (centroid plot) and PCA (dimensionless weighted scores); there is good agreement between
the methods showing association between Cluster 3 and increased platelet activation, Cluster 1 with inflammation and Cluster 2 with the absence of
markers of endothelial dysfunction. (b) Combined graphical representation of PC scores and co-morbidity; IHD and DM are clustered according to their
different pattern of PC scores.
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components identified through PCA; additional PCs were
identified that warrant further investigation in a larger vali-
dation cohort but were excluded from further analysis here to
avoid Type 1 statistical error. The advantage to this approach
is that while biomarkers are likely to correlate to each other
as they all reflect endothelial function, it enables identifica-
tion of possible multiple biomarker functions or different
metabolic or signalling pathways involved in endothelial
dysfunction. For example, CD40L is expressed in lymph
cells, epithelial cells, fibroblasts, endothelial cells and plate-
lets in response to pro-inflammatory cytokines, platelet acti-
vators and nitric oxide signalling. After combining with
CD40, it subsequently up-regulates the pro-inflammatory
and pro-atherogenic genes [25]. Although results from our
PCA should be taken as exploratory, we find that PC1 (HC3
phenotype) is composed primarily of MMP-1, P-selectin,
CD40L and VEGF, all of which are released in significant
amounts from platelets and reflect platelet activation [26].
PC2, composed by IFN-c, TNF-a and VCAM-1 and nega-
tively contributed by MMP-3, is mainly involved in pro-
inflammatory pathways and defined the inflamed, overhy-
drated and hypoalbuminaemic HC1 phenotype. HC2 was
a relatively healthy phenotype with most normal body
composition and least abnormal TERalb. PC1 and PC2
could explain a significant proportion (34.3%) of the var-
iance in the whole biomarker matrix.
One important finding of this study is the demonstration
that the link between platelet activation and increased en-
dothelial permeability may not be just through inflamma-
tion. The links between inflammations as a trigger for
platelet activation in vascular lesions and between inflam-
mation, atherosclerosis and endothelial dysfunction in
uraemia are well established [27]. These pathways may,
however, act either independently or sequentially; activated
platelets can induce secretion of chemokines for monocyte
recruitment [28] whereas single micro-vessel perfusion
with TNF-a alone, without platelet activation, does not
alter endothelial permeability [29]. In an aseptic animal
injury model, systemic depletion of neutrophils with anti-
body failed to prevent the increase in vascular permeability,
whereas anti-platelet pre-treatment reduced this by 25%
[30]. These findings suggest that platelet activation may
have a critical role in endothelial hyperpermeability that
may not necessarily be through inflammation, especially
in the low-grade inflammatory status seen in uraemia. Lo-
cal release of VEGF by activated platelets, especially as-
sociated with HCA Cluster 3 and increased TERalb in this
study, may explain this.
This study found that DM and IHD tend to cluster with
different patterns of biomarkers associated with endothelial
dysfunction and in keeping with other studies, we found
that diabetics more commonly display an increase in pla-
telet reactivity [31]. Worse cardiovascular outcomes in
diabetics may reflect inadequate responses to anti-platelet
therapy [32]. Another important finding of this study is that
the systemic leak of albumin from the circulation to ex-
travascular space is not correlated to hypoalbuminaemia
and thus is unlikely to be causally related. It is well estab-
lished that the single strongest predictor of plasma albumin
concentration in PD patients is the daily peritoneal protein
loss [33, 34], in turn strongly correlated to the rate of peri-
toneal small solute transport, an indicator of the effective
vascular area in contact with dialysate. There is, however,
residual variability in peritoneal protein losses which has
now been shown in several studies to be an independent
predictor of patient survival [6, 7]. This link between peri-
toneal protein leak and survival can at least in part be ex-
plained by an association with increasing age and
cardiovascular co-morbidity, raising the possibility that
some of the variability may reflect endothelial dysfunction.
Table 3. PCs in different co-morbidity statusa
IHD (n ¼ 13) Non-IHD (n ¼ 28) P-valueb DM (n ¼ 12) Non-DM (n ¼ 29) P-valueb PVD (n ¼ 12) Non-PVD (n ¼ 29) P-valueb
PC1 0.01 6 0.80 0.01 6 1.09 0.951 0.62 6 0.94 0.26 6 0.92 0.009** 0.01 6 0.76 0.01 6 1.10 0.96
PC2 0.51 6 0.89 0.23 6 0.51 0.025* 0.19 6 0.97 0.08 6 1.02 0.436 0.06 6 0.85 0.02 6 1.07 0.814
aPVD, Peripheral vascular disease.
bUnpaired t-test.
*P < 0.05.
**P < 0.01.
Table 4. Univariate correlation of TERalb
a
Correlation coefficient P-valueb
Age (years) 0.21 0.19
BMI (kg/m2) 0.09 0.57
PD duration (months) 0.26 0.11
Pulse pressure (mmHg) 0.10 0.54
Albumin (g/L) 0.09 0.56
Log2CRP(mg/L) 0.04 0.81
D/P creatinine 0.12 0.46
UF capacity (mL) 0.03 0.88
Peritoneal protein loss (g/24 h) 0.23 0.16
Peritoneal Pcl (mL/day) 0.15 0.36
Urine protein loss (g/24 h) 0.16 0.34
Total protein loss (g/24 h) 0.20 0.23
Urine volume (mL) 0.22 0.17
Gender 0.1
Ever smoking 0.28
IHD 0.39
Diabetes 0.19
PVD 0.71
PC 1 0.33 0.03*
PC 2 0.07 0.69
aPVD, Peripheral vascular disease; UF, ultrafiltration.
bPearson or Spearman correlation for continuous variables as appropriate
according to the distribution and unpaired t-test for between group
difference.
*P < 0.05.
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We did not see any clear relationship between systemic
protein leak and peritoneal protein losses in this study
probably because the latter is dominated by effective peri-
toneal vascular area in contact with dialysate. It is also
possible, given that this was a study of prevalent patients,
that some had acquired membrane changes that could in-
fluence protein losses. The reason that plasma albumin is
more strongly associated with peritoneal protein losses
than with systemic leak is that the former represents net
daily losses (typically 5–10 g/day) whereas the latter re-
flects the re-circulation between intra- and extravascular
pools of up to 10 times this amount daily. Net plasma
albumin concentration will also be determined by the bal-
ance of synthesis and catabolism, and the former in rela-
tively fit PD patients has been shown to be increased
above normal.[33] The patients with the lowest albumin
in this study were those with inflammation compared to
markers of platelet activation, in keeping with previous
observations that hypoalbuminaemia in inflamed patients
is associated with reduced synthesis.
This study has a number of limitations. Firstly, the num-
ber of patients would ideally be greater to enable a more
extensive correlation of the PCA with clinical phenotype.
Despite this, it remains the largest study of TERalb in dial-
ysis patients to date and the numbers were limited by the
ethical permission which was primarily obtained to meas-
ure plasma volume in an adequately powered study of fluid
status and hypoalbuminaemia [8]. Secondly, the biomarker
patterns identified, while good evidence that the relation-
ship in more complex that originally envisaged can only be
considered as hypothesis generating at this stage. Further
validation in a larger patient cohort of selected biomarkers
is planned. Thirdly, we did not have ethics permission to
study normal subjects, so limiting our comparison to a non-
uraemic control group under clinical investigation, which
might be expected to have worse endothelial function than
normal subjects [35]. As acknowledged above, the cross-
sectional design means that there may be confounding of
the data by factors known and unknown that change with
time on treatment.
In conclusion, this study elaborates a more complex re-
lationship between abnormal endothelial dysfunction and
clinical phenotype in patients on PD, emphasizing the
importance of platelet activation as well as inflammation
(Figure 1b). In addition, it further clarifies our understand-
ing of the mechanisms of hypoalbuminaemia, an important
predictor of survival in patients on PD.
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